Connecting to database specified by database.yml


Started GET "/" for 127.0.0.1 at 2013-11-13 15:28:54 +0000
Processing by PagesController#preregistration as HTML
  Rendered layouts/_title.html.erb (0.3ms)
  Rendered layouts/_preregistration.html.erb (3.7ms)
  Rendered pages/preregistration.html.erb within layouts/application (37.3ms)
Compiled styles.css  (2369ms)  (pid 12403)
Compiled application.css  (2418ms)  (pid 12403)
Compiled jquery.js  (1ms)  (pid 12403)
Compiled jquery_ujs.js  (0ms)  (pid 12403)
Compiled bootstrap-transition.js  (0ms)  (pid 12403)
Compiled bootstrap-affix.js  (0ms)  (pid 12403)
Compiled bootstrap-alert.js  (0ms)  (pid 12403)
Compiled bootstrap-button.js  (0ms)  (pid 12403)
Compiled bootstrap-carousel.js  (0ms)  (pid 12403)
Compiled bootstrap-collapse.js  (0ms)  (pid 12403)
Compiled bootstrap-dropdown.js  (0ms)  (pid 12403)
Compiled bootstrap-modal.js  (0ms)  (pid 12403)
Compiled bootstrap-scrollspy.js  (0ms)  (pid 12403)
Compiled bootstrap-tab.js  (0ms)  (pid 12403)
Compiled bootstrap-tooltip.js  (0ms)  (pid 12403)
Compiled bootstrap-popover.js  (0ms)  (pid 12403)
Compiled bootstrap-typeahead.js  (0ms)  (pid 12403)
Compiled bootstrap.js  (177ms)  (pid 12403)
Compiled application.js  (292ms)  (pid 12403)
  Rendered layouts/_header.html.erb (1.6ms)
  Rendered layouts/_messages.html.erb (0.5ms)
  Rendered layouts/_prefooter.html.erb (0.3ms)
Completed 200 OK in 2857ms (Views: 2856.5ms | ActiveRecord: 0.0ms)


Started GET "/users/sign_up" for 127.0.0.1 at 2013-11-13 15:28:59 +0000
Processing by Devise::RegistrationsController#new as HTML
Completed 500 Internal Server Error in 116ms

ActiveRecord::StatementInvalid - Could not find table 'users':
  activerecord (3.2.12) lib/active_record/connection_adapters/sqlite_adapter.rb:472:in `table_structure'
  activerecord (3.2.12) lib/active_record/connection_adapters/sqlite_adapter.rb:346:in `columns'
  activerecord (3.2.12) lib/active_record/connection_adapters/schema_cache.rb:12:in `block in initialize'
  activerecord (3.2.12) lib/active_record/model_schema.rb:228:in `yield'
  activerecord (3.2.12) lib/active_record/model_schema.rb:228:in `default'
  activerecord (3.2.12) lib/active_record/model_schema.rb:228:in `columns'
  activerecord (3.2.12) lib/active_record/model_schema.rb:243:in `column_defaults'
  activerecord (3.2.12) lib/active_record/base.rb:482:in `initialize'
  devise (3.0.3) lib/devise/models/registerable.rb:20:in `new'
  devise (3.0.3) lib/devise/models/registerable.rb:20:in `new_with_session'
  devise (3.0.3) app/controllers/devise/registrations_controller.rb:86:in `build_resource'
  devise (3.0.3) app/controllers/devise/registrations_controller.rb:7:in `new'
  actionpack (3.2.12) lib/action_controller/metal/implicit_render.rb:4:in `send_action'
  actionpack (3.2.12) lib/abstract_controller/base.rb:167:in `process_action'
  actionpack (3.2.12) lib/action_controller/metal/rendering.rb:10:in `process_action'
  actionpack (3.2.12) lib/abstract_controller/callbacks.rb:18:in `block in process_action'
  activesupport (3.2.12) lib/active_support/callbacks.rb:436:in `_run__2400884731930759549__process_action__3746172446387351734__callbacks'
  activesupport (3.2.12) lib/active_support/callbacks.rb:405:in `__run_callback'
  activesupport (3.2.12) lib/active_support/callbacks.rb:385:in `_run_process_action_callbacks'
  activesupport (3.2.12) lib/active_support/callbacks.rb:81:in `run_callbacks'
  actionpack (3.2.12) lib/abstract_controller/callbacks.rb:17:in `process_action'
  actionpack (3.2.12) lib/action_controller/metal/rescue.rb:29:in `process_action'
  actionpack (3.2.12) lib/action_controller/metal/instrumentation.rb:30:in `block in process_action'
  activesupport (3.2.12) lib/active_support/notifications.rb:123:in `block in instrument'
  activesupport (3.2.12) lib/active_support/notifications/instrumenter.rb:20:in `instrument'
  activesupport (3.2.12) lib/active_support/notifications.rb:123:in `instrument'
  actionpack (3.2.12) lib/action_controller/metal/instrumentation.rb:29:in `process_action'
  actionpack (3.2.12) lib/action_controller/metal/params_wrapper.rb:207:in `process_action'
  activerecord (3.2.12) lib/active_record/railties/controller_runtime.rb:18:in `process_action'
  newrelic_rpm (3.6.6.147) lib/new_relic/agent/instrumentation/rails3/action_controller.rb:38:in `block in process_action'
  newrelic_rpm (3.6.6.147) lib/new_relic/agent/instrumentation/controller_instrumentation.rb:318:in `perform_action_with_newrelic_trace'
  newrelic_rpm (3.6.6.147) lib/new_relic/agent/instrumentation/rails3/action_controller.rb:37:in `process_action'
  actionpack (3.2.12) lib/abstract_controller/base.rb:121:in `process'
  actionpack (3.2.12) lib/abstract_controller/rendering.rb:45:in `process'
  actionpack (3.2.12) lib/action_controller/metal.rb:203:in `dispatch'
  actionpack (3.2.12) lib/action_controller/metal/rack_delegation.rb:14:in `dispatch'
  actionpack (3.2.12) lib/action_controller/metal.rb:246:in `block in action'
  actionpack (3.2.12) lib/action_dispatch/routing/route_set.rb:73:in `call'
  actionpack (3.2.12) lib/action_dispatch/routing/route_set.rb:73:in `dispatch'
  actionpack (3.2.12) lib/action_dispatch/routing/route_set.rb:36:in `call'
  actionpack (3.2.12) lib/action_dispatch/routing/mapper.rb:42:in `call'
  journey (1.0.4) lib/journey/router.rb:68:in `block in call'
  journey (1.0.4) lib/journey/router.rb:56:in `each'
  journey (1.0.4) lib/journey/router.rb:56:in `call'
  actionpack (3.2.12) lib/action_dispatch/routing/route_set.rb:601:in `call'
  newrelic_rpm (3.6.6.147) lib/new_relic/rack/error_collector.rb:43:in `call'
  newrelic_rpm (3.6.6.147) lib/new_relic/rack/agent_hooks.rb:22:in `call'
  newrelic_rpm (3.6.6.147) lib/new_relic/rack/browser_monitoring.rb:16:in `call'
  newrelic_rpm (3.6.6.147) lib/new_relic/rack/developer_mode.rb:28:in `call'
  warden (1.2.3) lib/warden/manager.rb:35:in `block in call'
  warden (1.2.3) lib/warden/manager.rb:34:in `catch'
  warden (1.2.3) lib/warden/manager.rb:34:in `call'
  actionpack (3.2.12) lib/action_dispatch/middleware/best_standards_support.rb:17:in `call'
  rack (1.4.5) lib/rack/etag.rb:23:in `call'
  rack (1.4.5) lib/rack/conditionalget.rb:25:in `call'
  actionpack (3.2.12) lib/action_dispatch/middleware/head.rb:14:in `call'
  actionpack (3.2.12) lib/action_dispatch/middleware/params_parser.rb:21:in `call'
  actionpack (3.2.12) lib/action_dispatch/middleware/flash.rb:242:in `call'
  rack (1.4.5) lib/rack/session/abstract/id.rb:210:in `context'
  rack (1.4.5) lib/rack/session/abstract/id.rb:205:in `call'
  actionpack (3.2.12) lib/action_dispatch/middleware/cookies.rb:341:in `call'
  activerecord (3.2.12) lib/active_record/query_cache.rb:64:in `call'
  activerecord (3.2.12) lib/active_record/connection_adapters/abstract/connection_pool.rb:479:in `call'
  actionpack (3.2.12) lib/action_dispatch/middleware/callbacks.rb:28:in `block in call'
  activesupport (3.2.12) lib/active_support/callbacks.rb:405:in `_run__869322832274693381__call__2997946480729260686__callbacks'
  activesupport (3.2.12) lib/active_support/callbacks.rb:405:in `__run_callback'
  activesupport (3.2.12) lib/active_support/callbacks.rb:385:in `_run_call_callbacks'
  activesupport (3.2.12) lib/active_support/callbacks.rb:81:in `run_callbacks'
  actionpack (3.2.12) lib/action_dispatch/middleware/callbacks.rb:27:in `call'
  actionpack (3.2.12) lib/action_dispatch/middleware/reloader.rb:65:in `call'
  actionpack (3.2.12) lib/action_dispatch/middleware/remote_ip.rb:31:in `call'
  better_errors (1.0.1) lib/better_errors/middleware.rb:84:in `protected_app_call'
  better_errors (1.0.1) lib/better_errors/middleware.rb:79:in `better_errors_call'
  better_errors (1.0.1) lib/better_errors/middleware.rb:56:in `call'
  actionpack (3.2.12) lib/action_dispatch/middleware/debug_exceptions.rb:16:in `call'
  actionpack (3.2.12) lib/action_dispatch/middleware/show_exceptions.rb:56:in `call'
  railties (3.2.12) lib/rails/rack/logger.rb:32:in `call_app'
  railties (3.2.12) lib/rails/rack/logger.rb:16:in `block in call'
  activesupport (3.2.12) lib/active_support/tagged_logging.rb:22:in `tagged'
  railties (3.2.12) lib/rails/rack/logger.rb:16:in `call'
  quiet_assets (1.0.2) lib/quiet_assets.rb:18:in `call_with_quiet_assets'
  actionpack (3.2.12) lib/action_dispatch/middleware/request_id.rb:22:in `call'
  rack (1.4.5) lib/rack/methodoverride.rb:21:in `call'
  rack (1.4.5) lib/rack/runtime.rb:17:in `call'
  activesupport (3.2.12) lib/active_support/cache/strategy/local_cache.rb:72:in `call'
  rack (1.4.5) lib/rack/lock.rb:15:in `call'
  actionpack (3.2.12) lib/action_dispatch/middleware/static.rb:62:in `call'
  railties (3.2.12) lib/rails/engine.rb:479:in `call'
  railties (3.2.12) lib/rails/application.rb:223:in `call'
  rack (1.4.5) lib/rack/content_length.rb:14:in `call'
  railties (3.2.12) lib/rails/rack/log_tailer.rb:17:in `call'
  thin (1.5.1) lib/thin/connection.rb:81:in `block in pre_process'
  thin (1.5.1) lib/thin/connection.rb:79:in `catch'
  thin (1.5.1) lib/thin/connection.rb:79:in `pre_process'
  thin (1.5.1) lib/thin/connection.rb:54:in `process'
  thin (1.5.1) lib/thin/connection.rb:39:in `receive_data'
  eventmachine (1.0.3) lib/eventmachine.rb:187:in `run_machine'
  eventmachine (1.0.3) lib/eventmachine.rb:187:in `run'
  thin (1.5.1) lib/thin/backends/base.rb:63:in `start'
  thin (1.5.1) lib/thin/server.rb:159:in `start'
  rack (1.4.5) lib/rack/handler/thin.rb:13:in `run'
  rack (1.4.5) lib/rack/server.rb:268:in `start'
  railties (3.2.12) lib/rails/commands/server.rb:70:in `start'
  railties (3.2.12) lib/rails/commands.rb:55:in `block in <top (required)>'
  railties (3.2.12) lib/rails/commands.rb:50:in `tap'
  railties (3.2.12) lib/rails/commands.rb:50:in `<top (required)>'
  script/rails:6:in `require'
  script/rails:6:in `<main>'



Started POST "/__better_errors/2186210340/variables" for 127.0.0.1 at 2013-11-13 15:28:59 +0000
Connecting to database specified by database.yml
  [1m[36m (0.1ms)[0m  [1mselect sqlite_version(*)[0m
  [1m[35m (1.8ms)[0m  CREATE TABLE "schema_migrations" ("version" varchar(255) NOT NULL) 
  [1m[36m (1.5ms)[0m  [1mCREATE UNIQUE INDEX "unique_schema_migrations" ON "schema_migrations" ("version")[0m
  [1m[35m (1.5ms)[0m  SELECT "schema_migrations"."version" FROM "schema_migrations" 
Migrating to DeviseCreateUsers (20130820150151)
  [1m[36m (0.0ms)[0m  [1mbegin transaction[0m
  [1m[35m (0.5ms)[0m  CREATE TABLE "users" ("id" INTEGER PRIMARY KEY AUTOINCREMENT NOT NULL, "email" varchar(255) DEFAULT '' NOT NULL, "encrypted_password" varchar(255) DEFAULT '' NOT NULL, "reset_password_token" varchar(255), "reset_password_sent_at" datetime, "remember_created_at" datetime, "sign_in_count" integer DEFAULT 0, "current_sign_in_at" datetime, "last_sign_in_at" datetime, "current_sign_in_ip" varchar(255), "last_sign_in_ip" varchar(255), "confirmation_token" varchar(255), "created_at" datetime NOT NULL, "updated_at" datetime NOT NULL) 
  [1m[36m (0.4ms)[0m  [1mCREATE UNIQUE INDEX "index_users_on_email" ON "users" ("email")[0m
  [1m[35m (0.2ms)[0m  CREATE UNIQUE INDEX "index_users_on_reset_password_token" ON "users" ("reset_password_token")
  [1m[36m (0.1ms)[0m  [1mINSERT INTO "schema_migrations" ("version") VALUES ('20130820150151')[0m
  [1m[35m (1.5ms)[0m  commit transaction
Migrating to AddNameToUsers (20130821113459)
  [1m[36m (0.0ms)[0m  [1mbegin transaction[0m
  [1m[35m (0.5ms)[0m  ALTER TABLE "users" ADD "name" varchar(255)
  [1m[36m (0.1ms)[0m  [1mINSERT INTO "schema_migrations" ("version") VALUES ('20130821113459')[0m
  [1m[35m (1.2ms)[0m  commit transaction
Migrating to AddCompanyToUsers (20130821122929)
  [1m[36m (0.0ms)[0m  [1mbegin transaction[0m
  [1m[35m (0.4ms)[0m  ALTER TABLE "users" ADD "company" varchar(255)
  [1m[36m (0.1ms)[0m  [1mINSERT INTO "schema_migrations" ("version") VALUES ('20130821122929')[0m
  [1m[35m (1.0ms)[0m  commit transaction
Migrating to AddJobToUsers (20130821123002)
  [1m[36m (0.0ms)[0m  [1mbegin transaction[0m
  [1m[35m (0.5ms)[0m  ALTER TABLE "users" ADD "job" varchar(255)
  [1m[36m (0.1ms)[0m  [1mINSERT INTO "schema_migrations" ("version") VALUES ('20130821123002')[0m
  [1m[35m (1.1ms)[0m  commit transaction
Migrating to AddHcpToUsers (20130822111502)
  [1m[36m (0.0ms)[0m  [1mbegin transaction[0m
  [1m[35m (0.5ms)[0m  ALTER TABLE "users" ADD "hcp" boolean
  [1m[36m (0.1ms)[0m  [1mINSERT INTO "schema_migrations" ("version") VALUES ('20130822111502')[0m
  [1m[35m (1.0ms)[0m  commit transaction
Migrating to AddReminderToUsers (20130822111843)
  [1m[36m (0.0ms)[0m  [1mbegin transaction[0m
  [1m[35m (0.5ms)[0m  ALTER TABLE "users" ADD "reminder" boolean
  [1m[36m (0.1ms)[0m  [1mINSERT INTO "schema_migrations" ("version") VALUES ('20130822111843')[0m
  [1m[35m (1.1ms)[0m  commit transaction
Migrating to AddNothcpToUsers (20130823123449)
  [1m[36m (0.0ms)[0m  [1mbegin transaction[0m
  [1m[35m (0.4ms)[0m  ALTER TABLE "users" ADD "nothcp" boolean
  [1m[36m (0.1ms)[0m  [1mINSERT INTO "schema_migrations" ("version") VALUES ('20130823123449')[0m
  [1m[35m (2.5ms)[0m  commit transaction
Migrating to AddFutureToUsers (20130920111529)
  [1m[36m (0.0ms)[0m  [1mbegin transaction[0m
  [1m[35m (0.4ms)[0m  ALTER TABLE "users" ADD "future" boolean
  [1m[36m (0.1ms)[0m  [1mINSERT INTO "schema_migrations" ("version") VALUES ('20130920111529')[0m
  [1m[35m (1.0ms)[0m  commit transaction
Migrating to DeviseCreateAdmins (20130923110231)
  [1m[36m (0.0ms)[0m  [1mbegin transaction[0m
  [1m[35m (0.5ms)[0m  CREATE TABLE "admins" ("id" INTEGER PRIMARY KEY AUTOINCREMENT NOT NULL, "email" varchar(255) DEFAULT '' NOT NULL, "encrypted_password" varchar(255) DEFAULT '' NOT NULL, "sign_in_count" integer DEFAULT 0, "current_sign_in_at" datetime, "last_sign_in_at" datetime, "current_sign_in_ip" varchar(255), "last_sign_in_ip" varchar(255), "failed_attempts" integer DEFAULT 0, "unlock_token" varchar(255), "locked_at" datetime, "created_at" datetime NOT NULL, "updated_at" datetime NOT NULL) 
  [1m[36m (0.1ms)[0m  [1mINSERT INTO "schema_migrations" ("version") VALUES ('20130923110231')[0m
  [1m[35m (2.2ms)[0m  commit transaction
  [1m[36m (0.1ms)[0m  [1mSELECT "schema_migrations"."version" FROM "schema_migrations" [0m


Started GET "/" for 127.0.0.1 at 2013-11-13 15:30:34 +0000
Processing by PagesController#preregistration as HTML
  Rendered layouts/_title.html.erb (0.0ms)
  Rendered layouts/_preregistration.html.erb (1.8ms)
  Rendered pages/preregistration.html.erb within layouts/application (9.2ms)
  Rendered layouts/_header.html.erb (0.4ms)
  Rendered layouts/_messages.html.erb (0.0ms)
  Rendered layouts/_prefooter.html.erb (0.0ms)
Completed 200 OK in 23ms (Views: 23.1ms | ActiveRecord: 0.0ms)
Connecting to database specified by database.yml


Started GET "/" for 127.0.0.1 at 2013-11-13 15:31:39 +0000
Processing by PagesController#preregistration as HTML
  Rendered layouts/_title.html.erb (0.2ms)
  Rendered layouts/_preregistration.html.erb (2.8ms)
  Rendered pages/preregistration.html.erb within layouts/application (28.0ms)
  Rendered layouts/_header.html.erb (1.3ms)
  Rendered layouts/_messages.html.erb (0.3ms)
  Rendered layouts/_prefooter.html.erb (0.2ms)
Completed 200 OK in 79ms (Views: 78.3ms | ActiveRecord: 0.0ms)


Started GET "/users/sign_up" for 127.0.0.1 at 2013-11-13 15:31:40 +0000
Processing by Devise::RegistrationsController#new as HTML
  Rendered layouts/_title.html.erb (0.0ms)
  Rendered devise/registrations/new.html.erb within layouts/application (305.4ms)
  Rendered layouts/_header.html.erb (0.7ms)
  Rendered layouts/_messages.html.erb (0.1ms)
  Rendered layouts/_prefooter.html.erb (0.0ms)
Completed 200 OK in 383ms (Views: 321.4ms | ActiveRecord: 2.3ms)


Started POST "/users" for 127.0.0.1 at 2013-11-13 15:31:54 +0000
Processing by Devise::RegistrationsController#create as HTML
  Parameters: {"utf8"=>"âœ“", "authenticity_token"=>"fv/q3tO+F/jqo7kU4suTdfbmQ4l+7Gwlrkx4aEG2/0I=", "user"=>{"name"=>"Branden", "email"=>"branden.mittra@streamingwell.com", "company"=>"", "job"=>"", "password"=>"[FILTERED]", "password_confirmation"=>"[FILTERED]", "reminder"=>"0", "future"=>"0"}, "commit"=>"Submit"}
  [1m[36m (0.1ms)[0m  [1mbegin transaction[0m
  [1m[35mUser Exists (0.1ms)[0m  SELECT 1 AS one FROM "users" WHERE "users"."email" = 'branden.mittra@streamingwell.com' LIMIT 1
Binary data inserted for `string` type on column `encrypted_password`
  [1m[36mSQL (34.0ms)[0m  [1mINSERT INTO "users" ("company", "confirmation_token", "created_at", "current_sign_in_at", "current_sign_in_ip", "email", "encrypted_password", "future", "hcp", "job", "last_sign_in_at", "last_sign_in_ip", "name", "nothcp", "remember_created_at", "reminder", "reset_password_sent_at", "reset_password_token", "sign_in_count", "updated_at") VALUES (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?)[0m  [["company", ""], ["confirmation_token", nil], ["created_at", Wed, 13 Nov 2013 15:31:54 UTC +00:00], ["current_sign_in_at", nil], ["current_sign_in_ip", nil], ["email", "branden.mittra@streamingwell.com"], ["encrypted_password", "$2a$10$jpTLNNZSqod4rvJhCHCbpuZsuba08oQymPnie4uZ.10AetvGMWLIS"], ["future", false], ["hcp", nil], ["job", ""], ["last_sign_in_at", nil], ["last_sign_in_ip", nil], ["name", "Branden"], ["nothcp", nil], ["remember_created_at", nil], ["reminder", false], ["reset_password_sent_at", nil], ["reset_password_token", nil], ["sign_in_count", 0], ["updated_at", Wed, 13 Nov 2013 15:31:54 UTC +00:00]]
  Rendered admin_mailer/registration_notification.text.erb (0.4ms)

Sent mail to branden.mittra@streamingwell.com (80ms)
Date: Wed, 13 Nov 2013 15:31:54 +0000
From: noreply@astellasoncology.co.uk
To: branden.mittra@streamingwell.com
Message-ID: <52839b6ab5468_30f080434a4c6179@Franciss-iMac.local.mail>
Subject: New Registration
Mime-Version: 1.0
Content-Type: text/plain;
 charset=UTF-8
Content-Transfer-Encoding: 7bit

New notification alert
--------------------------

The following user just registered:

Name: Branden
Email: branden.mittra@streamingwell.com
Place of Work: 
Job Title: 
Reminder Emails: false
Future contact: false

  Rendered user_mailer/welcome.html.erb within layouts/mail (2.0ms)
  Rendered user_mailer/welcome.text.erb (0.7ms)

Sent mail to branden.mittra@streamingwell.com (42ms)
Date: Wed, 13 Nov 2013 15:31:54 +0000
From: noreply@astellasoncology.co.uk
To: branden.mittra@streamingwell.com
Message-ID: <52839b6ad7ef2_30f080434a4c621f9@Franciss-iMac.local.mail>
Subject: Log-in details for the Prostate Cancer Lunchtime Webinars
Mime-Version: 1.0
Content-Type: multipart/alternative;
 boundary="--==_mimepart_52839b6ad457b_30f080434a4c618ea";
 charset=UTF-8
Content-Transfer-Encoding: 7bit



----==_mimepart_52839b6ad457b_30f080434a4c618ea
Date: Wed, 13 Nov 2013 15:31:54 +0000
Mime-Version: 1.0
Content-Type: text/plain;
 charset=UTF-8
Content-Transfer-Encoding: quoted-printable
Content-ID: <52839b6ad6fda_30f080434a4c6198a@Franciss-iMac.local.mail>

Prostate Cancer Lunchtime Webinars =

A multidisciplinary approach to prostate cancer understanding and managem=
ent
-------------------------------------------------------------------------=
---

Dear Branden

Thank you for registering your interest in the Astellas Oncology live web=
inars.


Your log-in details are as follows:
Username: branden.mittra@streamingwell.com
Password: emergo35

Please use these log-in details every time you wish to visit the webinar =
website:
www.astellasoncology.co.uk


The next live webinar is as follows:

Date: Tuesday 26th November 2013
Time: 12.30 to 13.15
Title: Working together: organising care for optimal management of prosta=
te cancer
Speaker(s): Dr Simon Hughes, Consultant in Clinical Oncology and Louisa F=
leure, Advanced Prostate Cancer Specialist Nurse Guy's Hospital, London

Summary: Dr Simon Hughes and Ms Louisa Fleure will provide expert first-h=
and insights regarding the successful management of patients with prostat=
e cancer in a multidisciplinary team (MDT) setup.
Topics:
The multidisciplinary team (MDT) structure and roles

Managing patients with differing needs in an MDT environment

Newly diagnosed patients

Patients with advanced disease

Meeting the challenges of a =E2=80=98working=E2=80=99 MDT at Guy=E2=80=99=
s Hospital



We do hope that you will be able to join us and you find the webinar inte=
resting and informative.

Please note, details regarding speakers, topics and timings for the full =
webinar programme are available on the website.

Yours sincerely,

Astellas Oncology

Astellas Pharma Ltd. =

2000 Hillswood Drive =

Chertsey =

KT16 0RS =

United Kingdom =

Registered in England and Wales under Registered No 00787610 =


Please do not reply to this email.
Date of preparation: September 2013 	Jobcode:XTD13057UKl
These webinars are organised and funded by Astellas Pharma Ltd.

-------------------------------------------------------------------------=
---

Important: The information transmitted in this message is intended only f=
or the person or entity to which it is addressed and may contain confiden=
tial and/or privileged material. Any review, retransmission, disseminatio=
n or other use of, or taking of any action in reliance upon, this informa=
tion by persons or entities other than the intended recipient is prohibit=
ed. If you receive this message in error, please contact the sender and d=
elete the material from any computer.

													=


														&nbsp;<a href=3D"*|UNSUB|*">unsubscribe from this list</a>&=
nbsp;
														<!-- // Begin PI \\ -->
												=


Xtandi&trade; (enzalutamide) Prescribing Information - For full prescribi=
ng information please refer to the Summary of Product Characteristics.

Presentation: Xtandi&trade; 40 mg soft capsules each containing 40 mg of =
enzalutamide.

Indication: Xtandi&trade; is indicated for the treatment of adult men wit=
h metastatic castration resistant prostate cancer whose disease has progr=
essed on or after docetaxel therapy

Posology and method of administration: Adults and elderly (=E2=89=A5 65 y=
ears of age): The recommended dose is 160 mg enzalutamide (four 40 mg cap=
sules) as a single oral daily dose. If a patient misses taking Xtandi&tra=
de; at the usual time, the prescribed dose should be taken as close as po=
ssible to the usual time.  If a patient misses a dose for a whole day, tr=
eatment should be resumed the following day with the usual daily dose.
If a patient experiences a =E2=89=A5 Grade 3 toxicity or an intolerable a=
dverse reaction, dosing should be withheld for one week or until symptoms=
 improve to =E2=89=A4 Grade 2, then resumed at the same or a reduced dose=
 (120 mg or 80 mg) if warranted.

Older people: No dose adjustment is necessary for older people.

Hepatic impairment: No dose adjustment is necessary for patients with mil=
d hepatic impairment; caution is advised in patients with moderate hepati=
c impairment; Xtandi&trade; is not recommended in patients with severe he=
patic impairment.

Renal impairment: No dose adjustment is necessary for patients with mild =
or moderate renal impairment.  Caution is advised in patients with severe=
 renal impairment or end stage renal disease. Paediatric population:There=
 is no relevant use of enzalutamide in the paediatric population.Contrace=
ption in males and females: It is not known whether enzalutamide or its m=
etabolites are present in semen. A condom is required during and for 3 mo=
nths after treatment with enzalutamide if the patient is engaged in sexua=
l activity with a pregnant woman. If the patient engages in sexual interc=
ourse with a woman of childbearing potential, a condom and another form o=
f birth control must be used during and for 3 months after treatment. Stu=
dies in animals have shown reproductive toxicity.

Contraindications: Hypersensitivity to the active substance or to any of =
the excipients.
	Women who are or may become pregnant.

	Warnings and Precautions: Caution should be used in administering Xtandi=
&trade; to patients with a history of seizures or otherpredisposing facto=
rs. In addition, the risk of seizure may be increased in patients receivi=
ng concomitant medicinal products that lower the seizure threshold. The A=
FFIRM study excluded patients with recent myocardial infarction, unstable=
 angina, heart failure, long QT, bradycardia or uncontrolled hypertension=
. This should be taken into account if Xtandi&trade; is prescribed in the=
se patients. =


	Xtandi&trade; contains sorbitol (E420). Patients with rare hereditary pr=
oblems of fructose intolerance should not take this medicinal product.

	Drug interactions: Strong inhibitors (e.g. gemfibrozil) or inducers (e.g=
. rifampicin) of CYP2C8 are to be avoided or used with caution during enz=
alutamide treatment. If patients must be co-administered a strong CYP2C8 =
inhibitor, the dose of enzalutamide should be reduced to 80 mg once daily=
 CYP3A4 plays a minor role in the metabolism of enzalutamide. No dose adj=
ustment is necessary when Xtandi&trade; is co-administered with inhibitor=
s or inducers of CYP3A4. Enzalutamide is a potent enzyme inducer and incr=
eases the synthesis of many enzymes and transporters; therefore, interact=
ion with many common medicinal products that are substrates of enzymes or=
 transporters is expected. Enzymes that may be induced include CYP3A4 in =
the liver and gut, CYP2C9, CYP2C19, CYP1A2 and uridine 5'-diphospho-glucu=
ronosyltransferase (UGTs - glucuronide conjugating enzymes). The transpor=
t protein P-gp may also be induced, and probably other transporters as we=
ll, e.g. multidrug resistance-associated protein 2 (MRP2), breast cancer =
resistant protein (BCRP) and the organic anion transporting polypeptide 1=
B1 (OATP1B1). In vivo studies have shown that enzalutamide is a strong in=
ducer of CYP3A4 and a moderate inducer of CYP2C9 and CYP2C19. The full in=
duction potential of enzalutamide may not occur until approximately 1 mon=
th after the start of treatment, when steady-state plasma concentrations =
of enzalutamide are reached, although some induction effects may be appar=
ent earlier. Patients taking medicinal products that are substrates of CY=
P3A4, CYP2C9, CYP2C19, CYP1A2 or UGT1A1 should be evaluated for possible =
loss of pharmacological effects (or increase in effects in cases where ac=
tive metabolites are formed) during the first month of enzalutamide treat=
ment, and dose adjustment should be considered as appropriate. If their t=
herapeutic effect is of large importance to the patient, and dose adjustm=
ents are not easily performed based on monitoring of efficacy or plasma c=
oncentrations, these medicinal products are to be avoided or used with ca=
ution. In consideration of the long half-life of enzalutamide (5.8 days),=
 effects on enzymes may persist for one month or longer after stopping en=
zalutamide. A gradual dose reduction of the concomitant medicinal product=
 may be necessary when stopping enzalutamide treatment. In vitro data ind=
icate that enzalutamide may be an inhibitor of the efflux transporter P-g=
p. The effect of enzalutamide on P-gp substrates has not been evaluated i=
n vivo; however, under conditions of clinical use, enzalutamide may be an=
 inducer of P-gp via activation of the nuclear pregnane receptor (PXR). M=
edicinal products with a narrow therapeutic range that are substrates for=
 P-gp (e.g. colchicine, dabigatran etexilate, digoxin) should be used wit=
h caution when administered concomitantly with Xtandi&trade; and may requ=
ire dose adjustment to maintain optimal plasma concentrations.
		The safety and efficacy of concomitant use of Xtandi&trade; with cytoto=
xic chemotherapy has not been established.

		Undesirable effects:  Very Common (=E2=89=A5 1/10): headache, hot flush=
; Common (=E2=89=A5 1/100 to < 1/10): neutropenia, visual hallucinations,=
 anxiety, cognitive disorders, memory impairment, hypertension, dry skin,=
 pruritus, fractures, falls; Uncommon (=E2=89=A5 1/1,000 to < 1/100): leu=
copenia, seizure, amnesia, disturbance in attention. (In the AFFIRM study=
, six patients (0.8%) experienced a seizure out of 800 patients treated w=
ith a daily dose of 160 mg enzalutamide).

		Packs and Cost: 40mg capsules x 112: =C2=A32,734.67 Legal Classificatio=
n: POM. Marketing authorisation number: EU/1/13/846/001

		Date of Preparation of PI: June 2013. Job number of PI: PRE13003UK  Fur=
ther information available from: Astellas Pharma Ltd, 2000 Hillswood Driv=
e, Chertsey. KT16 0RS.  For Medical Information phone: 0800 783 5018 =


		Adverse events should be reported. Reporting forms and information can =
be found at www.mhra.gov.uk/yellowcard. Adverse events should also be rep=
orted to Astellas Pharma Ltd. Please contact 0800 783 501 =


----==_mimepart_52839b6ad457b_30f080434a4c618ea
Date: Wed, 13 Nov 2013 15:31:54 +0000
Mime-Version: 1.0
Content-Type: text/html;
 charset=UTF-8
Content-Transfer-Encoding: quoted-printable
Content-ID: <52839b6ad7953_30f080434a4c620c@Franciss-iMac.local.mail>

<html>
<head>
  <title></title>
</head>
<body>
  <!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://=
www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html>
<head>
	<meta http-equiv=3D"Content-Type" content=3D"text/html; charset=3DUTF-8"=
 />

	<!-- Facebook sharing information tags -->
	<meta property=3D"og:title" content=3D"*|MC:SUBJECT|*" />

	<title>*|MC:SUBJECT|*</title>
	<style type=3D"text/css">
	/* Client-specific Styles */
	#outlook a{padding:0;} /* Force Outlook to provide a "view in browser" b=
utton. */
	body{width:100% !important;} .ReadMsgBody{width:100%;} .ExternalClass{wi=
dth:100%;} /* Force Hotmail to display emails at full width */
	body{-webkit-text-size-adjust:none;} /* Prevent Webkit platforms from ch=
anging default text sizes. */

	/* Reset Styles */
	body{margin:0; padding:0;}
	img{border:0; height:auto; line-height:100%; outline:none; text-decorati=
on:none;}
	table td{border-collapse:collapse;}
	#backgroundTable{height:100% !important; margin:0; padding:0; width:100%=
 !important;}

	/* Template Styles */

	/* /\/\/\/\/\/\/\/\/\/\ STANDARD STYLING: COMMON PAGE ELEMENTS /\/\/\/\/=
\/\/\/\/\/\ */

			/**
			* @tab Page
			* @section background color
			* @tip Set the background color for your email. You may want to choose=
 one that matches your company's branding.
			* @theme page
			*/
			body, #backgroundTable{
				/*@editable*/ background-color:#FAFAFA;

			}

			/**
			* @tab Page
			* @section email border
			* @tip Set the border for your email.
			*/
			#templateContainer{
				/*@editable*/ border: 1px solid #DDDDDD;
				background-image: url('http://streamingwell.tv/img/email-bg.jpg');
				background-repeat: no-repeat;
			}

			/**
			* @tab Page
			* @section heading 1
			* @tip Set the styling for all first-level headings in your emails. Th=
ese should be the largest of your headings.
			* @style heading 1
			*/
			h1, .h1{
				/*@editable*/ color:#939598;
				display:block;
				/*@editable*/ font-family:Arial;
				/*@editable*/ font-size:20px;
				/*@editable*/ font-weight:bold;
				/*@editable*/ line-height:100%;
				margin-top:10px;
				margin-right:0;
				margin-bottom:10px;
				margin-left:0;
				/*@editable*/ text-align:left;
			}

			/**
			* @tab Page
			* @section heading 2
			* @tip Set the styling for all second-level headings in your emails.
			* @style heading 2
			*/
			h2, .h2{
				/*@editable*/ color:#202020;
				display:block;
				/*@editable*/ font-family:Arial;
				/*@editable*/ font-size:30px;
				/*@editable*/ font-weight:bold;
				/*@editable*/ line-height:100%;
				margin-top:0;
				margin-right:0;
				margin-bottom:10px;
				margin-left:0;
				/*@editable*/ text-align:left;
			}

			/**
			* @tab Page
			* @section heading 3
			* @tip Set the styling for all third-level headings in your emails.
			* @style heading 3
			*/
			h3, .h3{
				/*@editable*/ color:#202020;
				display:block;
				/*@editable*/ font-family:Arial;
				/*@editable*/ font-size:26px;
				/*@editable*/ font-weight:bold;
				/*@editable*/ line-height:100%;
				margin-top:0;
				margin-right:0;
				margin-bottom:10px;
				margin-left:0;
				/*@editable*/ text-align:left;
			}

			/**
			* @tab Page
			* @section heading 4
			* @tip Set the styling for all fourth-level headings in your emails. T=
hese should be the smallest of your headings.
			* @style heading 4
			*/
			h4, .h4{
				/*@editable*/ color:#202020;
				display:block;
				/*@editable*/ font-family:Arial;
				/*@editable*/ font-size:11px;
				/*@editable*/ font-weight:100;
				/*@editable*/ line-height:100%;
				margin-top:0;
				margin-right:0;
				margin-bottom:10px;
				margin-left:0;
				/*@editable*/ text-align:left;
			}

			.h4 i {
				font-weight: 100;
				color: rgb(167, 43, 77);
				background: #fff;
			}



			/* /\/\/\/\/\/\/\/\/\/\ STANDARD STYLING: PREHEADER /\/\/\/\/\/\/\/\/\=
/\ */

			/**
			* @tab Header
			* @section preheader style
			* @tip Set the background color for your email's preheader area.
			* @theme page
			*/
			#templatePreheader{
				/*@editable*/ background-color:#FAFAFA;
			}

			/**
			* @tab Header
			* @section preheader text
			* @tip Set the styling for your email's preheader text. Choose a size =
and color that is easy to read.
			*/
			.preheaderContent div{
				/*@editable*/ color:#505050;
				/*@editable*/ font-family:Arial;
				/*@editable*/ font-size:10px;
				/*@editable*/ line-height:100%;
				/*@editable*/ text-align:left;
			}

			/**
			* @tab Header
			* @section preheader link
			* @tip Set the styling for your email's preheader links. Choose a colo=
r that helps them stand out from your text.
			*/
			.preheaderContent div a:link, .preheaderContent div a:visited, /* Yaho=
o! Mail Override */ .preheaderContent div a .yshortcuts /* Yahoo! Mail Ov=
erride */{
				/*@editable*/ color:#336699;
				/*@editable*/ font-weight:normal;
				/*@editable*/ text-decoration:underline;
			}



			/* /\/\/\/\/\/\/\/\/\/\ STANDARD STYLING: HEADER /\/\/\/\/\/\/\/\/\/\ =
*/

			/**
			* @tab Header
			* @section header style
			* @tip Set the background color and border for your email's header are=
a.
			* @theme header
			*/
			#templateHeader{
				/*@editable*/ background-color:#FFFFFF;
				/*@editable*/ border-bottom:0;
			}

			/**
			* @tab Header
			* @section header text
			* @tip Set the styling for your email's header text. Choose a size and=
 color that is easy to read.
			*/
			.headerContent{
				/*@editable*/ color:#202020;
				/*@editable*/ font-family:Arial;
				/*@editable*/ font-size:34px;
				/*@editable*/ font-weight:bold;
				/*@editable*/ line-height:100%;
				/*@editable*/ padding:0;
				/*@editable*/ text-align:center;
				/*@editable*/ vertical-align:middle;
			}

			/**
			* @tab Header
			* @section header link
			* @tip Set the styling for your email's header links. Choose a color t=
hat helps them stand out from your text.
			*/
			.headerContent a:link, .headerContent a:visited, /* Yahoo! Mail Overri=
de */ .headerContent a .yshortcuts /* Yahoo! Mail Override */{
				/*@editable*/ color:#336699;
				/*@editable*/ font-weight:normal;
				/*@editable*/ text-decoration:underline;
			}

			#headerImage{
				height:auto;
				max-width:600px;
			}

			/* /\/\/\/\/\/\/\/\/\/\ STANDARD STYLING: MAIN BODY /\/\/\/\/\/\/\/\/\=
/\ */

			/**
			* @tab Body
			* @section body style
			* @tip Set the background color for your email's body area.
			*/
			#templateContainer, .bodyContent{
				/*@editable*/ background-color:#FFFFFF;
				background-image: url('http://streamingwell.tv/img/email-bg.jpg');
				background-repeat: no-repeat;
			}

			/**
			* @tab Body
			* @section body text
			* @tip Set the styling for your email's main content text. Choose a si=
ze and color that is easy to read.
			* @theme main
			*/
			.bodyContent div{
				/*@editable*/ color:#505050;
				/*@editable*/ font-family:Arial;
				/*@editable*/ font-size:14px;
				/*@editable*/ line-height:150%;
				/*@editable*/ text-align:left;
			}

			/**
			* @tab Body
			* @section body link
			* @tip Set the styling for your email's main content links. Choose a c=
olor that helps them stand out from your text.
			*/
			.bodyContent div a:link, .bodyContent div a:visited, /* Yahoo! Mail Ov=
erride */ .bodyContent div a .yshortcuts /* Yahoo! Mail Override */{
				/*@editable*/ color:#336699;
				/*@editable*/ font-weight:normal;
				/*@editable*/ text-decoration:underline;
			}

			.bodyContent img{
				display:inline;
				height:auto;
			}

			/* /\/\/\/\/\/\/\/\/\/\ STANDARD STYLING: FOOTER /\/\/\/\/\/\/\/\/\/\ =
*/

			/**
			* @tab Footer
			* @section footer style
			* @tip Set the background color and top border for your email's footer=
 area.
			* @theme footer
			*/
			#templateFooter{
				/*@editable*/ background-color:#FFFFFF;
				/*@editable*/ border-top:0;
			}

			/**
			* @tab Footer
			* @section footer text
			* @tip Set the styling for your email's footer text. Choose a size and=
 color that is easy to read.
			* @theme footer
			*/
			.footerContent div{
				/*@editable*/ color:#707070;
				/*@editable*/ font-family:Arial;
				/*@editable*/ font-size:12px;
				/*@editable*/ line-height:125%;
				/*@editable*/ text-align:left;
			}

			/**
			* @tab Footer
			* @section footer link
			* @tip Set the styling for your email's footer links. Choose a color t=
hat helps them stand out from your text.
			*/
			.footerContent div a:link, .footerContent div a:visited, /* Yahoo! Mai=
l Override */ .footerContent div a .yshortcuts /* Yahoo! Mail Override */=
{
				/*@editable*/ color:#336699;
				/*@editable*/ font-weight:normal;
				/*@editable*/ text-decoration:underline;
			}

			.footerContent img{
				display:inline;
			}

			/**
			* @tab Footer
			* @section social bar style
			* @tip Set the background color and border for your email's footer soc=
ial bar.
			* @theme footer
			*/
			#social{
				/*@editable*/ background-color:#FAFAFA;
				/*@editable*/ border:0;
			}

			/**
			* @tab Footer
			* @section social bar style
			* @tip Set the background color and border for your email's footer soc=
ial bar.
			*/
			#social div{
				/*@editable*/ text-align:center;
			}

			/**
			* @tab Footer
			* @section utility bar style
			* @tip Set the background color and border for your email's footer uti=
lity bar.
			* @theme footer
			*/
			#utility{
				/*@editable*/ background-color:#FFFFFF;
				/*@editable*/ border:0;
			}

			/**
			* @tab Footer
			* @section utility bar style
			* @tip Set the background color and border for your email's footer uti=
lity bar.
			*/
			#utility div{
				/*@editable*/ text-align:center;
			}

			#monkeyRewards img{
				max-width:190px;
			}
			</style>
		</head>
		<body leftmargin=3D"0" marginwidth=3D"0" topmargin=3D"0" marginheight=3D=
"0" offset=3D"0">
			<center>
				<table border=3D"0" cellpadding=3D"0" cellspacing=3D"0" height=3D"100=
%" width=3D"100%" id=3D"backgroundTable">
					<tr>
						<td align=3D"center" valign=3D"top">
							<!-- // Begin Template Preheader \\ -->
							<table border=3D"0" cellpadding=3D"10" cellspacing=3D"0" width=3D"=
600" id=3D"templatePreheader">
								<tr>
									<td valign=3D"top" class=3D"preheaderContent">

										<!-- // Begin Module: Standard Preheader \ -->
										<table border=3D"0" cellpadding=3D"10" cellspacing=3D"0" width=3D=
"100%">
											<tr>
												<td valign=3D"top">
													<div mc:edit=3D"std_preheader_content"></div>
												</td>
												<!-- *|IFNOT:ARCHIVE_PAGE|* -->
												<td valign=3D"top" width=3D"190">
													<div mc:edit=3D"std_preheader_links"></div>
												</td>
												<!-- *|END:IF|* -->
											</tr>
										</table>
										<!-- // End Module: Standard Preheader \ -->

									</td>
								</tr>
							</table>

						</td>
					</tr>
					<tr>
						<td align=3D"center" valign=3D"top">
							<!-- // Begin Template Body \\ -->
							<table border=3D"0" cellpadding=3D"0" cellspacing=3D"0" width=3D"6=
00" id=3D"templateBody">
								<tr>
									<td valign=3D"top" class=3D"bodyContent">

										<!-- // Begin Module: Standard Postcard Content \\ -->
										<table border=3D"0" cellpadding=3D"20" cellspacing=3D"0" width=3D=
"80%">
											<tr mc:repeatable>
												<td valign=3D"top">
													<div mc:edit=3D"postcard_heading00">
														<img src=3D"http://img855.imageshack.us/img855/4207/aome.jp=
g">
														<h1 class=3D"h1"><span style=3D"color: rgb(167, 43, 77)">Pr=
ostate Cancer Lunchtime Webinars</span></h1>
														<h4><i>A multidisciplinary approach to prostate cancer unde=
rstanding and management</i></h4>
													</div>
													<br>
													<div mc:edit=3D"std_content00">
														<p>Dear Branden</p>

														<p>Thank you for registering your interest in the Astellas =
Oncology live webinars.</p>
														<p><strong>Your log-in details are as follows:</strong></p>=

														<p><strong>Username: branden.mittra@streamingwell.com</stro=
ng></p>
														<p><strong>Password: emergo35</strong></p>

														<p>Please use these log-in details every time you wish to v=
isit the webinar website: http://www.astellasoncology.co.uk/users/sign_in=
</p>

														<br>
														<p><strong>The next live webinar is as follows:</strong></p=
>

														<p>Date: Tuesday 26th November 2013</p>
														<p>Time: 12.30 to 13.15</p>
														<p><strong>Title:</strong><i>Working together: organising c=
are for optimal management of prostate cancer</i></p>
														<p><strong>Speaker(s):</strong>  Dr Simon Hughes, Consultan=
t in Clinical Oncology and Ms Louisa Fleure, Advanced Prostate Cancer Spe=
cialist Nurse Guy's Hospital, London</p>

														<p><strong>Summary:</strong>Dr Simon Hughes and Ms Louisa F=
leure will provide expert first-hand insights regarding the successful ma=
nagement of patients with prostate cancer in a multidisciplinary team (MD=
T) setup.</p>

														<p><strong>Topics:</strong></p>
														<p><li>The multidisciplinary team (MDT) structure and roles=
</li></p>

														<p><li>Managing patients with differing needs in an MDT env=
ironment</li></p>

														<p><li>Newly diagnosed patients</li></p>

														<p><li>Patients with advanced disease</li></p>

														<p><li>Meeting the challenges of a =E2=80=98working=E2=80=99=
 MDT at Guy=E2=80=99s Hospital</li></p>
														<br>
														<p>We do hope that you will be able to join us and you find=
 the webinar interesting and informative.</p>

														<p>Please note, details regarding speakers, topics and timi=
ngs for the full webinar programme are available on the website.</p>


														<p>Yours sincerely,</p>

														<p>Astellas Oncology</p>

                                                        </td>
                                                    </tr>
                                                </table>
                                                <!-- // End Module: Stand=
ard Postcard Content \\ -->
                                                =

                                            </td>
                                        </tr>
                                    </table>
                                    <!-- // End Template Body \\ -->
                                </td>
                            </tr>
                        	<tr>
                            	<td align=3D"center" valign=3D"top">
                                    <!-- // Begin Template Footer \\ -->
                                	<table border=3D"0" cellpadding=3D"10" c=
ellspacing=3D"0" width=3D"600" id=3D"templateFooter">
                                    	<tr>
                                        	<td valign=3D"top" class=3D"foot=
erContent">
                                            =

                                                <!-- // Begin Module: Sta=
ndard Footer \\ -->
                                                <table border=3D"0" cellp=
adding=3D"10" cellspacing=3D"0" width=3D"100%">
                                                    <tr>
                          =

                                                        <td valign=3D"top=
" width=3D"350">
                                                            <div mc:edit=3D=
"std_footer">
																<p><em>Astellas Pharma Ltd.</em> </p>
																<p><em>2000 Hillswood Drive </em></p>
																<p><em>Chertsey</em> </p>
																<p><em>KT16 0RS </em></p>
																<p><em>United Kingdom </em></p>
																<p><em>Registered in England and Wales under Registered N=
o 00787610 </em></p>
																<br />
																=

																<em>Please do not reply to this email</em>
																<em>Date of preparation: October 2013 Job code: XTD13057U=
Kl</em>
                                                            <p><em>These =
webinars are organised and funded by Astellas Pharma Ltd.</em></p>
												=

											=


															<small>Important: The information transmitted in this mess=
age is intended only for the person or entity to which it is addressed an=
d may contain confidential and/or privileged material. Any review, retran=
smission, dissemination or other use of, or taking of any action in relia=
nce upon, this information by persons or entities other than the intended=
 recipient is prohibited. If you receive this message in error, please co=
ntact the sender and delete the material from any computer.</small>

														<br>
														<br>
														&nbsp;<a href=3D"*|UNSUB|*">unsubscribe from this list</a>&=
nbsp;

														</div>
													</td>
												</tr>
														=

														<!-- // Begin PI \\ -->
                                                                <tr>
                                                        <td colspan=3D"2"=
 valign=3D"left">
                                                            <div>
                             =

<p><img src=3D"http://warm-dawn-9465.herokuapp.com/assets/xtandi-logo-134=
.png" align=3D"right"></p>

<br>
<br>     =


<p><strong>Xtandi&trade;</span> (enzalutamide) Prescribing Information -<=
/strong> For full prescribing information please refer to the Summary of =
Product Characteristics.</p>

<p><strong>Presentation:</strong> Xtandi&trade; 40 mg soft capsules each =
containing 40 mg of enzalutamide.</p>

<p><strong>Indication:</strong> Xtandi&trade; is indicated for the treatm=
ent of adult men with metastatic castration resistant prostate cancer who=
se disease has progressed on or after docetaxel therapy</p>

<p><strong>Posology and method of administration:</strong> Adults and eld=
erly (=E2=89=A5 65 years of age): The recommended dose is 160 mg enzaluta=
mide (four 40 mg capsules) as a single oral daily dose. If a patient miss=
es taking Xtandi&trade; at the usual time, the prescribed dose should be =
taken as close as possible to the usual time.  If a patient misses a dose=
 for a whole day, treatment should be resumed the following day with the =
usual daily dose.</p>
<p>If a patient experiences a =E2=89=A5 Grade 3 toxicity or an intolerabl=
e adverse reaction, dosing should be withheld for one week or until sympt=
oms improve to =E2=89=A4 Grade 2, then resumed at the same or a reduced d=
ose (120 mg or 80 mg) if warranted.</p>

<p>Older people: No dose adjustment is necessary for older people.</p>

<p>Hepatic impairment: No dose adjustment is necessary for patients with =
mild hepatic impairment; caution is advised in patients with moderate hep=
atic impairment; Xtandi&trade; is not recommended in patients with severe=
 hepatic impairment.</p>

<p>Renal impairment: No dose adjustment is necessary for patients with mi=
ld or moderate renal impairment.  Caution is advised in patients with sev=
ere renal impairment or end stage renal disease. Paediatric population:Th=
ere is no relevant use of enzalutamide in the paediatric population.Contr=
aception in males and females: It is not known whether enzalutamide or it=
s metabolites are present in semen. A condom is required during and for 3=
 months after treatment with enzalutamide if the patient is engaged in se=
xual activity with a pregnant woman. If the patient engages in sexual int=
ercourse with a woman of childbearing potential, a condom and another for=
m of birth control must be used during and for 3 months after treatment. =
Studies in animals have shown reproductive toxicity.</p>

<p><strong>Contraindications:</strong> Hypersensitivity to the active sub=
stance or to any of the excipients.
Women who are or may become pregnant.</p>

<p><strong>Warnings and Precautions:</strong> Caution should be used in a=
dministering Xtandi&trade; to patients with a history of seizures or othe=
rpredisposing factors. In addition, the risk of seizure may be increased =
in patients receiving concomitant medicinal products that lower the seizu=
re threshold. The AFFIRM study excluded patients with recent myocardial i=
nfarction, unstable angina, heart failure, long QT, bradycardia or uncont=
rolled hypertension. This should be taken into account if Xtandi&trade; i=
s prescribed in these patients. </p>

<p>Xtandi&trade; contains sorbitol (E420). Patients with rare hereditary =
problems of fructose intolerance should not take this medicinal product.<=
/p>

<p><strong>Drug interactions:</strong> Strong inhibitors (e.g. gemfibrozi=
l) or inducers (e.g. rifampicin) of CYP2C8 are to be avoided or used with=
 caution during enzalutamide treatment. If patients must be co-administer=
ed a strong CYP2C8 inhibitor, the dose of enzalutamide should be reduced =
to 80 mg once daily CYP3A4 plays a minor role in the metabolism of enzalu=
tamide. No dose adjustment is necessary when Xtandi&trade; is co-administ=
ered with inhibitors or inducers of CYP3A4. Enzalutamide is a potent enzy=
me inducer and increases the synthesis of many enzymes and transporters; =
therefore, interaction with many common medicinal products that are subst=
rates of enzymes or transporters is expected. Enzymes that may be induced=
 include CYP3A4 in the liver and gut, CYP2C9, CYP2C19, CYP1A2 and uridine=
 5'-diphospho-glucuronosyltransferase (UGTs - glucuronide conjugating enz=
ymes). The transport protein P-gp may also be induced, and probably other=
 transporters as well, e.g. multidrug resistance-associated protein 2 (MR=
P2), breast cancer resistant protein (BCRP) and the organic anion transpo=
rting polypeptide 1B1 (OATP1B1). In vivo studies have shown that enzaluta=
mide is a strong inducer of CYP3A4 and a moderate inducer of CYP2C9 and C=
YP2C19. The full induction potential of enzalutamide may not occur until =
approximately 1 month after the start of treatment, when steady-state pla=
sma concentrations of enzalutamide are reached, although some induction e=
ffects may be apparent earlier. Patients taking medicinal products that a=
re substrates of CYP3A4, CYP2C9, CYP2C19, CYP1A2 or UGT1A1 should be eval=
uated for possible loss of pharmacological effects (or increase in effect=
s in cases where active metabolites are formed) during the first month of=
 enzalutamide treatment, and dose adjustment should be considered as appr=
opriate. If their therapeutic effect is of large importance to the patien=
t, and dose adjustments are not easily performed based on monitoring of e=
fficacy or plasma concentrations, these medicinal products are to be avoi=
ded or used with caution. In consideration of the long half-life of enzal=
utamide (5.8 days), effects on enzymes may persist for one month or longe=
r after stopping enzalutamide. A gradual dose reduction of the concomitan=
t medicinal product may be necessary when stopping enzalutamide treatment=
. In vitro data indicate that enzalutamide may be an inhibitor of the eff=
lux transporter P-gp. The effect of enzalutamide on P-gp substrates has n=
ot been evaluated in vivo; however, under conditions of clinical use, enz=
alutamide may be an inducer of P-gp via activation of the nuclear pregnan=
e receptor (PXR). Medicinal products with a narrow therapeutic range that=
 are substrates for P-gp (e.g. colchicine, dabigatran etexilate, digoxin)=
 should be used with caution when administered concomitantly with Xtandi&=
trade; and may require dose adjustment to maintain optimal plasma concent=
rations.
The safety and efficacy of concomitant use of Xtandi&trade; with cytotoxi=
c chemotherapy has not been established.</p>

<p><strong>Undesirable effects:</strong>  Very Common (=E2=89=A5 1/10): h=
eadache, hot flush; Common (=E2=89=A5 1/100 to < 1/10): neutropenia, visu=
al hallucinations, anxiety, cognitive disorders, memory impairment, hyper=
tension, dry skin, pruritus, fractures, falls; Uncommon (=E2=89=A5 1/1,00=
0 to < 1/100): leucopenia, seizure, amnesia, disturbance in attention. (I=
n the AFFIRM study, six patients (0.8%) experienced a seizure out of 800 =
patients treated with a daily dose of 160 mg enzalutamide).</p>

<p><strong>Packs and Cost:</strong> 40mg capsules x 112: =C2=A32,734.67 L=
egal Classification: POM. Marketing authorisation number: EU/1/13/846/001=
</p>

<p><strong>Date of Preparation of PI:</strong> June 2013. <strong>Job num=
ber of PI:</strong> PRE13003UK  <strong>Further information available fro=
m:</strong> Astellas Pharma Ltd, 2000 Hillswood Drive, Chertsey. KT16 0RS=
.  <strong>For Medical Information phone:</strong> 0800 783 5018 </p>

<div class=3D"adverse">
<p>Adverse events should be reported. Reporting forms and information can=
 be found at <a href=3D"www.mhra.gov.uk/yellowcard">www.mhra.gov.uk/yello=
wcard</a>. Adverse events should also be reported to Astellas Pharma Ltd.=
 Please contact 0800 783 501 </p>
</div>
<!-- // Begin PI \\ -->
                                                            </div>
                                                        </td>
                                                    </tr>
                                                </table>
                                                <!-- // End Module: Stand=
ard Footer \\ -->
                                            =

                                            </td>
                                        </tr>
                                    </table>
                                    <!-- // End Template Footer \\ -->
                                </td>
                            </tr>
                        </table>
                        <br />
                    </td>
                </tr>
            </table>
        </center>
    </body>
</html>
</body>
</html>=


----==_mimepart_52839b6ad457b_30f080434a4c618ea--

  [1m[35m (3.1ms)[0m  commit transaction
  [1m[36m (0.1ms)[0m  [1mbegin transaction[0m
  [1m[35m (0.4ms)[0m  UPDATE "users" SET "last_sign_in_at" = '2013-11-13 15:31:54.928517', "current_sign_in_at" = '2013-11-13 15:31:54.928517', "last_sign_in_ip" = '127.0.0.1', "current_sign_in_ip" = '127.0.0.1', "sign_in_count" = 1, "updated_at" = '2013-11-13 15:31:54.930566' WHERE "users"."id" = 1
  [1m[36m (1.2ms)[0m  [1mcommit transaction[0m
Redirected to http://localhost:3000/
Completed 302 Found in 604ms (ActiveRecord: 0.0ms)


Started GET "/" for 127.0.0.1 at 2013-11-13 15:31:55 +0000
Processing by PagesController#preregistration as HTML
  [1m[35mUser Load (0.3ms)[0m  SELECT "users".* FROM "users" WHERE "users"."id" = 1 LIMIT 1
  Rendered layouts/_title.html.erb (0.1ms)
  Rendered pages/preregistration.html.erb within layouts/application (47.9ms)
  Rendered layouts/_header.html.erb (0.4ms)
  Rendered layouts/_messages.html.erb (0.1ms)
  Rendered layouts/_footer.html.erb (0.6ms)
Completed 200 OK in 64ms (Views: 63.7ms | ActiveRecord: 0.3ms)


Started DELETE "/users/sign_out" for 127.0.0.1 at 2013-11-13 15:41:04 +0000
Processing by Devise::SessionsController#destroy as HTML
  Parameters: {"authenticity_token"=>"fv/q3tO+F/jqo7kU4suTdfbmQ4l+7Gwlrkx4aEG2/0I="}
  [1m[36mUser Load (0.1ms)[0m  [1mSELECT "users".* FROM "users" WHERE "users"."id" = 1 LIMIT 1[0m
  [1m[35m (0.1ms)[0m  begin transaction
  [1m[36m (0.0ms)[0m  [1mcommit transaction[0m
Redirected to http://localhost:3000/
Completed 302 Found in 46ms (ActiveRecord: 1.0ms)


Started GET "/" for 127.0.0.1 at 2013-11-13 15:41:04 +0000
Processing by PagesController#preregistration as HTML
  Rendered layouts/_title.html.erb (0.0ms)
  Rendered layouts/_preregistration.html.erb (1.9ms)
  Rendered pages/preregistration.html.erb within layouts/application (3.6ms)
  Rendered layouts/_header.html.erb (0.5ms)
  Rendered layouts/_messages.html.erb (0.1ms)
  Rendered layouts/_prefooter.html.erb (0.0ms)
Completed 200 OK in 18ms (Views: 17.6ms | ActiveRecord: 0.0ms)


Started GET "/" for 127.0.0.1 at 2013-11-13 15:41:06 +0000
Processing by PagesController#preregistration as HTML
  Rendered layouts/_title.html.erb (0.0ms)
  Rendered layouts/_preregistration.html.erb (1.8ms)
  Rendered pages/preregistration.html.erb within layouts/application (3.6ms)
  Rendered layouts/_header.html.erb (0.6ms)
  Rendered layouts/_messages.html.erb (0.0ms)
  Rendered layouts/_prefooter.html.erb (0.0ms)
Completed 200 OK in 17ms (Views: 17.3ms | ActiveRecord: 0.0ms)


Started GET "/users/sign_up" for 127.0.0.1 at 2013-11-13 15:41:07 +0000
Processing by Devise::RegistrationsController#new as HTML
  Rendered layouts/_title.html.erb (0.0ms)
  Rendered devise/registrations/new.html.erb within layouts/application (8.8ms)
  Rendered layouts/_header.html.erb (0.6ms)
  Rendered layouts/_messages.html.erb (0.0ms)
  Rendered layouts/_prefooter.html.erb (0.0ms)
Completed 200 OK in 24ms (Views: 22.9ms | ActiveRecord: 0.0ms)


Started POST "/users" for 127.0.0.1 at 2013-11-13 15:41:18 +0000
Processing by Devise::RegistrationsController#create as HTML
  Parameters: {"utf8"=>"âœ“", "authenticity_token"=>"55TwsaOvdxZH/MZYsrAF66pJGRnWNT7M8x3WAG6138o=", "user"=>{"name"=>"Test", "email"=>"test@foobarstreamingwell.com", "company"=>"", "job"=>"", "password"=>"[FILTERED]", "password_confirmation"=>"[FILTERED]", "reminder"=>"0", "future"=>"0"}, "commit"=>"Submit"}
  [1m[35m (0.1ms)[0m  begin transaction
  [1m[36mUser Exists (0.1ms)[0m  [1mSELECT 1 AS one FROM "users" WHERE "users"."email" = 'test@foobarstreamingwell.com' LIMIT 1[0m
Binary data inserted for `string` type on column `encrypted_password`
  [1m[35mSQL (0.6ms)[0m  INSERT INTO "users" ("company", "confirmation_token", "created_at", "current_sign_in_at", "current_sign_in_ip", "email", "encrypted_password", "future", "hcp", "job", "last_sign_in_at", "last_sign_in_ip", "name", "nothcp", "remember_created_at", "reminder", "reset_password_sent_at", "reset_password_token", "sign_in_count", "updated_at") VALUES (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?)  [["company", ""], ["confirmation_token", nil], ["created_at", Wed, 13 Nov 2013 15:41:18 UTC +00:00], ["current_sign_in_at", nil], ["current_sign_in_ip", nil], ["email", "test@foobarstreamingwell.com"], ["encrypted_password", "$2a$10$8.4zYJ8Bx0ZVvzXmBr9Ehei32fcw9rQefSrsS8mAI1dn24ND/m4cq"], ["future", false], ["hcp", nil], ["job", ""], ["last_sign_in_at", nil], ["last_sign_in_ip", nil], ["name", "Test"], ["nothcp", nil], ["remember_created_at", nil], ["reminder", false], ["reset_password_sent_at", nil], ["reset_password_token", nil], ["sign_in_count", 0], ["updated_at", Wed, 13 Nov 2013 15:41:18 UTC +00:00]]
  Rendered admin_mailer/registration_notification.text.erb (0.1ms)

Sent mail to branden.mittra@streamingwell.com (42ms)
Date: Wed, 13 Nov 2013 15:41:18 +0000
From: noreply@astellasoncology.co.uk
To: branden.mittra@streamingwell.com
Message-ID: <52839d9eb4e16_30f080434a4c6222c@Franciss-iMac.local.mail>
Subject: New Registration
Mime-Version: 1.0
Content-Type: text/plain;
 charset=UTF-8
Content-Transfer-Encoding: 7bit

New notification alert
--------------------------

The following user just registered:

Name: Test
Email: test@foobarstreamingwell.com
Place of Work: 
Job Title: 
Reminder Emails: false
Future contact: false

  Rendered user_mailer/welcome.html.erb within layouts/mail (0.5ms)
  Rendered user_mailer/welcome.text.erb (0.1ms)

Sent mail to test@foobarstreamingwell.com (75ms)
Date: Wed, 13 Nov 2013 15:41:18 +0000
From: noreply@astellasoncology.co.uk
To: test@foobarstreamingwell.com
Message-ID: <52839d9ed032c_30f080434a4c62670@Franciss-iMac.local.mail>
Subject: Log-in details for the Prostate Cancer Lunchtime Webinars
Mime-Version: 1.0
Content-Type: multipart/alternative;
 boundary="--==_mimepart_52839d9ecd341_30f080434a4c6235a";
 charset=UTF-8
Content-Transfer-Encoding: 7bit



----==_mimepart_52839d9ecd341_30f080434a4c6235a
Date: Wed, 13 Nov 2013 15:41:18 +0000
Mime-Version: 1.0
Content-Type: text/plain;
 charset=UTF-8
Content-Transfer-Encoding: quoted-printable
Content-ID: <52839d9ecf406_30f080434a4c62477@Franciss-iMac.local.mail>

Prostate Cancer Lunchtime Webinars =

A multidisciplinary approach to prostate cancer understanding and managem=
ent
-------------------------------------------------------------------------=
---

Dear Test

Thank you for registering your interest in the Astellas Oncology live web=
inars.


Your log-in details are as follows:
Username: test@foobarstreamingwell.com
Password: foobar

Please use these log-in details every time you wish to visit the webinar =
website:
www.astellasoncology.co.uk


The next live webinar is as follows:

Date: Tuesday 26th November 2013
Time: 12.30 to 13.15
Title: Working together: organising care for optimal management of prosta=
te cancer
Speaker(s): Dr Simon Hughes, Consultant in Clinical Oncology and Louisa F=
leure, Advanced Prostate Cancer Specialist Nurse Guy's Hospital, London

Summary: Dr Simon Hughes and Ms Louisa Fleure will provide expert first-h=
and insights regarding the successful management of patients with prostat=
e cancer in a multidisciplinary team (MDT) setup.
Topics:
The multidisciplinary team (MDT) structure and roles

Managing patients with differing needs in an MDT environment

Newly diagnosed patients

Patients with advanced disease

Meeting the challenges of a =E2=80=98working=E2=80=99 MDT at Guy=E2=80=99=
s Hospital



We do hope that you will be able to join us and you find the webinar inte=
resting and informative.

Please note, details regarding speakers, topics and timings for the full =
webinar programme are available on the website.

Yours sincerely,

Astellas Oncology

Astellas Pharma Ltd. =

2000 Hillswood Drive =

Chertsey =

KT16 0RS =

United Kingdom =

Registered in England and Wales under Registered No 00787610 =


Please do not reply to this email.
Date of preparation: September 2013 	Jobcode:XTD13057UKl
These webinars are organised and funded by Astellas Pharma Ltd.

-------------------------------------------------------------------------=
---

Important: The information transmitted in this message is intended only f=
or the person or entity to which it is addressed and may contain confiden=
tial and/or privileged material. Any review, retransmission, disseminatio=
n or other use of, or taking of any action in reliance upon, this informa=
tion by persons or entities other than the intended recipient is prohibit=
ed. If you receive this message in error, please contact the sender and d=
elete the material from any computer.

													=


														&nbsp;<a href=3D"*|UNSUB|*">unsubscribe from this list</a>&=
nbsp;
														<!-- // Begin PI \\ -->
												=


Xtandi&trade; (enzalutamide) Prescribing Information - For full prescribi=
ng information please refer to the Summary of Product Characteristics.

Presentation: Xtandi&trade; 40 mg soft capsules each containing 40 mg of =
enzalutamide.

Indication: Xtandi&trade; is indicated for the treatment of adult men wit=
h metastatic castration resistant prostate cancer whose disease has progr=
essed on or after docetaxel therapy

Posology and method of administration: Adults and elderly (=E2=89=A5 65 y=
ears of age): The recommended dose is 160 mg enzalutamide (four 40 mg cap=
sules) as a single oral daily dose. If a patient misses taking Xtandi&tra=
de; at the usual time, the prescribed dose should be taken as close as po=
ssible to the usual time.  If a patient misses a dose for a whole day, tr=
eatment should be resumed the following day with the usual daily dose.
If a patient experiences a =E2=89=A5 Grade 3 toxicity or an intolerable a=
dverse reaction, dosing should be withheld for one week or until symptoms=
 improve to =E2=89=A4 Grade 2, then resumed at the same or a reduced dose=
 (120 mg or 80 mg) if warranted.

Older people: No dose adjustment is necessary for older people.

Hepatic impairment: No dose adjustment is necessary for patients with mil=
d hepatic impairment; caution is advised in patients with moderate hepati=
c impairment; Xtandi&trade; is not recommended in patients with severe he=
patic impairment.

Renal impairment: No dose adjustment is necessary for patients with mild =
or moderate renal impairment.  Caution is advised in patients with severe=
 renal impairment or end stage renal disease. Paediatric population:There=
 is no relevant use of enzalutamide in the paediatric population.Contrace=
ption in males and females: It is not known whether enzalutamide or its m=
etabolites are present in semen. A condom is required during and for 3 mo=
nths after treatment with enzalutamide if the patient is engaged in sexua=
l activity with a pregnant woman. If the patient engages in sexual interc=
ourse with a woman of childbearing potential, a condom and another form o=
f birth control must be used during and for 3 months after treatment. Stu=
dies in animals have shown reproductive toxicity.

Contraindications: Hypersensitivity to the active substance or to any of =
the excipients.
	Women who are or may become pregnant.

	Warnings and Precautions: Caution should be used in administering Xtandi=
&trade; to patients with a history of seizures or otherpredisposing facto=
rs. In addition, the risk of seizure may be increased in patients receivi=
ng concomitant medicinal products that lower the seizure threshold. The A=
FFIRM study excluded patients with recent myocardial infarction, unstable=
 angina, heart failure, long QT, bradycardia or uncontrolled hypertension=
. This should be taken into account if Xtandi&trade; is prescribed in the=
se patients. =


	Xtandi&trade; contains sorbitol (E420). Patients with rare hereditary pr=
oblems of fructose intolerance should not take this medicinal product.

	Drug interactions: Strong inhibitors (e.g. gemfibrozil) or inducers (e.g=
. rifampicin) of CYP2C8 are to be avoided or used with caution during enz=
alutamide treatment. If patients must be co-administered a strong CYP2C8 =
inhibitor, the dose of enzalutamide should be reduced to 80 mg once daily=
 CYP3A4 plays a minor role in the metabolism of enzalutamide. No dose adj=
ustment is necessary when Xtandi&trade; is co-administered with inhibitor=
s or inducers of CYP3A4. Enzalutamide is a potent enzyme inducer and incr=
eases the synthesis of many enzymes and transporters; therefore, interact=
ion with many common medicinal products that are substrates of enzymes or=
 transporters is expected. Enzymes that may be induced include CYP3A4 in =
the liver and gut, CYP2C9, CYP2C19, CYP1A2 and uridine 5'-diphospho-glucu=
ronosyltransferase (UGTs - glucuronide conjugating enzymes). The transpor=
t protein P-gp may also be induced, and probably other transporters as we=
ll, e.g. multidrug resistance-associated protein 2 (MRP2), breast cancer =
resistant protein (BCRP) and the organic anion transporting polypeptide 1=
B1 (OATP1B1). In vivo studies have shown that enzalutamide is a strong in=
ducer of CYP3A4 and a moderate inducer of CYP2C9 and CYP2C19. The full in=
duction potential of enzalutamide may not occur until approximately 1 mon=
th after the start of treatment, when steady-state plasma concentrations =
of enzalutamide are reached, although some induction effects may be appar=
ent earlier. Patients taking medicinal products that are substrates of CY=
P3A4, CYP2C9, CYP2C19, CYP1A2 or UGT1A1 should be evaluated for possible =
loss of pharmacological effects (or increase in effects in cases where ac=
tive metabolites are formed) during the first month of enzalutamide treat=
ment, and dose adjustment should be considered as appropriate. If their t=
herapeutic effect is of large importance to the patient, and dose adjustm=
ents are not easily performed based on monitoring of efficacy or plasma c=
oncentrations, these medicinal products are to be avoided or used with ca=
ution. In consideration of the long half-life of enzalutamide (5.8 days),=
 effects on enzymes may persist for one month or longer after stopping en=
zalutamide. A gradual dose reduction of the concomitant medicinal product=
 may be necessary when stopping enzalutamide treatment. In vitro data ind=
icate that enzalutamide may be an inhibitor of the efflux transporter P-g=
p. The effect of enzalutamide on P-gp substrates has not been evaluated i=
n vivo; however, under conditions of clinical use, enzalutamide may be an=
 inducer of P-gp via activation of the nuclear pregnane receptor (PXR). M=
edicinal products with a narrow therapeutic range that are substrates for=
 P-gp (e.g. colchicine, dabigatran etexilate, digoxin) should be used wit=
h caution when administered concomitantly with Xtandi&trade; and may requ=
ire dose adjustment to maintain optimal plasma concentrations.
		The safety and efficacy of concomitant use of Xtandi&trade; with cytoto=
xic chemotherapy has not been established.

		Undesirable effects:  Very Common (=E2=89=A5 1/10): headache, hot flush=
; Common (=E2=89=A5 1/100 to < 1/10): neutropenia, visual hallucinations,=
 anxiety, cognitive disorders, memory impairment, hypertension, dry skin,=
 pruritus, fractures, falls; Uncommon (=E2=89=A5 1/1,000 to < 1/100): leu=
copenia, seizure, amnesia, disturbance in attention. (In the AFFIRM study=
, six patients (0.8%) experienced a seizure out of 800 patients treated w=
ith a daily dose of 160 mg enzalutamide).

		Packs and Cost: 40mg capsules x 112: =C2=A32,734.67 Legal Classificatio=
n: POM. Marketing authorisation number: EU/1/13/846/001

		Date of Preparation of PI: June 2013. Job number of PI: PRE13003UK  Fur=
ther information available from: Astellas Pharma Ltd, 2000 Hillswood Driv=
e, Chertsey. KT16 0RS.  For Medical Information phone: 0800 783 5018 =


		Adverse events should be reported. Reporting forms and information can =
be found at www.mhra.gov.uk/yellowcard. Adverse events should also be rep=
orted to Astellas Pharma Ltd. Please contact 0800 783 501 =


----==_mimepart_52839d9ecd341_30f080434a4c6235a
Date: Wed, 13 Nov 2013 15:41:18 +0000
Mime-Version: 1.0
Content-Type: text/html;
 charset=UTF-8
Content-Transfer-Encoding: quoted-printable
Content-ID: <52839d9ecfdbd_30f080434a4c6252@Franciss-iMac.local.mail>

<html>
<head>
  <title></title>
</head>
<body>
  <!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://=
www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html>
<head>
	<meta http-equiv=3D"Content-Type" content=3D"text/html; charset=3DUTF-8"=
 />

	<!-- Facebook sharing information tags -->
	<meta property=3D"og:title" content=3D"*|MC:SUBJECT|*" />

	<title>*|MC:SUBJECT|*</title>
	<style type=3D"text/css">
	/* Client-specific Styles */
	#outlook a{padding:0;} /* Force Outlook to provide a "view in browser" b=
utton. */
	body{width:100% !important;} .ReadMsgBody{width:100%;} .ExternalClass{wi=
dth:100%;} /* Force Hotmail to display emails at full width */
	body{-webkit-text-size-adjust:none;} /* Prevent Webkit platforms from ch=
anging default text sizes. */

	/* Reset Styles */
	body{margin:0; padding:0;}
	img{border:0; height:auto; line-height:100%; outline:none; text-decorati=
on:none;}
	table td{border-collapse:collapse;}
	#backgroundTable{height:100% !important; margin:0; padding:0; width:100%=
 !important;}

	/* Template Styles */

	/* /\/\/\/\/\/\/\/\/\/\ STANDARD STYLING: COMMON PAGE ELEMENTS /\/\/\/\/=
\/\/\/\/\/\ */

			/**
			* @tab Page
			* @section background color
			* @tip Set the background color for your email. You may want to choose=
 one that matches your company's branding.
			* @theme page
			*/
			body, #backgroundTable{
				/*@editable*/ background-color:#FAFAFA;

			}

			/**
			* @tab Page
			* @section email border
			* @tip Set the border for your email.
			*/
			#templateContainer{
				/*@editable*/ border: 1px solid #DDDDDD;
				background-image: url('http://streamingwell.tv/img/email-bg.jpg');
				background-repeat: no-repeat;
			}

			/**
			* @tab Page
			* @section heading 1
			* @tip Set the styling for all first-level headings in your emails. Th=
ese should be the largest of your headings.
			* @style heading 1
			*/
			h1, .h1{
				/*@editable*/ color:#939598;
				display:block;
				/*@editable*/ font-family:Arial;
				/*@editable*/ font-size:20px;
				/*@editable*/ font-weight:bold;
				/*@editable*/ line-height:100%;
				margin-top:10px;
				margin-right:0;
				margin-bottom:10px;
				margin-left:0;
				/*@editable*/ text-align:left;
			}

			/**
			* @tab Page
			* @section heading 2
			* @tip Set the styling for all second-level headings in your emails.
			* @style heading 2
			*/
			h2, .h2{
				/*@editable*/ color:#202020;
				display:block;
				/*@editable*/ font-family:Arial;
				/*@editable*/ font-size:30px;
				/*@editable*/ font-weight:bold;
				/*@editable*/ line-height:100%;
				margin-top:0;
				margin-right:0;
				margin-bottom:10px;
				margin-left:0;
				/*@editable*/ text-align:left;
			}

			/**
			* @tab Page
			* @section heading 3
			* @tip Set the styling for all third-level headings in your emails.
			* @style heading 3
			*/
			h3, .h3{
				/*@editable*/ color:#202020;
				display:block;
				/*@editable*/ font-family:Arial;
				/*@editable*/ font-size:26px;
				/*@editable*/ font-weight:bold;
				/*@editable*/ line-height:100%;
				margin-top:0;
				margin-right:0;
				margin-bottom:10px;
				margin-left:0;
				/*@editable*/ text-align:left;
			}

			/**
			* @tab Page
			* @section heading 4
			* @tip Set the styling for all fourth-level headings in your emails. T=
hese should be the smallest of your headings.
			* @style heading 4
			*/
			h4, .h4{
				/*@editable*/ color:#202020;
				display:block;
				/*@editable*/ font-family:Arial;
				/*@editable*/ font-size:11px;
				/*@editable*/ font-weight:100;
				/*@editable*/ line-height:100%;
				margin-top:0;
				margin-right:0;
				margin-bottom:10px;
				margin-left:0;
				/*@editable*/ text-align:left;
			}

			.h4 i {
				font-weight: 100;
				color: rgb(167, 43, 77);
				background: #fff;
			}



			/* /\/\/\/\/\/\/\/\/\/\ STANDARD STYLING: PREHEADER /\/\/\/\/\/\/\/\/\=
/\ */

			/**
			* @tab Header
			* @section preheader style
			* @tip Set the background color for your email's preheader area.
			* @theme page
			*/
			#templatePreheader{
				/*@editable*/ background-color:#FAFAFA;
			}

			/**
			* @tab Header
			* @section preheader text
			* @tip Set the styling for your email's preheader text. Choose a size =
and color that is easy to read.
			*/
			.preheaderContent div{
				/*@editable*/ color:#505050;
				/*@editable*/ font-family:Arial;
				/*@editable*/ font-size:10px;
				/*@editable*/ line-height:100%;
				/*@editable*/ text-align:left;
			}

			/**
			* @tab Header
			* @section preheader link
			* @tip Set the styling for your email's preheader links. Choose a colo=
r that helps them stand out from your text.
			*/
			.preheaderContent div a:link, .preheaderContent div a:visited, /* Yaho=
o! Mail Override */ .preheaderContent div a .yshortcuts /* Yahoo! Mail Ov=
erride */{
				/*@editable*/ color:#336699;
				/*@editable*/ font-weight:normal;
				/*@editable*/ text-decoration:underline;
			}



			/* /\/\/\/\/\/\/\/\/\/\ STANDARD STYLING: HEADER /\/\/\/\/\/\/\/\/\/\ =
*/

			/**
			* @tab Header
			* @section header style
			* @tip Set the background color and border for your email's header are=
a.
			* @theme header
			*/
			#templateHeader{
				/*@editable*/ background-color:#FFFFFF;
				/*@editable*/ border-bottom:0;
			}

			/**
			* @tab Header
			* @section header text
			* @tip Set the styling for your email's header text. Choose a size and=
 color that is easy to read.
			*/
			.headerContent{
				/*@editable*/ color:#202020;
				/*@editable*/ font-family:Arial;
				/*@editable*/ font-size:34px;
				/*@editable*/ font-weight:bold;
				/*@editable*/ line-height:100%;
				/*@editable*/ padding:0;
				/*@editable*/ text-align:center;
				/*@editable*/ vertical-align:middle;
			}

			/**
			* @tab Header
			* @section header link
			* @tip Set the styling for your email's header links. Choose a color t=
hat helps them stand out from your text.
			*/
			.headerContent a:link, .headerContent a:visited, /* Yahoo! Mail Overri=
de */ .headerContent a .yshortcuts /* Yahoo! Mail Override */{
				/*@editable*/ color:#336699;
				/*@editable*/ font-weight:normal;
				/*@editable*/ text-decoration:underline;
			}

			#headerImage{
				height:auto;
				max-width:600px;
			}

			/* /\/\/\/\/\/\/\/\/\/\ STANDARD STYLING: MAIN BODY /\/\/\/\/\/\/\/\/\=
/\ */

			/**
			* @tab Body
			* @section body style
			* @tip Set the background color for your email's body area.
			*/
			#templateContainer, .bodyContent{
				/*@editable*/ background-color:#FFFFFF;
				background-image: url('http://streamingwell.tv/img/email-bg.jpg');
				background-repeat: no-repeat;
			}

			/**
			* @tab Body
			* @section body text
			* @tip Set the styling for your email's main content text. Choose a si=
ze and color that is easy to read.
			* @theme main
			*/
			.bodyContent div{
				/*@editable*/ color:#505050;
				/*@editable*/ font-family:Arial;
				/*@editable*/ font-size:14px;
				/*@editable*/ line-height:150%;
				/*@editable*/ text-align:left;
			}

			/**
			* @tab Body
			* @section body link
			* @tip Set the styling for your email's main content links. Choose a c=
olor that helps them stand out from your text.
			*/
			.bodyContent div a:link, .bodyContent div a:visited, /* Yahoo! Mail Ov=
erride */ .bodyContent div a .yshortcuts /* Yahoo! Mail Override */{
				/*@editable*/ color:#336699;
				/*@editable*/ font-weight:normal;
				/*@editable*/ text-decoration:underline;
			}

			.bodyContent img{
				display:inline;
				height:auto;
			}

			/* /\/\/\/\/\/\/\/\/\/\ STANDARD STYLING: FOOTER /\/\/\/\/\/\/\/\/\/\ =
*/

			/**
			* @tab Footer
			* @section footer style
			* @tip Set the background color and top border for your email's footer=
 area.
			* @theme footer
			*/
			#templateFooter{
				/*@editable*/ background-color:#FFFFFF;
				/*@editable*/ border-top:0;
			}

			/**
			* @tab Footer
			* @section footer text
			* @tip Set the styling for your email's footer text. Choose a size and=
 color that is easy to read.
			* @theme footer
			*/
			.footerContent div{
				/*@editable*/ color:#707070;
				/*@editable*/ font-family:Arial;
				/*@editable*/ font-size:12px;
				/*@editable*/ line-height:125%;
				/*@editable*/ text-align:left;
			}

			/**
			* @tab Footer
			* @section footer link
			* @tip Set the styling for your email's footer links. Choose a color t=
hat helps them stand out from your text.
			*/
			.footerContent div a:link, .footerContent div a:visited, /* Yahoo! Mai=
l Override */ .footerContent div a .yshortcuts /* Yahoo! Mail Override */=
{
				/*@editable*/ color:#336699;
				/*@editable*/ font-weight:normal;
				/*@editable*/ text-decoration:underline;
			}

			.footerContent img{
				display:inline;
			}

			/**
			* @tab Footer
			* @section social bar style
			* @tip Set the background color and border for your email's footer soc=
ial bar.
			* @theme footer
			*/
			#social{
				/*@editable*/ background-color:#FAFAFA;
				/*@editable*/ border:0;
			}

			/**
			* @tab Footer
			* @section social bar style
			* @tip Set the background color and border for your email's footer soc=
ial bar.
			*/
			#social div{
				/*@editable*/ text-align:center;
			}

			/**
			* @tab Footer
			* @section utility bar style
			* @tip Set the background color and border for your email's footer uti=
lity bar.
			* @theme footer
			*/
			#utility{
				/*@editable*/ background-color:#FFFFFF;
				/*@editable*/ border:0;
			}

			/**
			* @tab Footer
			* @section utility bar style
			* @tip Set the background color and border for your email's footer uti=
lity bar.
			*/
			#utility div{
				/*@editable*/ text-align:center;
			}

			#monkeyRewards img{
				max-width:190px;
			}
			</style>
		</head>
		<body leftmargin=3D"0" marginwidth=3D"0" topmargin=3D"0" marginheight=3D=
"0" offset=3D"0">
			<center>
				<table border=3D"0" cellpadding=3D"0" cellspacing=3D"0" height=3D"100=
%" width=3D"100%" id=3D"backgroundTable">
					<tr>
						<td align=3D"center" valign=3D"top">
							<!-- // Begin Template Preheader \\ -->
							<table border=3D"0" cellpadding=3D"10" cellspacing=3D"0" width=3D"=
600" id=3D"templatePreheader">
								<tr>
									<td valign=3D"top" class=3D"preheaderContent">

										<!-- // Begin Module: Standard Preheader \ -->
										<table border=3D"0" cellpadding=3D"10" cellspacing=3D"0" width=3D=
"100%">
											<tr>
												<td valign=3D"top">
													<div mc:edit=3D"std_preheader_content"></div>
												</td>
												<!-- *|IFNOT:ARCHIVE_PAGE|* -->
												<td valign=3D"top" width=3D"190">
													<div mc:edit=3D"std_preheader_links"></div>
												</td>
												<!-- *|END:IF|* -->
											</tr>
										</table>
										<!-- // End Module: Standard Preheader \ -->

									</td>
								</tr>
							</table>

						</td>
					</tr>
					<tr>
						<td align=3D"center" valign=3D"top">
							<!-- // Begin Template Body \\ -->
							<table border=3D"0" cellpadding=3D"0" cellspacing=3D"0" width=3D"6=
00" id=3D"templateBody">
								<tr>
									<td valign=3D"top" class=3D"bodyContent">

										<!-- // Begin Module: Standard Postcard Content \\ -->
										<table border=3D"0" cellpadding=3D"20" cellspacing=3D"0" width=3D=
"80%">
											<tr mc:repeatable>
												<td valign=3D"top">
													<div mc:edit=3D"postcard_heading00">
														<img src=3D"http://img855.imageshack.us/img855/4207/aome.jp=
g">
														<h1 class=3D"h1"><span style=3D"color: rgb(167, 43, 77)">Pr=
ostate Cancer Lunchtime Webinars</span></h1>
														<h4><i>A multidisciplinary approach to prostate cancer unde=
rstanding and management</i></h4>
													</div>
													<br>
													<div mc:edit=3D"std_content00">
														<p>Dear Test</p>

														<p>Thank you for registering your interest in the Astellas =
Oncology live webinars.</p>
														<p><strong>Your log-in details are as follows:</strong></p>=

														<p><strong>Username: test@foobarstreamingwell.com</strong><=
/p>
														<p><strong>Password: foobar</strong></p>

														<p>Please use these log-in details every time you wish to v=
isit the webinar website: http://www.astellasoncology.co.uk/users/sign_in=
</p>

														<br>
														<p><strong>The next live webinar is as follows:</strong></p=
>

														<p>Date: Tuesday 26th November 2013</p>
														<p>Time: 12.30 to 13.15</p>
														<p><strong>Title:</strong><i>Working together: organising c=
are for optimal management of prostate cancer</i></p>
														<p><strong>Speaker(s):</strong>  Dr Simon Hughes, Consultan=
t in Clinical Oncology and Ms Louisa Fleure, Advanced Prostate Cancer Spe=
cialist Nurse Guy's Hospital, London</p>

														<p><strong>Summary:</strong>Dr Simon Hughes and Ms Louisa F=
leure will provide expert first-hand insights regarding the successful ma=
nagement of patients with prostate cancer in a multidisciplinary team (MD=
T) setup.</p>

														<p><strong>Topics:</strong></p>
														<p><li>The multidisciplinary team (MDT) structure and roles=
</li></p>

														<p><li>Managing patients with differing needs in an MDT env=
ironment</li></p>

														<p><li>Newly diagnosed patients</li></p>

														<p><li>Patients with advanced disease</li></p>

														<p><li>Meeting the challenges of a =E2=80=98working=E2=80=99=
 MDT at Guy=E2=80=99s Hospital</li></p>
														<br>
														<p>We do hope that you will be able to join us and you find=
 the webinar interesting and informative.</p>

														<p>Please note, details regarding speakers, topics and timi=
ngs for the full webinar programme are available on the website.</p>


														<p>Yours sincerely,</p>

														<p>Astellas Oncology</p>

                                                        </td>
                                                    </tr>
                                                </table>
                                                <!-- // End Module: Stand=
ard Postcard Content \\ -->
                                                =

                                            </td>
                                        </tr>
                                    </table>
                                    <!-- // End Template Body \\ -->
                                </td>
                            </tr>
                        	<tr>
                            	<td align=3D"center" valign=3D"top">
                                    <!-- // Begin Template Footer \\ -->
                                	<table border=3D"0" cellpadding=3D"10" c=
ellspacing=3D"0" width=3D"600" id=3D"templateFooter">
                                    	<tr>
                                        	<td valign=3D"top" class=3D"foot=
erContent">
                                            =

                                                <!-- // Begin Module: Sta=
ndard Footer \\ -->
                                                <table border=3D"0" cellp=
adding=3D"10" cellspacing=3D"0" width=3D"100%">
                                                    <tr>
                          =

                                                        <td valign=3D"top=
" width=3D"350">
                                                            <div mc:edit=3D=
"std_footer">
																<p><em>Astellas Pharma Ltd.</em> </p>
																<p><em>2000 Hillswood Drive </em></p>
																<p><em>Chertsey</em> </p>
																<p><em>KT16 0RS </em></p>
																<p><em>United Kingdom </em></p>
																<p><em>Registered in England and Wales under Registered N=
o 00787610 </em></p>
																<br />
																=

																<em>Please do not reply to this email</em>
																<em>Date of preparation: October 2013 Job code: XTD13057U=
Kl</em>
                                                            <p><em>These =
webinars are organised and funded by Astellas Pharma Ltd.</em></p>
												=

											=


															<small>Important: The information transmitted in this mess=
age is intended only for the person or entity to which it is addressed an=
d may contain confidential and/or privileged material. Any review, retran=
smission, dissemination or other use of, or taking of any action in relia=
nce upon, this information by persons or entities other than the intended=
 recipient is prohibited. If you receive this message in error, please co=
ntact the sender and delete the material from any computer.</small>

														<br>
														<br>
														&nbsp;<a href=3D"*|UNSUB|*">unsubscribe from this list</a>&=
nbsp;

														</div>
													</td>
												</tr>
														=

														<!-- // Begin PI \\ -->
                                                                <tr>
                                                        <td colspan=3D"2"=
 valign=3D"left">
                                                            <div>
                             =

<p><img src=3D"http://warm-dawn-9465.herokuapp.com/assets/xtandi-logo-134=
.png" align=3D"right"></p>

<br>
<br>     =


<p><strong>Xtandi&trade;</span> (enzalutamide) Prescribing Information -<=
/strong> For full prescribing information please refer to the Summary of =
Product Characteristics.</p>

<p><strong>Presentation:</strong> Xtandi&trade; 40 mg soft capsules each =
containing 40 mg of enzalutamide.</p>

<p><strong>Indication:</strong> Xtandi&trade; is indicated for the treatm=
ent of adult men with metastatic castration resistant prostate cancer who=
se disease has progressed on or after docetaxel therapy</p>

<p><strong>Posology and method of administration:</strong> Adults and eld=
erly (=E2=89=A5 65 years of age): The recommended dose is 160 mg enzaluta=
mide (four 40 mg capsules) as a single oral daily dose. If a patient miss=
es taking Xtandi&trade; at the usual time, the prescribed dose should be =
taken as close as possible to the usual time.  If a patient misses a dose=
 for a whole day, treatment should be resumed the following day with the =
usual daily dose.</p>
<p>If a patient experiences a =E2=89=A5 Grade 3 toxicity or an intolerabl=
e adverse reaction, dosing should be withheld for one week or until sympt=
oms improve to =E2=89=A4 Grade 2, then resumed at the same or a reduced d=
ose (120 mg or 80 mg) if warranted.</p>

<p>Older people: No dose adjustment is necessary for older people.</p>

<p>Hepatic impairment: No dose adjustment is necessary for patients with =
mild hepatic impairment; caution is advised in patients with moderate hep=
atic impairment; Xtandi&trade; is not recommended in patients with severe=
 hepatic impairment.</p>

<p>Renal impairment: No dose adjustment is necessary for patients with mi=
ld or moderate renal impairment.  Caution is advised in patients with sev=
ere renal impairment or end stage renal disease. Paediatric population:Th=
ere is no relevant use of enzalutamide in the paediatric population.Contr=
aception in males and females: It is not known whether enzalutamide or it=
s metabolites are present in semen. A condom is required during and for 3=
 months after treatment with enzalutamide if the patient is engaged in se=
xual activity with a pregnant woman. If the patient engages in sexual int=
ercourse with a woman of childbearing potential, a condom and another for=
m of birth control must be used during and for 3 months after treatment. =
Studies in animals have shown reproductive toxicity.</p>

<p><strong>Contraindications:</strong> Hypersensitivity to the active sub=
stance or to any of the excipients.
Women who are or may become pregnant.</p>

<p><strong>Warnings and Precautions:</strong> Caution should be used in a=
dministering Xtandi&trade; to patients with a history of seizures or othe=
rpredisposing factors. In addition, the risk of seizure may be increased =
in patients receiving concomitant medicinal products that lower the seizu=
re threshold. The AFFIRM study excluded patients with recent myocardial i=
nfarction, unstable angina, heart failure, long QT, bradycardia or uncont=
rolled hypertension. This should be taken into account if Xtandi&trade; i=
s prescribed in these patients. </p>

<p>Xtandi&trade; contains sorbitol (E420). Patients with rare hereditary =
problems of fructose intolerance should not take this medicinal product.<=
/p>

<p><strong>Drug interactions:</strong> Strong inhibitors (e.g. gemfibrozi=
l) or inducers (e.g. rifampicin) of CYP2C8 are to be avoided or used with=
 caution during enzalutamide treatment. If patients must be co-administer=
ed a strong CYP2C8 inhibitor, the dose of enzalutamide should be reduced =
to 80 mg once daily CYP3A4 plays a minor role in the metabolism of enzalu=
tamide. No dose adjustment is necessary when Xtandi&trade; is co-administ=
ered with inhibitors or inducers of CYP3A4. Enzalutamide is a potent enzy=
me inducer and increases the synthesis of many enzymes and transporters; =
therefore, interaction with many common medicinal products that are subst=
rates of enzymes or transporters is expected. Enzymes that may be induced=
 include CYP3A4 in the liver and gut, CYP2C9, CYP2C19, CYP1A2 and uridine=
 5'-diphospho-glucuronosyltransferase (UGTs - glucuronide conjugating enz=
ymes). The transport protein P-gp may also be induced, and probably other=
 transporters as well, e.g. multidrug resistance-associated protein 2 (MR=
P2), breast cancer resistant protein (BCRP) and the organic anion transpo=
rting polypeptide 1B1 (OATP1B1). In vivo studies have shown that enzaluta=
mide is a strong inducer of CYP3A4 and a moderate inducer of CYP2C9 and C=
YP2C19. The full induction potential of enzalutamide may not occur until =
approximately 1 month after the start of treatment, when steady-state pla=
sma concentrations of enzalutamide are reached, although some induction e=
ffects may be apparent earlier. Patients taking medicinal products that a=
re substrates of CYP3A4, CYP2C9, CYP2C19, CYP1A2 or UGT1A1 should be eval=
uated for possible loss of pharmacological effects (or increase in effect=
s in cases where active metabolites are formed) during the first month of=
 enzalutamide treatment, and dose adjustment should be considered as appr=
opriate. If their therapeutic effect is of large importance to the patien=
t, and dose adjustments are not easily performed based on monitoring of e=
fficacy or plasma concentrations, these medicinal products are to be avoi=
ded or used with caution. In consideration of the long half-life of enzal=
utamide (5.8 days), effects on enzymes may persist for one month or longe=
r after stopping enzalutamide. A gradual dose reduction of the concomitan=
t medicinal product may be necessary when stopping enzalutamide treatment=
. In vitro data indicate that enzalutamide may be an inhibitor of the eff=
lux transporter P-gp. The effect of enzalutamide on P-gp substrates has n=
ot been evaluated in vivo; however, under conditions of clinical use, enz=
alutamide may be an inducer of P-gp via activation of the nuclear pregnan=
e receptor (PXR). Medicinal products with a narrow therapeutic range that=
 are substrates for P-gp (e.g. colchicine, dabigatran etexilate, digoxin)=
 should be used with caution when administered concomitantly with Xtandi&=
trade; and may require dose adjustment to maintain optimal plasma concent=
rations.
The safety and efficacy of concomitant use of Xtandi&trade; with cytotoxi=
c chemotherapy has not been established.</p>

<p><strong>Undesirable effects:</strong>  Very Common (=E2=89=A5 1/10): h=
eadache, hot flush; Common (=E2=89=A5 1/100 to < 1/10): neutropenia, visu=
al hallucinations, anxiety, cognitive disorders, memory impairment, hyper=
tension, dry skin, pruritus, fractures, falls; Uncommon (=E2=89=A5 1/1,00=
0 to < 1/100): leucopenia, seizure, amnesia, disturbance in attention. (I=
n the AFFIRM study, six patients (0.8%) experienced a seizure out of 800 =
patients treated with a daily dose of 160 mg enzalutamide).</p>

<p><strong>Packs and Cost:</strong> 40mg capsules x 112: =C2=A32,734.67 L=
egal Classification: POM. Marketing authorisation number: EU/1/13/846/001=
</p>

<p><strong>Date of Preparation of PI:</strong> June 2013. <strong>Job num=
ber of PI:</strong> PRE13003UK  <strong>Further information available fro=
m:</strong> Astellas Pharma Ltd, 2000 Hillswood Drive, Chertsey. KT16 0RS=
.  <strong>For Medical Information phone:</strong> 0800 783 5018 </p>

<div class=3D"adverse">
<p>Adverse events should be reported. Reporting forms and information can=
 be found at <a href=3D"www.mhra.gov.uk/yellowcard">www.mhra.gov.uk/yello=
wcard</a>. Adverse events should also be reported to Astellas Pharma Ltd.=
 Please contact 0800 783 501 </p>
</div>
<!-- // Begin PI \\ -->
                                                            </div>
                                                        </td>
                                                    </tr>
                                                </table>
                                                <!-- // End Module: Stand=
ard Footer \\ -->
                                            =

                                            </td>
                                        </tr>
                                    </table>
                                    <!-- // End Template Footer \\ -->
                                </td>
                            </tr>
                        </table>
                        <br />
                    </td>
                </tr>
            </table>
        </center>
    </body>
</html>
</body>
</html>=


----==_mimepart_52839d9ecd341_30f080434a4c6235a--

  [1m[36m (8.2ms)[0m  [1mcommit transaction[0m
  [1m[35m (0.1ms)[0m  begin transaction
  [1m[36m (0.3ms)[0m  [1mUPDATE "users" SET "last_sign_in_at" = '2013-11-13 15:41:18.932309', "current_sign_in_at" = '2013-11-13 15:41:18.932309', "last_sign_in_ip" = '127.0.0.1', "current_sign_in_ip" = '127.0.0.1', "sign_in_count" = 1, "updated_at" = '2013-11-13 15:41:18.933627' WHERE "users"."id" = 2[0m
  [1m[35m (8.5ms)[0m  commit transaction
Redirected to http://localhost:3000/
Completed 302 Found in 313ms (ActiveRecord: 0.0ms)


Started GET "/" for 127.0.0.1 at 2013-11-13 15:41:18 +0000
Processing by PagesController#preregistration as HTML
  [1m[36mUser Load (0.3ms)[0m  [1mSELECT "users".* FROM "users" WHERE "users"."id" = 2 LIMIT 1[0m
  Rendered layouts/_title.html.erb (0.0ms)
  Rendered pages/preregistration.html.erb within layouts/application (5.3ms)
  Rendered layouts/_header.html.erb (0.4ms)
  Rendered layouts/_messages.html.erb (0.1ms)
  Rendered layouts/_footer.html.erb (0.2ms)
Completed 200 OK in 21ms (Views: 20.4ms | ActiveRecord: 0.3ms)


Started DELETE "/users/sign_out" for 127.0.0.1 at 2013-11-13 15:41:25 +0000
Processing by Devise::SessionsController#destroy as HTML
  Parameters: {"authenticity_token"=>"55TwsaOvdxZH/MZYsrAF66pJGRnWNT7M8x3WAG6138o="}
  [1m[35mUser Load (0.2ms)[0m  SELECT "users".* FROM "users" WHERE "users"."id" = 2 LIMIT 1
  [1m[36m (0.0ms)[0m  [1mbegin transaction[0m
  [1m[35m (0.0ms)[0m  commit transaction
Redirected to http://localhost:3000/
Completed 302 Found in 4ms (ActiveRecord: 0.3ms)


Started GET "/" for 127.0.0.1 at 2013-11-13 15:41:25 +0000
Processing by PagesController#preregistration as HTML
  Rendered layouts/_title.html.erb (0.0ms)
  Rendered layouts/_preregistration.html.erb (2.3ms)
  Rendered pages/preregistration.html.erb within layouts/application (4.5ms)
  Rendered layouts/_header.html.erb (0.5ms)
  Rendered layouts/_messages.html.erb (0.1ms)
  Rendered layouts/_prefooter.html.erb (0.0ms)
Completed 200 OK in 18ms (Views: 17.5ms | ActiveRecord: 0.0ms)


Started GET "/login" for 127.0.0.1 at 2013-11-13 15:41:26 +0000
Processing by PagesController#login as HTML
  Rendered layouts/_title.html.erb (0.0ms)
  Rendered pages/login.html.erb within layouts/application (26.5ms)
  Rendered layouts/_header.html.erb (0.7ms)
  Rendered layouts/_messages.html.erb (0.0ms)
  Rendered layouts/_prefooter.html.erb (0.0ms)
Completed 200 OK in 41ms (Views: 40.5ms | ActiveRecord: 0.0ms)


Started POST "/users/sign_in" for 127.0.0.1 at 2013-11-13 15:41:32 +0000
Processing by Devise::SessionsController#create as HTML
  Parameters: {"utf8"=>"âœ“", "authenticity_token"=>"ee11eHyjNCsg3clCrdYAXDRic1iV3IG5decub1SxRbo=", "user"=>{"email"=>"branden.mittra@streamingwell.com", "password"=>"[FILTERED]"}, "commit"=>"Login"}
  [1m[36mUser Load (0.3ms)[0m  [1mSELECT "users".* FROM "users" WHERE "users"."email" = 'branden.mittra@streamingwell.com' LIMIT 1[0m
  [1m[35m (0.1ms)[0m  begin transaction
  [1m[36m (0.3ms)[0m  [1mUPDATE "users" SET "current_sign_in_at" = '2013-11-13 15:41:32.155597', "sign_in_count" = 2, "updated_at" = '2013-11-13 15:41:32.156858' WHERE "users"."id" = 1[0m
  [1m[35m (1.4ms)[0m  commit transaction
Redirected to http://localhost:3000/
Completed 302 Found in 118ms (ActiveRecord: 0.0ms)


Started GET "/" for 127.0.0.1 at 2013-11-13 15:41:32 +0000
Processing by PagesController#preregistration as HTML
  [1m[36mUser Load (0.2ms)[0m  [1mSELECT "users".* FROM "users" WHERE "users"."id" = 1 LIMIT 1[0m
  Rendered layouts/_title.html.erb (0.0ms)
  Rendered pages/preregistration.html.erb within layouts/application (4.6ms)
  Rendered layouts/_header.html.erb (0.3ms)
  Rendered layouts/_messages.html.erb (0.1ms)
  Rendered layouts/_footer.html.erb (0.1ms)
Completed 200 OK in 18ms (Views: 17.5ms | ActiveRecord: 0.2ms)


Started GET "/" for 127.0.0.1 at 2013-11-13 15:59:12 +0000
Processing by PagesController#preregistration as HTML
  [1m[35mUser Load (0.2ms)[0m  SELECT "users".* FROM "users" WHERE "users"."id" = 1 LIMIT 1
  Rendered layouts/_title.html.erb (0.0ms)
  Rendered pages/preregistration.html.erb within layouts/application (4.6ms)
  Rendered layouts/_header.html.erb (0.3ms)
  Rendered layouts/_messages.html.erb (0.0ms)
  Rendered layouts/_footer.html.erb (0.1ms)
Completed 200 OK in 48ms (Views: 47.7ms | ActiveRecord: 0.2ms)


Started DELETE "/users/sign_out" for 127.0.0.1 at 2013-11-13 15:59:14 +0000
Processing by Devise::SessionsController#destroy as HTML
  Parameters: {"authenticity_token"=>"+uEad6TU2vrga1Q4zDMbDm29Jyni76O0u0mzCvETm7g="}
  [1m[36mUser Load (0.2ms)[0m  [1mSELECT "users".* FROM "users" WHERE "users"."id" = 1 LIMIT 1[0m
  [1m[35m (0.1ms)[0m  begin transaction
  [1m[36m (0.0ms)[0m  [1mcommit transaction[0m
Redirected to http://localhost:3000/
Completed 302 Found in 5ms (ActiveRecord: 0.3ms)


Started GET "/" for 127.0.0.1 at 2013-11-13 15:59:14 +0000
Processing by PagesController#preregistration as HTML
  Rendered layouts/_title.html.erb (0.0ms)
  Rendered layouts/_preregistration.html.erb (2.3ms)
  Rendered pages/preregistration.html.erb within layouts/application (20.6ms)
  Rendered layouts/_header.html.erb (0.7ms)
  Rendered layouts/_messages.html.erb (0.1ms)
  Rendered layouts/_prefooter.html.erb (0.0ms)
Completed 200 OK in 36ms (Views: 35.8ms | ActiveRecord: 0.0ms)


Started GET "/users/sign_up" for 127.0.0.1 at 2013-11-13 15:59:15 +0000
Processing by Devise::RegistrationsController#new as HTML
  Rendered layouts/_title.html.erb (0.0ms)
  Rendered devise/registrations/new.html.erb within layouts/application (8.9ms)
  Rendered layouts/_header.html.erb (0.7ms)
  Rendered layouts/_messages.html.erb (0.1ms)
  Rendered layouts/_prefooter.html.erb (0.0ms)
Completed 200 OK in 23ms (Views: 23.0ms | ActiveRecord: 0.0ms)


Started POST "/users" for 127.0.0.1 at 2013-11-13 15:59:38 +0000
Processing by Devise::RegistrationsController#create as HTML
  Parameters: {"utf8"=>"âœ“", "authenticity_token"=>"KC30CEIjCpu2LLwqXzwSd0ghctqvOYMRqP/YEmqRPCg=", "user"=>{"name"=>"Branden", "email"=>"test@streamingwellreminder.com", "company"=>"", "job"=>"", "password"=>"[FILTERED]", "password_confirmation"=>"[FILTERED]", "reminder"=>"0", "future"=>"0"}, "commit"=>"Submit"}
  [1m[35m (0.1ms)[0m  begin transaction
  [1m[36mUser Exists (0.1ms)[0m  [1mSELECT 1 AS one FROM "users" WHERE "users"."email" = 'test@streamingwellreminder.com' LIMIT 1[0m
Binary data inserted for `string` type on column `encrypted_password`
  [1m[35mSQL (0.5ms)[0m  INSERT INTO "users" ("company", "confirmation_token", "created_at", "current_sign_in_at", "current_sign_in_ip", "email", "encrypted_password", "future", "hcp", "job", "last_sign_in_at", "last_sign_in_ip", "name", "nothcp", "remember_created_at", "reminder", "reset_password_sent_at", "reset_password_token", "sign_in_count", "updated_at") VALUES (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?)  [["company", ""], ["confirmation_token", nil], ["created_at", Wed, 13 Nov 2013 15:59:38 UTC +00:00], ["current_sign_in_at", nil], ["current_sign_in_ip", nil], ["email", "test@streamingwellreminder.com"], ["encrypted_password", "$2a$10$otleXnblxlnGitRI0I/fLOUUgR5N/D0iOO8/sCiSkJlztDGLy73OG"], ["future", false], ["hcp", nil], ["job", ""], ["last_sign_in_at", nil], ["last_sign_in_ip", nil], ["name", "Branden"], ["nothcp", nil], ["remember_created_at", nil], ["reminder", false], ["reset_password_sent_at", nil], ["reset_password_token", nil], ["sign_in_count", 0], ["updated_at", Wed, 13 Nov 2013 15:59:38 UTC +00:00]]
  Rendered admin_mailer/registration_notification.text.erb (0.1ms)

Sent mail to branden.mittra@streamingwell.com (66ms)
Date: Wed, 13 Nov 2013 15:59:38 +0000
From: noreply@astellasoncology.co.uk
To: branden.mittra@streamingwell.com
Message-ID: <5283a1ea31387_30f080434a4c627ce@Franciss-iMac.local.mail>
Subject: New Registration
Mime-Version: 1.0
Content-Type: text/plain;
 charset=UTF-8
Content-Transfer-Encoding: 7bit

New notification alert
--------------------------

The following user just registered:

Name: Branden
Email: test@streamingwellreminder.com
Place of Work: 
Job Title: 
Reminder Emails: false
Future contact: false

  Rendered user_mailer/welcome.html.erb within layouts/mail (1.7ms)
  Rendered user_mailer/welcome.text.erb (0.1ms)

Sent mail to test@streamingwellreminder.com (93ms)
Date: Wed, 13 Nov 2013 15:59:38 +0000
From: noreply@astellasoncology.co.uk
To: test@streamingwellreminder.com
Message-ID: <5283a1ea4a961_30f080434a4c63114@Franciss-iMac.local.mail>
Subject: Log-in details for the Prostate Cancer Lunchtime Webinars
Mime-Version: 1.0
Content-Type: multipart/alternative;
 boundary="--==_mimepart_5283a1ea474d7_30f080434a4c6287e";
 charset=UTF-8
Content-Transfer-Encoding: 7bit



----==_mimepart_5283a1ea474d7_30f080434a4c6287e
Date: Wed, 13 Nov 2013 15:59:38 +0000
Mime-Version: 1.0
Content-Type: text/plain;
 charset=UTF-8
Content-Transfer-Encoding: quoted-printable
Content-ID: <5283a1ea497ad_30f080434a4c6296f@Franciss-iMac.local.mail>

Prostate Cancer Lunchtime Webinars =

A multidisciplinary approach to prostate cancer understanding and managem=
ent
-------------------------------------------------------------------------=
---

Dear Branden

Thank you for registering your interest in the Astellas Oncology live web=
inars.


Your log-in details are as follows:
Username: test@streamingwellreminder.com
Password: foobar

Please use these log-in details every time you wish to visit the webinar =
website:
www.astellasoncology.co.uk


The next live webinar is as follows:

Date: Tuesday 26th November 2013
Time: 12.30 to 13.15
Title: Working together: organising care for optimal management of prosta=
te cancer
Speaker(s): Dr Simon Hughes, Consultant in Clinical Oncology and Louisa F=
leure, Advanced Prostate Cancer Specialist Nurse Guy's Hospital, London

Summary: Dr Simon Hughes and Ms Louisa Fleure will provide expert first-h=
and insights regarding the successful management of patients with prostat=
e cancer in a multidisciplinary team (MDT) setup.
Topics:
The multidisciplinary team (MDT) structure and roles

Managing patients with differing needs in an MDT environment

Newly diagnosed patients

Patients with advanced disease

Meeting the challenges of a =E2=80=98working=E2=80=99 MDT at Guy=E2=80=99=
s Hospital



We do hope that you will be able to join us and you find the webinar inte=
resting and informative.

Please note, details regarding speakers, topics and timings for the full =
webinar programme are available on the website.

Yours sincerely,

Astellas Oncology

Astellas Pharma Ltd. =

2000 Hillswood Drive =

Chertsey =

KT16 0RS =

United Kingdom =

Registered in England and Wales under Registered No 00787610 =


Please do not reply to this email.
Date of preparation: September 2013 	Jobcode:XTD13057UKl
These webinars are organised and funded by Astellas Pharma Ltd.

-------------------------------------------------------------------------=
---

Important: The information transmitted in this message is intended only f=
or the person or entity to which it is addressed and may contain confiden=
tial and/or privileged material. Any review, retransmission, disseminatio=
n or other use of, or taking of any action in reliance upon, this informa=
tion by persons or entities other than the intended recipient is prohibit=
ed. If you receive this message in error, please contact the sender and d=
elete the material from any computer.

													=


														&nbsp;<a href=3D"*|UNSUB|*">unsubscribe from this list</a>&=
nbsp;
														<!-- // Begin PI \\ -->
												=


Xtandi&trade; (enzalutamide) Prescribing Information - For full prescribi=
ng information please refer to the Summary of Product Characteristics.

Presentation: Xtandi&trade; 40 mg soft capsules each containing 40 mg of =
enzalutamide.

Indication: Xtandi&trade; is indicated for the treatment of adult men wit=
h metastatic castration resistant prostate cancer whose disease has progr=
essed on or after docetaxel therapy

Posology and method of administration: Adults and elderly (=E2=89=A5 65 y=
ears of age): The recommended dose is 160 mg enzalutamide (four 40 mg cap=
sules) as a single oral daily dose. If a patient misses taking Xtandi&tra=
de; at the usual time, the prescribed dose should be taken as close as po=
ssible to the usual time.  If a patient misses a dose for a whole day, tr=
eatment should be resumed the following day with the usual daily dose.
If a patient experiences a =E2=89=A5 Grade 3 toxicity or an intolerable a=
dverse reaction, dosing should be withheld for one week or until symptoms=
 improve to =E2=89=A4 Grade 2, then resumed at the same or a reduced dose=
 (120 mg or 80 mg) if warranted.

Older people: No dose adjustment is necessary for older people.

Hepatic impairment: No dose adjustment is necessary for patients with mil=
d hepatic impairment; caution is advised in patients with moderate hepati=
c impairment; Xtandi&trade; is not recommended in patients with severe he=
patic impairment.

Renal impairment: No dose adjustment is necessary for patients with mild =
or moderate renal impairment.  Caution is advised in patients with severe=
 renal impairment or end stage renal disease. Paediatric population:There=
 is no relevant use of enzalutamide in the paediatric population.Contrace=
ption in males and females: It is not known whether enzalutamide or its m=
etabolites are present in semen. A condom is required during and for 3 mo=
nths after treatment with enzalutamide if the patient is engaged in sexua=
l activity with a pregnant woman. If the patient engages in sexual interc=
ourse with a woman of childbearing potential, a condom and another form o=
f birth control must be used during and for 3 months after treatment. Stu=
dies in animals have shown reproductive toxicity.

Contraindications: Hypersensitivity to the active substance or to any of =
the excipients.
	Women who are or may become pregnant.

	Warnings and Precautions: Caution should be used in administering Xtandi=
&trade; to patients with a history of seizures or otherpredisposing facto=
rs. In addition, the risk of seizure may be increased in patients receivi=
ng concomitant medicinal products that lower the seizure threshold. The A=
FFIRM study excluded patients with recent myocardial infarction, unstable=
 angina, heart failure, long QT, bradycardia or uncontrolled hypertension=
. This should be taken into account if Xtandi&trade; is prescribed in the=
se patients. =


	Xtandi&trade; contains sorbitol (E420). Patients with rare hereditary pr=
oblems of fructose intolerance should not take this medicinal product.

	Drug interactions: Strong inhibitors (e.g. gemfibrozil) or inducers (e.g=
. rifampicin) of CYP2C8 are to be avoided or used with caution during enz=
alutamide treatment. If patients must be co-administered a strong CYP2C8 =
inhibitor, the dose of enzalutamide should be reduced to 80 mg once daily=
 CYP3A4 plays a minor role in the metabolism of enzalutamide. No dose adj=
ustment is necessary when Xtandi&trade; is co-administered with inhibitor=
s or inducers of CYP3A4. Enzalutamide is a potent enzyme inducer and incr=
eases the synthesis of many enzymes and transporters; therefore, interact=
ion with many common medicinal products that are substrates of enzymes or=
 transporters is expected. Enzymes that may be induced include CYP3A4 in =
the liver and gut, CYP2C9, CYP2C19, CYP1A2 and uridine 5'-diphospho-glucu=
ronosyltransferase (UGTs - glucuronide conjugating enzymes). The transpor=
t protein P-gp may also be induced, and probably other transporters as we=
ll, e.g. multidrug resistance-associated protein 2 (MRP2), breast cancer =
resistant protein (BCRP) and the organic anion transporting polypeptide 1=
B1 (OATP1B1). In vivo studies have shown that enzalutamide is a strong in=
ducer of CYP3A4 and a moderate inducer of CYP2C9 and CYP2C19. The full in=
duction potential of enzalutamide may not occur until approximately 1 mon=
th after the start of treatment, when steady-state plasma concentrations =
of enzalutamide are reached, although some induction effects may be appar=
ent earlier. Patients taking medicinal products that are substrates of CY=
P3A4, CYP2C9, CYP2C19, CYP1A2 or UGT1A1 should be evaluated for possible =
loss of pharmacological effects (or increase in effects in cases where ac=
tive metabolites are formed) during the first month of enzalutamide treat=
ment, and dose adjustment should be considered as appropriate. If their t=
herapeutic effect is of large importance to the patient, and dose adjustm=
ents are not easily performed based on monitoring of efficacy or plasma c=
oncentrations, these medicinal products are to be avoided or used with ca=
ution. In consideration of the long half-life of enzalutamide (5.8 days),=
 effects on enzymes may persist for one month or longer after stopping en=
zalutamide. A gradual dose reduction of the concomitant medicinal product=
 may be necessary when stopping enzalutamide treatment. In vitro data ind=
icate that enzalutamide may be an inhibitor of the efflux transporter P-g=
p. The effect of enzalutamide on P-gp substrates has not been evaluated i=
n vivo; however, under conditions of clinical use, enzalutamide may be an=
 inducer of P-gp via activation of the nuclear pregnane receptor (PXR). M=
edicinal products with a narrow therapeutic range that are substrates for=
 P-gp (e.g. colchicine, dabigatran etexilate, digoxin) should be used wit=
h caution when administered concomitantly with Xtandi&trade; and may requ=
ire dose adjustment to maintain optimal plasma concentrations.
		The safety and efficacy of concomitant use of Xtandi&trade; with cytoto=
xic chemotherapy has not been established.

		Undesirable effects:  Very Common (=E2=89=A5 1/10): headache, hot flush=
; Common (=E2=89=A5 1/100 to < 1/10): neutropenia, visual hallucinations,=
 anxiety, cognitive disorders, memory impairment, hypertension, dry skin,=
 pruritus, fractures, falls; Uncommon (=E2=89=A5 1/1,000 to < 1/100): leu=
copenia, seizure, amnesia, disturbance in attention. (In the AFFIRM study=
, six patients (0.8%) experienced a seizure out of 800 patients treated w=
ith a daily dose of 160 mg enzalutamide).

		Packs and Cost: 40mg capsules x 112: =C2=A32,734.67 Legal Classificatio=
n: POM. Marketing authorisation number: EU/1/13/846/001

		Date of Preparation of PI: June 2013. Job number of PI: PRE13003UK  Fur=
ther information available from: Astellas Pharma Ltd, 2000 Hillswood Driv=
e, Chertsey. KT16 0RS.  For Medical Information phone: 0800 783 5018 =


		Adverse events should be reported. Reporting forms and information can =
be found at www.mhra.gov.uk/yellowcard. Adverse events should also be rep=
orted to Astellas Pharma Ltd. Please contact 0800 783 501 =


----==_mimepart_5283a1ea474d7_30f080434a4c6287e
Date: Wed, 13 Nov 2013 15:59:38 +0000
Mime-Version: 1.0
Content-Type: text/html;
 charset=UTF-8
Content-Transfer-Encoding: quoted-printable
Content-ID: <5283a1ea4a2ac_30f080434a4c6300@Franciss-iMac.local.mail>

<html>
<head>
  <title></title>
</head>
<body>
  <!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://=
www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html>
<head>
	<meta http-equiv=3D"Content-Type" content=3D"text/html; charset=3DUTF-8"=
 />

	<!-- Facebook sharing information tags -->
	<meta property=3D"og:title" content=3D"*|MC:SUBJECT|*" />

	<title>*|MC:SUBJECT|*</title>
	<style type=3D"text/css">
	/* Client-specific Styles */
	#outlook a{padding:0;} /* Force Outlook to provide a "view in browser" b=
utton. */
	body{width:100% !important;} .ReadMsgBody{width:100%;} .ExternalClass{wi=
dth:100%;} /* Force Hotmail to display emails at full width */
	body{-webkit-text-size-adjust:none;} /* Prevent Webkit platforms from ch=
anging default text sizes. */

	/* Reset Styles */
	body{margin:0; padding:0;}
	img{border:0; height:auto; line-height:100%; outline:none; text-decorati=
on:none;}
	table td{border-collapse:collapse;}
	#backgroundTable{height:100% !important; margin:0; padding:0; width:100%=
 !important;}

	/* Template Styles */

	/* /\/\/\/\/\/\/\/\/\/\ STANDARD STYLING: COMMON PAGE ELEMENTS /\/\/\/\/=
\/\/\/\/\/\ */

			/**
			* @tab Page
			* @section background color
			* @tip Set the background color for your email. You may want to choose=
 one that matches your company's branding.
			* @theme page
			*/
			body, #backgroundTable{
				/*@editable*/ background-color:#FAFAFA;

			}

			/**
			* @tab Page
			* @section email border
			* @tip Set the border for your email.
			*/
			#templateContainer{
				/*@editable*/ border: 1px solid #DDDDDD;
				background-image: url('http://streamingwell.tv/img/email-bg.jpg');
				background-repeat: no-repeat;
			}

			/**
			* @tab Page
			* @section heading 1
			* @tip Set the styling for all first-level headings in your emails. Th=
ese should be the largest of your headings.
			* @style heading 1
			*/
			h1, .h1{
				/*@editable*/ color:#939598;
				display:block;
				/*@editable*/ font-family:Arial;
				/*@editable*/ font-size:20px;
				/*@editable*/ font-weight:bold;
				/*@editable*/ line-height:100%;
				margin-top:10px;
				margin-right:0;
				margin-bottom:10px;
				margin-left:0;
				/*@editable*/ text-align:left;
			}

			/**
			* @tab Page
			* @section heading 2
			* @tip Set the styling for all second-level headings in your emails.
			* @style heading 2
			*/
			h2, .h2{
				/*@editable*/ color:#202020;
				display:block;
				/*@editable*/ font-family:Arial;
				/*@editable*/ font-size:30px;
				/*@editable*/ font-weight:bold;
				/*@editable*/ line-height:100%;
				margin-top:0;
				margin-right:0;
				margin-bottom:10px;
				margin-left:0;
				/*@editable*/ text-align:left;
			}

			/**
			* @tab Page
			* @section heading 3
			* @tip Set the styling for all third-level headings in your emails.
			* @style heading 3
			*/
			h3, .h3{
				/*@editable*/ color:#202020;
				display:block;
				/*@editable*/ font-family:Arial;
				/*@editable*/ font-size:26px;
				/*@editable*/ font-weight:bold;
				/*@editable*/ line-height:100%;
				margin-top:0;
				margin-right:0;
				margin-bottom:10px;
				margin-left:0;
				/*@editable*/ text-align:left;
			}

			/**
			* @tab Page
			* @section heading 4
			* @tip Set the styling for all fourth-level headings in your emails. T=
hese should be the smallest of your headings.
			* @style heading 4
			*/
			h4, .h4{
				/*@editable*/ color:#202020;
				display:block;
				/*@editable*/ font-family:Arial;
				/*@editable*/ font-size:11px;
				/*@editable*/ font-weight:100;
				/*@editable*/ line-height:100%;
				margin-top:0;
				margin-right:0;
				margin-bottom:10px;
				margin-left:0;
				/*@editable*/ text-align:left;
			}

			.h4 i {
				font-weight: 100;
				color: rgb(167, 43, 77);
				background: #fff;
			}



			/* /\/\/\/\/\/\/\/\/\/\ STANDARD STYLING: PREHEADER /\/\/\/\/\/\/\/\/\=
/\ */

			/**
			* @tab Header
			* @section preheader style
			* @tip Set the background color for your email's preheader area.
			* @theme page
			*/
			#templatePreheader{
				/*@editable*/ background-color:#FAFAFA;
			}

			/**
			* @tab Header
			* @section preheader text
			* @tip Set the styling for your email's preheader text. Choose a size =
and color that is easy to read.
			*/
			.preheaderContent div{
				/*@editable*/ color:#505050;
				/*@editable*/ font-family:Arial;
				/*@editable*/ font-size:10px;
				/*@editable*/ line-height:100%;
				/*@editable*/ text-align:left;
			}

			/**
			* @tab Header
			* @section preheader link
			* @tip Set the styling for your email's preheader links. Choose a colo=
r that helps them stand out from your text.
			*/
			.preheaderContent div a:link, .preheaderContent div a:visited, /* Yaho=
o! Mail Override */ .preheaderContent div a .yshortcuts /* Yahoo! Mail Ov=
erride */{
				/*@editable*/ color:#336699;
				/*@editable*/ font-weight:normal;
				/*@editable*/ text-decoration:underline;
			}



			/* /\/\/\/\/\/\/\/\/\/\ STANDARD STYLING: HEADER /\/\/\/\/\/\/\/\/\/\ =
*/

			/**
			* @tab Header
			* @section header style
			* @tip Set the background color and border for your email's header are=
a.
			* @theme header
			*/
			#templateHeader{
				/*@editable*/ background-color:#FFFFFF;
				/*@editable*/ border-bottom:0;
			}

			/**
			* @tab Header
			* @section header text
			* @tip Set the styling for your email's header text. Choose a size and=
 color that is easy to read.
			*/
			.headerContent{
				/*@editable*/ color:#202020;
				/*@editable*/ font-family:Arial;
				/*@editable*/ font-size:34px;
				/*@editable*/ font-weight:bold;
				/*@editable*/ line-height:100%;
				/*@editable*/ padding:0;
				/*@editable*/ text-align:center;
				/*@editable*/ vertical-align:middle;
			}

			/**
			* @tab Header
			* @section header link
			* @tip Set the styling for your email's header links. Choose a color t=
hat helps them stand out from your text.
			*/
			.headerContent a:link, .headerContent a:visited, /* Yahoo! Mail Overri=
de */ .headerContent a .yshortcuts /* Yahoo! Mail Override */{
				/*@editable*/ color:#336699;
				/*@editable*/ font-weight:normal;
				/*@editable*/ text-decoration:underline;
			}

			#headerImage{
				height:auto;
				max-width:600px;
			}

			/* /\/\/\/\/\/\/\/\/\/\ STANDARD STYLING: MAIN BODY /\/\/\/\/\/\/\/\/\=
/\ */

			/**
			* @tab Body
			* @section body style
			* @tip Set the background color for your email's body area.
			*/
			#templateContainer, .bodyContent{
				/*@editable*/ background-color:#FFFFFF;
				background-image: url('http://streamingwell.tv/img/email-bg.jpg');
				background-repeat: no-repeat;
			}

			/**
			* @tab Body
			* @section body text
			* @tip Set the styling for your email's main content text. Choose a si=
ze and color that is easy to read.
			* @theme main
			*/
			.bodyContent div{
				/*@editable*/ color:#505050;
				/*@editable*/ font-family:Arial;
				/*@editable*/ font-size:14px;
				/*@editable*/ line-height:150%;
				/*@editable*/ text-align:left;
			}

			/**
			* @tab Body
			* @section body link
			* @tip Set the styling for your email's main content links. Choose a c=
olor that helps them stand out from your text.
			*/
			.bodyContent div a:link, .bodyContent div a:visited, /* Yahoo! Mail Ov=
erride */ .bodyContent div a .yshortcuts /* Yahoo! Mail Override */{
				/*@editable*/ color:#336699;
				/*@editable*/ font-weight:normal;
				/*@editable*/ text-decoration:underline;
			}

			.bodyContent img{
				display:inline;
				height:auto;
			}

			/* /\/\/\/\/\/\/\/\/\/\ STANDARD STYLING: FOOTER /\/\/\/\/\/\/\/\/\/\ =
*/

			/**
			* @tab Footer
			* @section footer style
			* @tip Set the background color and top border for your email's footer=
 area.
			* @theme footer
			*/
			#templateFooter{
				/*@editable*/ background-color:#FFFFFF;
				/*@editable*/ border-top:0;
			}

			/**
			* @tab Footer
			* @section footer text
			* @tip Set the styling for your email's footer text. Choose a size and=
 color that is easy to read.
			* @theme footer
			*/
			.footerContent div{
				/*@editable*/ color:#707070;
				/*@editable*/ font-family:Arial;
				/*@editable*/ font-size:12px;
				/*@editable*/ line-height:125%;
				/*@editable*/ text-align:left;
			}

			/**
			* @tab Footer
			* @section footer link
			* @tip Set the styling for your email's footer links. Choose a color t=
hat helps them stand out from your text.
			*/
			.footerContent div a:link, .footerContent div a:visited, /* Yahoo! Mai=
l Override */ .footerContent div a .yshortcuts /* Yahoo! Mail Override */=
{
				/*@editable*/ color:#336699;
				/*@editable*/ font-weight:normal;
				/*@editable*/ text-decoration:underline;
			}

			.footerContent img{
				display:inline;
			}

			/**
			* @tab Footer
			* @section social bar style
			* @tip Set the background color and border for your email's footer soc=
ial bar.
			* @theme footer
			*/
			#social{
				/*@editable*/ background-color:#FAFAFA;
				/*@editable*/ border:0;
			}

			/**
			* @tab Footer
			* @section social bar style
			* @tip Set the background color and border for your email's footer soc=
ial bar.
			*/
			#social div{
				/*@editable*/ text-align:center;
			}

			/**
			* @tab Footer
			* @section utility bar style
			* @tip Set the background color and border for your email's footer uti=
lity bar.
			* @theme footer
			*/
			#utility{
				/*@editable*/ background-color:#FFFFFF;
				/*@editable*/ border:0;
			}

			/**
			* @tab Footer
			* @section utility bar style
			* @tip Set the background color and border for your email's footer uti=
lity bar.
			*/
			#utility div{
				/*@editable*/ text-align:center;
			}

			#monkeyRewards img{
				max-width:190px;
			}
			</style>
		</head>
		<body leftmargin=3D"0" marginwidth=3D"0" topmargin=3D"0" marginheight=3D=
"0" offset=3D"0">
			<center>
				<table border=3D"0" cellpadding=3D"0" cellspacing=3D"0" height=3D"100=
%" width=3D"100%" id=3D"backgroundTable">
					<tr>
						<td align=3D"center" valign=3D"top">
							<!-- // Begin Template Preheader \\ -->
							<table border=3D"0" cellpadding=3D"10" cellspacing=3D"0" width=3D"=
600" id=3D"templatePreheader">
								<tr>
									<td valign=3D"top" class=3D"preheaderContent">

										<!-- // Begin Module: Standard Preheader \ -->
										<table border=3D"0" cellpadding=3D"10" cellspacing=3D"0" width=3D=
"100%">
											<tr>
												<td valign=3D"top">
													<div mc:edit=3D"std_preheader_content"></div>
												</td>
												<!-- *|IFNOT:ARCHIVE_PAGE|* -->
												<td valign=3D"top" width=3D"190">
													<div mc:edit=3D"std_preheader_links"></div>
												</td>
												<!-- *|END:IF|* -->
											</tr>
										</table>
										<!-- // End Module: Standard Preheader \ -->

									</td>
								</tr>
							</table>

						</td>
					</tr>
					<tr>
						<td align=3D"center" valign=3D"top">
							<!-- // Begin Template Body \\ -->
							<table border=3D"0" cellpadding=3D"0" cellspacing=3D"0" width=3D"6=
00" id=3D"templateBody">
								<tr>
									<td valign=3D"top" class=3D"bodyContent">

										<!-- // Begin Module: Standard Postcard Content \\ -->
										<table border=3D"0" cellpadding=3D"20" cellspacing=3D"0" width=3D=
"80%">
											<tr mc:repeatable>
												<td valign=3D"top">
													<div mc:edit=3D"postcard_heading00">
														<img src=3D"http://img855.imageshack.us/img855/4207/aome.jp=
g">
														<h1 class=3D"h1"><span style=3D"color: rgb(167, 43, 77)">Pr=
ostate Cancer Lunchtime Webinars</span></h1>
														<h4><i>A multidisciplinary approach to prostate cancer unde=
rstanding and management</i></h4>
													</div>
													<br>
													<div mc:edit=3D"std_content00">
														<p>Dear Branden</p>

														<p>Thank you for registering your interest in the Astellas =
Oncology live webinars.</p>
														<p><strong>Your log-in details are as follows:</strong></p>=

														<p><strong>Username: test@streamingwellreminder.com</strong=
></p>
														<p><strong>Password: foobar</strong></p>

														<p>Please use these log-in details every time you wish to v=
isit the webinar website: http://www.astellasoncology.co.uk/users/sign_in=
</p>

														<br>
														<p><strong>The next live webinar is as follows:</strong></p=
>

														<p>Date: Tuesday 26th November 2013</p>
														<p>Time: 12.30 to 13.15</p>
														<p><strong>Title:</strong><i>Working together: organising c=
are for optimal management of prostate cancer</i></p>
														<p><strong>Speaker(s):</strong>  Dr Simon Hughes, Consultan=
t in Clinical Oncology and Ms Louisa Fleure, Advanced Prostate Cancer Spe=
cialist Nurse Guy's Hospital, London</p>

														<p><strong>Summary:</strong>Dr Simon Hughes and Ms Louisa F=
leure will provide expert first-hand insights regarding the successful ma=
nagement of patients with prostate cancer in a multidisciplinary team (MD=
T) setup.</p>

														<p><strong>Topics:</strong></p>
														<p><li>The multidisciplinary team (MDT) structure and roles=
</li></p>

														<p><li>Managing patients with differing needs in an MDT env=
ironment</li></p>

														<p><li>Newly diagnosed patients</li></p>

														<p><li>Patients with advanced disease</li></p>

														<p><li>Meeting the challenges of a =E2=80=98working=E2=80=99=
 MDT at Guy=E2=80=99s Hospital</li></p>
														<br>
														<p>We do hope that you will be able to join us and you find=
 the webinar interesting and informative.</p>

														<p>Please note, details regarding speakers, topics and timi=
ngs for the full webinar programme are available on the website.</p>


														<p>Yours sincerely,</p>

														<p>Astellas Oncology</p>

                                                        </td>
                                                    </tr>
                                                </table>
                                                <!-- // End Module: Stand=
ard Postcard Content \\ -->
                                                =

                                            </td>
                                        </tr>
                                    </table>
                                    <!-- // End Template Body \\ -->
                                </td>
                            </tr>
                        	<tr>
                            	<td align=3D"center" valign=3D"top">
                                    <!-- // Begin Template Footer \\ -->
                                	<table border=3D"0" cellpadding=3D"10" c=
ellspacing=3D"0" width=3D"600" id=3D"templateFooter">
                                    	<tr>
                                        	<td valign=3D"top" class=3D"foot=
erContent">
                                            =

                                                <!-- // Begin Module: Sta=
ndard Footer \\ -->
                                                <table border=3D"0" cellp=
adding=3D"10" cellspacing=3D"0" width=3D"100%">
                                                    <tr>
                          =

                                                        <td valign=3D"top=
" width=3D"350">
                                                            <div mc:edit=3D=
"std_footer">
																<p><em>Astellas Pharma Ltd.</em> </p>
																<p><em>2000 Hillswood Drive </em></p>
																<p><em>Chertsey</em> </p>
																<p><em>KT16 0RS </em></p>
																<p><em>United Kingdom </em></p>
																<p><em>Registered in England and Wales under Registered N=
o 00787610 </em></p>
																<br />
																=

																<em>Please do not reply to this email</em>
																<em>Date of preparation: October 2013 Job code: XTD13057U=
Kl</em>
                                                            <p><em>These =
webinars are organised and funded by Astellas Pharma Ltd.</em></p>
												=

											=


															<small>Important: The information transmitted in this mess=
age is intended only for the person or entity to which it is addressed an=
d may contain confidential and/or privileged material. Any review, retran=
smission, dissemination or other use of, or taking of any action in relia=
nce upon, this information by persons or entities other than the intended=
 recipient is prohibited. If you receive this message in error, please co=
ntact the sender and delete the material from any computer.</small>

														<br>
														<br>
														&nbsp;<a href=3D"*|UNSUB|*">unsubscribe from this list</a>&=
nbsp;

														</div>
													</td>
												</tr>
														=

														<!-- // Begin PI \\ -->
                                                                <tr>
                                                        <td colspan=3D"2"=
 valign=3D"left">
                                                            <div>
                             =

<p><img src=3D"http://warm-dawn-9465.herokuapp.com/assets/xtandi-logo-134=
.png" align=3D"right"></p>

<br>
<br>     =


<p><strong>Xtandi&trade;</span> (enzalutamide) Prescribing Information -<=
/strong> For full prescribing information please refer to the Summary of =
Product Characteristics.</p>

<p><strong>Presentation:</strong> Xtandi&trade; 40 mg soft capsules each =
containing 40 mg of enzalutamide.</p>

<p><strong>Indication:</strong> Xtandi&trade; is indicated for the treatm=
ent of adult men with metastatic castration resistant prostate cancer who=
se disease has progressed on or after docetaxel therapy</p>

<p><strong>Posology and method of administration:</strong> Adults and eld=
erly (=E2=89=A5 65 years of age): The recommended dose is 160 mg enzaluta=
mide (four 40 mg capsules) as a single oral daily dose. If a patient miss=
es taking Xtandi&trade; at the usual time, the prescribed dose should be =
taken as close as possible to the usual time.  If a patient misses a dose=
 for a whole day, treatment should be resumed the following day with the =
usual daily dose.</p>
<p>If a patient experiences a =E2=89=A5 Grade 3 toxicity or an intolerabl=
e adverse reaction, dosing should be withheld for one week or until sympt=
oms improve to =E2=89=A4 Grade 2, then resumed at the same or a reduced d=
ose (120 mg or 80 mg) if warranted.</p>

<p>Older people: No dose adjustment is necessary for older people.</p>

<p>Hepatic impairment: No dose adjustment is necessary for patients with =
mild hepatic impairment; caution is advised in patients with moderate hep=
atic impairment; Xtandi&trade; is not recommended in patients with severe=
 hepatic impairment.</p>

<p>Renal impairment: No dose adjustment is necessary for patients with mi=
ld or moderate renal impairment.  Caution is advised in patients with sev=
ere renal impairment or end stage renal disease. Paediatric population:Th=
ere is no relevant use of enzalutamide in the paediatric population.Contr=
aception in males and females: It is not known whether enzalutamide or it=
s metabolites are present in semen. A condom is required during and for 3=
 months after treatment with enzalutamide if the patient is engaged in se=
xual activity with a pregnant woman. If the patient engages in sexual int=
ercourse with a woman of childbearing potential, a condom and another for=
m of birth control must be used during and for 3 months after treatment. =
Studies in animals have shown reproductive toxicity.</p>

<p><strong>Contraindications:</strong> Hypersensitivity to the active sub=
stance or to any of the excipients.
Women who are or may become pregnant.</p>

<p><strong>Warnings and Precautions:</strong> Caution should be used in a=
dministering Xtandi&trade; to patients with a history of seizures or othe=
rpredisposing factors. In addition, the risk of seizure may be increased =
in patients receiving concomitant medicinal products that lower the seizu=
re threshold. The AFFIRM study excluded patients with recent myocardial i=
nfarction, unstable angina, heart failure, long QT, bradycardia or uncont=
rolled hypertension. This should be taken into account if Xtandi&trade; i=
s prescribed in these patients. </p>

<p>Xtandi&trade; contains sorbitol (E420). Patients with rare hereditary =
problems of fructose intolerance should not take this medicinal product.<=
/p>

<p><strong>Drug interactions:</strong> Strong inhibitors (e.g. gemfibrozi=
l) or inducers (e.g. rifampicin) of CYP2C8 are to be avoided or used with=
 caution during enzalutamide treatment. If patients must be co-administer=
ed a strong CYP2C8 inhibitor, the dose of enzalutamide should be reduced =
to 80 mg once daily CYP3A4 plays a minor role in the metabolism of enzalu=
tamide. No dose adjustment is necessary when Xtandi&trade; is co-administ=
ered with inhibitors or inducers of CYP3A4. Enzalutamide is a potent enzy=
me inducer and increases the synthesis of many enzymes and transporters; =
therefore, interaction with many common medicinal products that are subst=
rates of enzymes or transporters is expected. Enzymes that may be induced=
 include CYP3A4 in the liver and gut, CYP2C9, CYP2C19, CYP1A2 and uridine=
 5'-diphospho-glucuronosyltransferase (UGTs - glucuronide conjugating enz=
ymes). The transport protein P-gp may also be induced, and probably other=
 transporters as well, e.g. multidrug resistance-associated protein 2 (MR=
P2), breast cancer resistant protein (BCRP) and the organic anion transpo=
rting polypeptide 1B1 (OATP1B1). In vivo studies have shown that enzaluta=
mide is a strong inducer of CYP3A4 and a moderate inducer of CYP2C9 and C=
YP2C19. The full induction potential of enzalutamide may not occur until =
approximately 1 month after the start of treatment, when steady-state pla=
sma concentrations of enzalutamide are reached, although some induction e=
ffects may be apparent earlier. Patients taking medicinal products that a=
re substrates of CYP3A4, CYP2C9, CYP2C19, CYP1A2 or UGT1A1 should be eval=
uated for possible loss of pharmacological effects (or increase in effect=
s in cases where active metabolites are formed) during the first month of=
 enzalutamide treatment, and dose adjustment should be considered as appr=
opriate. If their therapeutic effect is of large importance to the patien=
t, and dose adjustments are not easily performed based on monitoring of e=
fficacy or plasma concentrations, these medicinal products are to be avoi=
ded or used with caution. In consideration of the long half-life of enzal=
utamide (5.8 days), effects on enzymes may persist for one month or longe=
r after stopping enzalutamide. A gradual dose reduction of the concomitan=
t medicinal product may be necessary when stopping enzalutamide treatment=
. In vitro data indicate that enzalutamide may be an inhibitor of the eff=
lux transporter P-gp. The effect of enzalutamide on P-gp substrates has n=
ot been evaluated in vivo; however, under conditions of clinical use, enz=
alutamide may be an inducer of P-gp via activation of the nuclear pregnan=
e receptor (PXR). Medicinal products with a narrow therapeutic range that=
 are substrates for P-gp (e.g. colchicine, dabigatran etexilate, digoxin)=
 should be used with caution when administered concomitantly with Xtandi&=
trade; and may require dose adjustment to maintain optimal plasma concent=
rations.
The safety and efficacy of concomitant use of Xtandi&trade; with cytotoxi=
c chemotherapy has not been established.</p>

<p><strong>Undesirable effects:</strong>  Very Common (=E2=89=A5 1/10): h=
eadache, hot flush; Common (=E2=89=A5 1/100 to < 1/10): neutropenia, visu=
al hallucinations, anxiety, cognitive disorders, memory impairment, hyper=
tension, dry skin, pruritus, fractures, falls; Uncommon (=E2=89=A5 1/1,00=
0 to < 1/100): leucopenia, seizure, amnesia, disturbance in attention. (I=
n the AFFIRM study, six patients (0.8%) experienced a seizure out of 800 =
patients treated with a daily dose of 160 mg enzalutamide).</p>

<p><strong>Packs and Cost:</strong> 40mg capsules x 112: =C2=A32,734.67 L=
egal Classification: POM. Marketing authorisation number: EU/1/13/846/001=
</p>

<p><strong>Date of Preparation of PI:</strong> June 2013. <strong>Job num=
ber of PI:</strong> PRE13003UK  <strong>Further information available fro=
m:</strong> Astellas Pharma Ltd, 2000 Hillswood Drive, Chertsey. KT16 0RS=
.  <strong>For Medical Information phone:</strong> 0800 783 5018 </p>

<div class=3D"adverse">
<p>Adverse events should be reported. Reporting forms and information can=
 be found at <a href=3D"www.mhra.gov.uk/yellowcard">www.mhra.gov.uk/yello=
wcard</a>. Adverse events should also be reported to Astellas Pharma Ltd.=
 Please contact 0800 783 501 </p>
</div>
<!-- // Begin PI \\ -->
                                                            </div>
                                                        </td>
                                                    </tr>
                                                </table>
                                                <!-- // End Module: Stand=
ard Footer \\ -->
                                            =

                                            </td>
                                        </tr>
                                    </table>
                                    <!-- // End Template Footer \\ -->
                                </td>
                            </tr>
                        </table>
                        <br />
                    </td>
                </tr>
            </table>
        </center>
    </body>
</html>
</body>
</html>=


----==_mimepart_5283a1ea474d7_30f080434a4c6287e--

  [1m[36m (2.9ms)[0m  [1mcommit transaction[0m
  [1m[35m (0.1ms)[0m  begin transaction
  [1m[36m (0.3ms)[0m  [1mUPDATE "users" SET "last_sign_in_at" = '2013-11-13 15:59:38.401017', "current_sign_in_at" = '2013-11-13 15:59:38.401017', "last_sign_in_ip" = '127.0.0.1', "current_sign_in_ip" = '127.0.0.1', "sign_in_count" = 1, "updated_at" = '2013-11-13 15:59:38.402729' WHERE "users"."id" = 3[0m
  [1m[35m (19.2ms)[0m  commit transaction
Redirected to http://localhost:3000/
Completed 302 Found in 372ms (ActiveRecord: 0.0ms)


Started GET "/" for 127.0.0.1 at 2013-11-13 15:59:38 +0000
Processing by PagesController#preregistration as HTML
  [1m[36mUser Load (0.2ms)[0m  [1mSELECT "users".* FROM "users" WHERE "users"."id" = 3 LIMIT 1[0m
  Rendered layouts/_title.html.erb (0.0ms)
  Rendered pages/preregistration.html.erb within layouts/application (4.9ms)
  Rendered layouts/_header.html.erb (0.4ms)
  Rendered layouts/_messages.html.erb (0.1ms)
  Rendered layouts/_footer.html.erb (0.1ms)
Completed 200 OK in 21ms (Views: 20.6ms | ActiveRecord: 0.2ms)


Started DELETE "/users/sign_out" for 127.0.0.1 at 2013-11-13 15:59:43 +0000
Processing by Devise::SessionsController#destroy as HTML
  Parameters: {"authenticity_token"=>"KC30CEIjCpu2LLwqXzwSd0ghctqvOYMRqP/YEmqRPCg="}
  [1m[35mUser Load (0.2ms)[0m  SELECT "users".* FROM "users" WHERE "users"."id" = 3 LIMIT 1
  [1m[36m (0.0ms)[0m  [1mbegin transaction[0m
  [1m[35m (0.0ms)[0m  commit transaction
Redirected to http://localhost:3000/
Completed 302 Found in 4ms (ActiveRecord: 0.3ms)


Started GET "/" for 127.0.0.1 at 2013-11-13 15:59:43 +0000
Processing by PagesController#preregistration as HTML
  Rendered layouts/_title.html.erb (0.0ms)
  Rendered layouts/_preregistration.html.erb (2.0ms)
  Rendered pages/preregistration.html.erb within layouts/application (3.9ms)
  Rendered layouts/_header.html.erb (0.5ms)
  Rendered layouts/_messages.html.erb (0.1ms)
  Rendered layouts/_prefooter.html.erb (0.0ms)
Completed 200 OK in 18ms (Views: 18.0ms | ActiveRecord: 0.0ms)


Started GET "/" for 127.0.0.1 at 2013-11-13 16:04:34 +0000
Processing by PagesController#preregistration as HTML
  Rendered layouts/_title.html.erb (0.0ms)
  Rendered layouts/_preregistration.html.erb (2.0ms)
  Rendered pages/preregistration.html.erb within layouts/application (3.8ms)
  Rendered layouts/_header.html.erb (0.6ms)
  Rendered layouts/_messages.html.erb (0.0ms)
  Rendered layouts/_prefooter.html.erb (0.0ms)
Completed 200 OK in 48ms (Views: 48.2ms | ActiveRecord: 0.0ms)


Started GET "/login" for 127.0.0.1 at 2013-11-13 16:04:36 +0000
Processing by PagesController#login as HTML
  Rendered layouts/_title.html.erb (0.0ms)
  Rendered pages/login.html.erb within layouts/application (5.0ms)
  Rendered layouts/_header.html.erb (0.5ms)
  Rendered layouts/_messages.html.erb (0.0ms)
  Rendered layouts/_prefooter.html.erb (0.0ms)
Completed 200 OK in 18ms (Views: 17.6ms | ActiveRecord: 0.0ms)


Started POST "/users/sign_in" for 127.0.0.1 at 2013-11-13 16:04:39 +0000
Processing by Devise::SessionsController#create as HTML
  Parameters: {"utf8"=>"âœ“", "authenticity_token"=>"7SX2ESVgjLKOxoL5uhSpHxh0XC9psQByFrhL1N3BaV0=", "user"=>{"email"=>"branden.mittra@stremingwell.com", "password"=>"[FILTERED]"}, "commit"=>"Login"}
  [1m[36mUser Load (0.2ms)[0m  [1mSELECT "users".* FROM "users" WHERE "users"."email" = 'branden.mittra@stremingwell.com' LIMIT 1[0m
Completed 401 Unauthorized in 2ms
Processing by Devise::SessionsController#new as HTML
  Parameters: {"utf8"=>"âœ“", "authenticity_token"=>"7SX2ESVgjLKOxoL5uhSpHxh0XC9psQByFrhL1N3BaV0=", "user"=>{"email"=>"branden.mittra@stremingwell.com", "password"=>"[FILTERED]"}, "commit"=>"Login"}
  Rendered layouts/_title.html.erb (0.0ms)
  Rendered devise/sessions/new.html.erb within layouts/application (24.3ms)
  Rendered layouts/_header.html.erb (0.7ms)
  Rendered layouts/_messages.html.erb (0.1ms)
  Rendered layouts/_prefooter.html.erb (0.0ms)
Completed 200 OK in 125ms (Views: 47.4ms | ActiveRecord: 0.0ms)


Started POST "/users/sign_in" for 127.0.0.1 at 2013-11-13 16:04:43 +0000
Processing by Devise::SessionsController#create as HTML
  Parameters: {"utf8"=>"âœ“", "authenticity_token"=>"7SX2ESVgjLKOxoL5uhSpHxh0XC9psQByFrhL1N3BaV0=", "user"=>{"email"=>"branden.mittra@streamingwell.com", "password"=>"[FILTERED]"}, "commit"=>"Login"}
  [1m[35mUser Load (0.2ms)[0m  SELECT "users".* FROM "users" WHERE "users"."email" = 'branden.mittra@streamingwell.com' LIMIT 1
  [1m[36m (0.1ms)[0m  [1mbegin transaction[0m
  [1m[35m (0.3ms)[0m  UPDATE "users" SET "last_sign_in_at" = '2013-11-13 15:41:32.155597', "current_sign_in_at" = '2013-11-13 16:04:43.144860', "sign_in_count" = 3, "updated_at" = '2013-11-13 16:04:43.146158' WHERE "users"."id" = 1
  [1m[36m (1.0ms)[0m  [1mcommit transaction[0m
Redirected to http://localhost:3000/
Completed 302 Found in 92ms (ActiveRecord: 0.0ms)


Started GET "/" for 127.0.0.1 at 2013-11-13 16:04:43 +0000
Processing by PagesController#preregistration as HTML
  [1m[35mUser Load (0.3ms)[0m  SELECT "users".* FROM "users" WHERE "users"."id" = 1 LIMIT 1
  Rendered layouts/_title.html.erb (0.0ms)
  Rendered pages/preregistration.html.erb within layouts/application (4.8ms)
  Rendered layouts/_header.html.erb (0.5ms)
  Rendered layouts/_messages.html.erb (0.1ms)
  Rendered layouts/_footer.html.erb (0.1ms)
Completed 200 OK in 21ms (Views: 20.3ms | ActiveRecord: 0.3ms)


Started GET "/live" for 127.0.0.1 at 2013-11-13 16:07:58 +0000
Processing by PagesController#live as HTML
  [1m[36mUser Load (0.2ms)[0m  [1mSELECT "users".* FROM "users" WHERE "users"."id" = 1 LIMIT 1[0m
  Rendered layouts/_title.html.erb (0.0ms)
  Rendered pages/live.html.erb within layouts/application (7.4ms)
  Rendered layouts/_header.html.erb (0.4ms)
  Rendered layouts/_messages.html.erb (0.1ms)
  Rendered layouts/_footer.html.erb (0.1ms)
Completed 200 OK in 43ms (Views: 24.7ms | ActiveRecord: 0.2ms)


Started GET "/" for 127.0.0.1 at 2013-11-13 17:55:17 +0000
Processing by PagesController#preregistration as HTML
  [1m[35mUser Load (57.2ms)[0m  SELECT "users".* FROM "users" WHERE "users"."id" = 1 LIMIT 1
  Rendered layouts/_title.html.erb (0.7ms)
  Rendered pages/preregistration.html.erb within layouts/application (2650.5ms)
  Rendered layouts/_header.html.erb (5.4ms)
  Rendered layouts/_messages.html.erb (0.1ms)
  Rendered layouts/_footer.html.erb (12.5ms)
Completed 200 OK in 3472ms (Views: 3408.3ms | ActiveRecord: 57.2ms)


Started GET "/" for 127.0.0.1 at 2013-11-14 10:42:31 +0000
Processing by PagesController#preregistration as HTML
  [1m[36mUser Load (0.2ms)[0m  [1mSELECT "users".* FROM "users" WHERE "users"."id" = 1 LIMIT 1[0m
  Rendered layouts/_title.html.erb (0.1ms)
  Rendered pages/preregistration.html.erb within layouts/application (47.0ms)
  Rendered layouts/_header.html.erb (0.5ms)
  Rendered layouts/_messages.html.erb (0.1ms)
  Rendered layouts/_footer.html.erb (0.2ms)
Completed 200 OK in 267ms (Views: 266.8ms | ActiveRecord: 0.2ms)


Started DELETE "/users/sign_out" for 127.0.0.1 at 2013-11-14 10:42:44 +0000
Processing by Devise::SessionsController#destroy as HTML
  Parameters: {"authenticity_token"=>"mpizbeU93QE57D132fUX+91LYpaBMTVIZSVrq2cBX7M="}
  [1m[35mUser Load (0.2ms)[0m  SELECT "users".* FROM "users" WHERE "users"."id" = 1 LIMIT 1
  [1m[36m (0.1ms)[0m  [1mbegin transaction[0m
  [1m[35m (0.1ms)[0m  commit transaction
Redirected to http://localhost:3000/
Completed 302 Found in 88ms (ActiveRecord: 0.4ms)


Started GET "/" for 127.0.0.1 at 2013-11-14 10:42:44 +0000
Processing by PagesController#preregistration as HTML
  Rendered layouts/_title.html.erb (0.0ms)
  Rendered layouts/_preregistration.html.erb (12.6ms)
  Rendered pages/preregistration.html.erb within layouts/application (61.0ms)
  Rendered layouts/_header.html.erb (0.8ms)
  Rendered layouts/_messages.html.erb (0.1ms)
  Rendered layouts/_prefooter.html.erb (0.0ms)
Completed 200 OK in 112ms (Views: 111.6ms | ActiveRecord: 0.0ms)


Started GET "/users/sign_up" for 127.0.0.1 at 2013-11-14 10:42:46 +0000
Processing by Devise::RegistrationsController#new as HTML
  Rendered layouts/_title.html.erb (0.0ms)
  Rendered devise/registrations/new.html.erb within layouts/application (98.3ms)
  Rendered layouts/_header.html.erb (0.7ms)
  Rendered layouts/_messages.html.erb (0.1ms)
  Rendered layouts/_prefooter.html.erb (0.0ms)
Completed 200 OK in 153ms (Views: 134.3ms | ActiveRecord: 0.0ms)


Started POST "/users" for 127.0.0.1 at 2013-11-14 10:43:15 +0000
Processing by Devise::RegistrationsController#create as HTML
  Parameters: {"utf8"=>"âœ“", "authenticity_token"=>"cRwBQrxsVSYuXdCiulDDLUSe/6BXt/03Rpf42y2NnjM=", "user"=>{"name"=>"Test", "email"=>"foobar@test-streamingwell.com", "company"=>"", "job"=>"", "password"=>"[FILTERED]", "password_confirmation"=>"[FILTERED]", "reminder"=>"0", "future"=>"0"}, "commit"=>"Submit"}
  [1m[36m (0.1ms)[0m  [1mbegin transaction[0m
  [1m[35mUser Exists (0.2ms)[0m  SELECT 1 AS one FROM "users" WHERE "users"."email" = 'foobar@test-streamingwell.com' LIMIT 1
Binary data inserted for `string` type on column `encrypted_password`
  [1m[36mSQL (45.3ms)[0m  [1mINSERT INTO "users" ("company", "confirmation_token", "created_at", "current_sign_in_at", "current_sign_in_ip", "email", "encrypted_password", "future", "hcp", "job", "last_sign_in_at", "last_sign_in_ip", "name", "nothcp", "remember_created_at", "reminder", "reset_password_sent_at", "reset_password_token", "sign_in_count", "updated_at") VALUES (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?)[0m  [["company", ""], ["confirmation_token", nil], ["created_at", Thu, 14 Nov 2013 10:43:15 UTC +00:00], ["current_sign_in_at", nil], ["current_sign_in_ip", nil], ["email", "foobar@test-streamingwell.com"], ["encrypted_password", "$2a$10$tDkikNd0WDl8Q06n8xYMq.nDRPjagugF.AduOoRQajnTaQQjnEyZe"], ["future", false], ["hcp", nil], ["job", ""], ["last_sign_in_at", nil], ["last_sign_in_ip", nil], ["name", "Test"], ["nothcp", nil], ["remember_created_at", nil], ["reminder", false], ["reset_password_sent_at", nil], ["reset_password_token", nil], ["sign_in_count", 0], ["updated_at", Thu, 14 Nov 2013 10:43:15 UTC +00:00]]
  Rendered admin_mailer/registration_notification.text.erb (26.6ms)

Sent mail to branden.mittra@streamingwell.com (351ms)
Date: Thu, 14 Nov 2013 10:43:16 +0000
From: noreply@astellasoncology.co.uk
To: branden.mittra@streamingwell.com
Message-ID: <5284a944b44d_30f080434a4c632bc@Franciss-iMac.local.mail>
Subject: New Registration
Mime-Version: 1.0
Content-Type: text/plain;
 charset=UTF-8
Content-Transfer-Encoding: 7bit

New notification alert
--------------------------

The following user just registered:

Name: Test
Email: foobar@test-streamingwell.com
Place of Work: 
Job Title: 
Reminder Emails: false
Future contact: false

  Rendered user_mailer/welcome.html.erb within layouts/mail (1.2ms)
  Rendered user_mailer/welcome.text.erb (15.9ms)

Sent mail to foobar@test-streamingwell.com (877ms)
Date: Thu, 14 Nov 2013 10:43:16 +0000
From: noreply@astellasoncology.co.uk
To: foobar@test-streamingwell.com
Message-ID: <5284a944c019a_30f080434a4c6369d@Franciss-iMac.local.mail>
Subject: Log-in details for the Prostate Cancer Lunchtime Webinars
Mime-Version: 1.0
Content-Type: multipart/alternative;
 boundary="--==_mimepart_5284a944a36ce_30f080434a4c633e3";
 charset=UTF-8
Content-Transfer-Encoding: 7bit



----==_mimepart_5284a944a36ce_30f080434a4c633e3
Date: Thu, 14 Nov 2013 10:43:16 +0000
Mime-Version: 1.0
Content-Type: text/plain;
 charset=UTF-8
Content-Transfer-Encoding: quoted-printable
Content-ID: <5284a944bf006_30f080434a4c6349a@Franciss-iMac.local.mail>

Prostate Cancer Lunchtime Webinars =

A multidisciplinary approach to prostate cancer understanding and managem=
ent
-------------------------------------------------------------------------=
---

Dear Test

Thank you for registering your interest in the Astellas Oncology live web=
inars.


Your log-in details are as follows:
Username: foobar@test-streamingwell.com
Password: foobar

Please use these log-in details every time you wish to visit the webinar =
website:
www.astellasoncology.co.uk


The next live webinar is as follows:

Date: Tuesday 26th November 2013
Time: 12.30 to 13.15
Title: Working together: organising care for optimal management of prosta=
te cancer
Speaker(s): Dr Simon Hughes, Consultant in Clinical Oncology and Louisa F=
leure, Advanced Prostate Cancer Specialist Nurse Guy's Hospital, London

Summary: Dr Simon Hughes and Ms Louisa Fleure will provide expert first-h=
and insights regarding the successful management of patients with prostat=
e cancer in a multidisciplinary team (MDT) setup.
Topics:
The multidisciplinary team (MDT) structure and roles

Managing patients with differing needs in an MDT environment

Newly diagnosed patients

Patients with advanced disease

Meeting the challenges of a =E2=80=98working=E2=80=99 MDT at Guy=E2=80=99=
s Hospital



We do hope that you will be able to join us and you find the webinar inte=
resting and informative.

Please note, details regarding speakers, topics and timings for the full =
webinar programme are available on the website.

Yours sincerely,

Astellas Oncology

Astellas Pharma Ltd. =

2000 Hillswood Drive =

Chertsey =

KT16 0RS =

United Kingdom =

Registered in England and Wales under Registered No 00787610 =


Please do not reply to this email.
Date of preparation: September 2013 	Jobcode:XTD13057UKl
These webinars are organised and funded by Astellas Pharma Ltd.

-------------------------------------------------------------------------=
---

Important: The information transmitted in this message is intended only f=
or the person or entity to which it is addressed and may contain confiden=
tial and/or privileged material. Any review, retransmission, disseminatio=
n or other use of, or taking of any action in reliance upon, this informa=
tion by persons or entities other than the intended recipient is prohibit=
ed. If you receive this message in error, please contact the sender and d=
elete the material from any computer.

													=


														&nbsp;<a href=3D"*|UNSUB|*">unsubscribe from this list</a>&=
nbsp;
														<!-- // Begin PI \\ -->
												=


Xtandi&trade; (enzalutamide) Prescribing Information - For full prescribi=
ng information please refer to the Summary of Product Characteristics.

Presentation: Xtandi&trade; 40 mg soft capsules each containing 40 mg of =
enzalutamide.

Indication: Xtandi&trade; is indicated for the treatment of adult men wit=
h metastatic castration resistant prostate cancer whose disease has progr=
essed on or after docetaxel therapy

Posology and method of administration: Adults and elderly (=E2=89=A5 65 y=
ears of age): The recommended dose is 160 mg enzalutamide (four 40 mg cap=
sules) as a single oral daily dose. If a patient misses taking Xtandi&tra=
de; at the usual time, the prescribed dose should be taken as close as po=
ssible to the usual time.  If a patient misses a dose for a whole day, tr=
eatment should be resumed the following day with the usual daily dose.
If a patient experiences a =E2=89=A5 Grade 3 toxicity or an intolerable a=
dverse reaction, dosing should be withheld for one week or until symptoms=
 improve to =E2=89=A4 Grade 2, then resumed at the same or a reduced dose=
 (120 mg or 80 mg) if warranted.

Older people: No dose adjustment is necessary for older people.

Hepatic impairment: No dose adjustment is necessary for patients with mil=
d hepatic impairment; caution is advised in patients with moderate hepati=
c impairment; Xtandi&trade; is not recommended in patients with severe he=
patic impairment.

Renal impairment: No dose adjustment is necessary for patients with mild =
or moderate renal impairment.  Caution is advised in patients with severe=
 renal impairment or end stage renal disease. Paediatric population:There=
 is no relevant use of enzalutamide in the paediatric population.Contrace=
ption in males and females: It is not known whether enzalutamide or its m=
etabolites are present in semen. A condom is required during and for 3 mo=
nths after treatment with enzalutamide if the patient is engaged in sexua=
l activity with a pregnant woman. If the patient engages in sexual interc=
ourse with a woman of childbearing potential, a condom and another form o=
f birth control must be used during and for 3 months after treatment. Stu=
dies in animals have shown reproductive toxicity.

Contraindications: Hypersensitivity to the active substance or to any of =
the excipients.
	Women who are or may become pregnant.

	Warnings and Precautions: Caution should be used in administering Xtandi=
&trade; to patients with a history of seizures or otherpredisposing facto=
rs. In addition, the risk of seizure may be increased in patients receivi=
ng concomitant medicinal products that lower the seizure threshold. The A=
FFIRM study excluded patients with recent myocardial infarction, unstable=
 angina, heart failure, long QT, bradycardia or uncontrolled hypertension=
. This should be taken into account if Xtandi&trade; is prescribed in the=
se patients. =


	Xtandi&trade; contains sorbitol (E420). Patients with rare hereditary pr=
oblems of fructose intolerance should not take this medicinal product.

	Drug interactions: Strong inhibitors (e.g. gemfibrozil) or inducers (e.g=
. rifampicin) of CYP2C8 are to be avoided or used with caution during enz=
alutamide treatment. If patients must be co-administered a strong CYP2C8 =
inhibitor, the dose of enzalutamide should be reduced to 80 mg once daily=
 CYP3A4 plays a minor role in the metabolism of enzalutamide. No dose adj=
ustment is necessary when Xtandi&trade; is co-administered with inhibitor=
s or inducers of CYP3A4. Enzalutamide is a potent enzyme inducer and incr=
eases the synthesis of many enzymes and transporters; therefore, interact=
ion with many common medicinal products that are substrates of enzymes or=
 transporters is expected. Enzymes that may be induced include CYP3A4 in =
the liver and gut, CYP2C9, CYP2C19, CYP1A2 and uridine 5'-diphospho-glucu=
ronosyltransferase (UGTs - glucuronide conjugating enzymes). The transpor=
t protein P-gp may also be induced, and probably other transporters as we=
ll, e.g. multidrug resistance-associated protein 2 (MRP2), breast cancer =
resistant protein (BCRP) and the organic anion transporting polypeptide 1=
B1 (OATP1B1). In vivo studies have shown that enzalutamide is a strong in=
ducer of CYP3A4 and a moderate inducer of CYP2C9 and CYP2C19. The full in=
duction potential of enzalutamide may not occur until approximately 1 mon=
th after the start of treatment, when steady-state plasma concentrations =
of enzalutamide are reached, although some induction effects may be appar=
ent earlier. Patients taking medicinal products that are substrates of CY=
P3A4, CYP2C9, CYP2C19, CYP1A2 or UGT1A1 should be evaluated for possible =
loss of pharmacological effects (or increase in effects in cases where ac=
tive metabolites are formed) during the first month of enzalutamide treat=
ment, and dose adjustment should be considered as appropriate. If their t=
herapeutic effect is of large importance to the patient, and dose adjustm=
ents are not easily performed based on monitoring of efficacy or plasma c=
oncentrations, these medicinal products are to be avoided or used with ca=
ution. In consideration of the long half-life of enzalutamide (5.8 days),=
 effects on enzymes may persist for one month or longer after stopping en=
zalutamide. A gradual dose reduction of the concomitant medicinal product=
 may be necessary when stopping enzalutamide treatment. In vitro data ind=
icate that enzalutamide may be an inhibitor of the efflux transporter P-g=
p. The effect of enzalutamide on P-gp substrates has not been evaluated i=
n vivo; however, under conditions of clinical use, enzalutamide may be an=
 inducer of P-gp via activation of the nuclear pregnane receptor (PXR). M=
edicinal products with a narrow therapeutic range that are substrates for=
 P-gp (e.g. colchicine, dabigatran etexilate, digoxin) should be used wit=
h caution when administered concomitantly with Xtandi&trade; and may requ=
ire dose adjustment to maintain optimal plasma concentrations.
		The safety and efficacy of concomitant use of Xtandi&trade; with cytoto=
xic chemotherapy has not been established.

		Undesirable effects:  Very Common (=E2=89=A5 1/10): headache, hot flush=
; Common (=E2=89=A5 1/100 to < 1/10): neutropenia, visual hallucinations,=
 anxiety, cognitive disorders, memory impairment, hypertension, dry skin,=
 pruritus, fractures, falls; Uncommon (=E2=89=A5 1/1,000 to < 1/100): leu=
copenia, seizure, amnesia, disturbance in attention. (In the AFFIRM study=
, six patients (0.8%) experienced a seizure out of 800 patients treated w=
ith a daily dose of 160 mg enzalutamide).

		Packs and Cost: 40mg capsules x 112: =C2=A32,734.67 Legal Classificatio=
n: POM. Marketing authorisation number: EU/1/13/846/001

		Date of Preparation of PI: June 2013. Job number of PI: PRE13003UK  Fur=
ther information available from: Astellas Pharma Ltd, 2000 Hillswood Driv=
e, Chertsey. KT16 0RS.  For Medical Information phone: 0800 783 5018 =


		Adverse events should be reported. Reporting forms and information can =
be found at www.mhra.gov.uk/yellowcard. Adverse events should also be rep=
orted to Astellas Pharma Ltd. Please contact 0800 783 501 =


----==_mimepart_5284a944a36ce_30f080434a4c633e3
Date: Thu, 14 Nov 2013 10:43:16 +0000
Mime-Version: 1.0
Content-Type: text/html;
 charset=UTF-8
Content-Transfer-Encoding: quoted-printable
Content-ID: <5284a944bfa74_30f080434a4c635ec@Franciss-iMac.local.mail>

<html>
<head>
  <title></title>
</head>
<body>
  <!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://=
www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html>
<head>
	<meta http-equiv=3D"Content-Type" content=3D"text/html; charset=3DUTF-8"=
 />

	<!-- Facebook sharing information tags -->
	<meta property=3D"og:title" content=3D"*|MC:SUBJECT|*" />

	<title>*|MC:SUBJECT|*</title>
	<style type=3D"text/css">
	/* Client-specific Styles */
	#outlook a{padding:0;} /* Force Outlook to provide a "view in browser" b=
utton. */
	body{width:100% !important;} .ReadMsgBody{width:100%;} .ExternalClass{wi=
dth:100%;} /* Force Hotmail to display emails at full width */
	body{-webkit-text-size-adjust:none;} /* Prevent Webkit platforms from ch=
anging default text sizes. */

	/* Reset Styles */
	body{margin:0; padding:0;}
	img{border:0; height:auto; line-height:100%; outline:none; text-decorati=
on:none;}
	table td{border-collapse:collapse;}
	#backgroundTable{height:100% !important; margin:0; padding:0; width:100%=
 !important;}

	/* Template Styles */

	/* /\/\/\/\/\/\/\/\/\/\ STANDARD STYLING: COMMON PAGE ELEMENTS /\/\/\/\/=
\/\/\/\/\/\ */

			/**
			* @tab Page
			* @section background color
			* @tip Set the background color for your email. You may want to choose=
 one that matches your company's branding.
			* @theme page
			*/
			body, #backgroundTable{
				/*@editable*/ background-color:#FAFAFA;

			}

			/**
			* @tab Page
			* @section email border
			* @tip Set the border for your email.
			*/
			#templateContainer{
				/*@editable*/ border: 1px solid #DDDDDD;
				background-image: url('http://streamingwell.tv/img/email-bg.jpg');
				background-repeat: no-repeat;
			}

			/**
			* @tab Page
			* @section heading 1
			* @tip Set the styling for all first-level headings in your emails. Th=
ese should be the largest of your headings.
			* @style heading 1
			*/
			h1, .h1{
				/*@editable*/ color:#939598;
				display:block;
				/*@editable*/ font-family:Arial;
				/*@editable*/ font-size:20px;
				/*@editable*/ font-weight:bold;
				/*@editable*/ line-height:100%;
				margin-top:10px;
				margin-right:0;
				margin-bottom:10px;
				margin-left:0;
				/*@editable*/ text-align:left;
			}

			/**
			* @tab Page
			* @section heading 2
			* @tip Set the styling for all second-level headings in your emails.
			* @style heading 2
			*/
			h2, .h2{
				/*@editable*/ color:#202020;
				display:block;
				/*@editable*/ font-family:Arial;
				/*@editable*/ font-size:30px;
				/*@editable*/ font-weight:bold;
				/*@editable*/ line-height:100%;
				margin-top:0;
				margin-right:0;
				margin-bottom:10px;
				margin-left:0;
				/*@editable*/ text-align:left;
			}

			/**
			* @tab Page
			* @section heading 3
			* @tip Set the styling for all third-level headings in your emails.
			* @style heading 3
			*/
			h3, .h3{
				/*@editable*/ color:#202020;
				display:block;
				/*@editable*/ font-family:Arial;
				/*@editable*/ font-size:26px;
				/*@editable*/ font-weight:bold;
				/*@editable*/ line-height:100%;
				margin-top:0;
				margin-right:0;
				margin-bottom:10px;
				margin-left:0;
				/*@editable*/ text-align:left;
			}

			/**
			* @tab Page
			* @section heading 4
			* @tip Set the styling for all fourth-level headings in your emails. T=
hese should be the smallest of your headings.
			* @style heading 4
			*/
			h4, .h4{
				/*@editable*/ color:#202020;
				display:block;
				/*@editable*/ font-family:Arial;
				/*@editable*/ font-size:11px;
				/*@editable*/ font-weight:100;
				/*@editable*/ line-height:100%;
				margin-top:0;
				margin-right:0;
				margin-bottom:10px;
				margin-left:0;
				/*@editable*/ text-align:left;
			}

			.h4 i {
				font-weight: 100;
				color: rgb(167, 43, 77);
				background: #fff;
			}



			/* /\/\/\/\/\/\/\/\/\/\ STANDARD STYLING: PREHEADER /\/\/\/\/\/\/\/\/\=
/\ */

			/**
			* @tab Header
			* @section preheader style
			* @tip Set the background color for your email's preheader area.
			* @theme page
			*/
			#templatePreheader{
				/*@editable*/ background-color:#FAFAFA;
			}

			/**
			* @tab Header
			* @section preheader text
			* @tip Set the styling for your email's preheader text. Choose a size =
and color that is easy to read.
			*/
			.preheaderContent div{
				/*@editable*/ color:#505050;
				/*@editable*/ font-family:Arial;
				/*@editable*/ font-size:10px;
				/*@editable*/ line-height:100%;
				/*@editable*/ text-align:left;
			}

			/**
			* @tab Header
			* @section preheader link
			* @tip Set the styling for your email's preheader links. Choose a colo=
r that helps them stand out from your text.
			*/
			.preheaderContent div a:link, .preheaderContent div a:visited, /* Yaho=
o! Mail Override */ .preheaderContent div a .yshortcuts /* Yahoo! Mail Ov=
erride */{
				/*@editable*/ color:#336699;
				/*@editable*/ font-weight:normal;
				/*@editable*/ text-decoration:underline;
			}



			/* /\/\/\/\/\/\/\/\/\/\ STANDARD STYLING: HEADER /\/\/\/\/\/\/\/\/\/\ =
*/

			/**
			* @tab Header
			* @section header style
			* @tip Set the background color and border for your email's header are=
a.
			* @theme header
			*/
			#templateHeader{
				/*@editable*/ background-color:#FFFFFF;
				/*@editable*/ border-bottom:0;
			}

			/**
			* @tab Header
			* @section header text
			* @tip Set the styling for your email's header text. Choose a size and=
 color that is easy to read.
			*/
			.headerContent{
				/*@editable*/ color:#202020;
				/*@editable*/ font-family:Arial;
				/*@editable*/ font-size:34px;
				/*@editable*/ font-weight:bold;
				/*@editable*/ line-height:100%;
				/*@editable*/ padding:0;
				/*@editable*/ text-align:center;
				/*@editable*/ vertical-align:middle;
			}

			/**
			* @tab Header
			* @section header link
			* @tip Set the styling for your email's header links. Choose a color t=
hat helps them stand out from your text.
			*/
			.headerContent a:link, .headerContent a:visited, /* Yahoo! Mail Overri=
de */ .headerContent a .yshortcuts /* Yahoo! Mail Override */{
				/*@editable*/ color:#336699;
				/*@editable*/ font-weight:normal;
				/*@editable*/ text-decoration:underline;
			}

			#headerImage{
				height:auto;
				max-width:600px;
			}

			/* /\/\/\/\/\/\/\/\/\/\ STANDARD STYLING: MAIN BODY /\/\/\/\/\/\/\/\/\=
/\ */

			/**
			* @tab Body
			* @section body style
			* @tip Set the background color for your email's body area.
			*/
			#templateContainer, .bodyContent{
				/*@editable*/ background-color:#FFFFFF;
				background-image: url('http://streamingwell.tv/img/email-bg.jpg');
				background-repeat: no-repeat;
			}

			/**
			* @tab Body
			* @section body text
			* @tip Set the styling for your email's main content text. Choose a si=
ze and color that is easy to read.
			* @theme main
			*/
			.bodyContent div{
				/*@editable*/ color:#505050;
				/*@editable*/ font-family:Arial;
				/*@editable*/ font-size:14px;
				/*@editable*/ line-height:150%;
				/*@editable*/ text-align:left;
			}

			/**
			* @tab Body
			* @section body link
			* @tip Set the styling for your email's main content links. Choose a c=
olor that helps them stand out from your text.
			*/
			.bodyContent div a:link, .bodyContent div a:visited, /* Yahoo! Mail Ov=
erride */ .bodyContent div a .yshortcuts /* Yahoo! Mail Override */{
				/*@editable*/ color:#336699;
				/*@editable*/ font-weight:normal;
				/*@editable*/ text-decoration:underline;
			}

			.bodyContent img{
				display:inline;
				height:auto;
			}

			/* /\/\/\/\/\/\/\/\/\/\ STANDARD STYLING: FOOTER /\/\/\/\/\/\/\/\/\/\ =
*/

			/**
			* @tab Footer
			* @section footer style
			* @tip Set the background color and top border for your email's footer=
 area.
			* @theme footer
			*/
			#templateFooter{
				/*@editable*/ background-color:#FFFFFF;
				/*@editable*/ border-top:0;
			}

			/**
			* @tab Footer
			* @section footer text
			* @tip Set the styling for your email's footer text. Choose a size and=
 color that is easy to read.
			* @theme footer
			*/
			.footerContent div{
				/*@editable*/ color:#707070;
				/*@editable*/ font-family:Arial;
				/*@editable*/ font-size:12px;
				/*@editable*/ line-height:125%;
				/*@editable*/ text-align:left;
			}

			/**
			* @tab Footer
			* @section footer link
			* @tip Set the styling for your email's footer links. Choose a color t=
hat helps them stand out from your text.
			*/
			.footerContent div a:link, .footerContent div a:visited, /* Yahoo! Mai=
l Override */ .footerContent div a .yshortcuts /* Yahoo! Mail Override */=
{
				/*@editable*/ color:#336699;
				/*@editable*/ font-weight:normal;
				/*@editable*/ text-decoration:underline;
			}

			.footerContent img{
				display:inline;
			}

			/**
			* @tab Footer
			* @section social bar style
			* @tip Set the background color and border for your email's footer soc=
ial bar.
			* @theme footer
			*/
			#social{
				/*@editable*/ background-color:#FAFAFA;
				/*@editable*/ border:0;
			}

			/**
			* @tab Footer
			* @section social bar style
			* @tip Set the background color and border for your email's footer soc=
ial bar.
			*/
			#social div{
				/*@editable*/ text-align:center;
			}

			/**
			* @tab Footer
			* @section utility bar style
			* @tip Set the background color and border for your email's footer uti=
lity bar.
			* @theme footer
			*/
			#utility{
				/*@editable*/ background-color:#FFFFFF;
				/*@editable*/ border:0;
			}

			/**
			* @tab Footer
			* @section utility bar style
			* @tip Set the background color and border for your email's footer uti=
lity bar.
			*/
			#utility div{
				/*@editable*/ text-align:center;
			}

			#monkeyRewards img{
				max-width:190px;
			}
			</style>
		</head>
		<body leftmargin=3D"0" marginwidth=3D"0" topmargin=3D"0" marginheight=3D=
"0" offset=3D"0">
			<center>
				<table border=3D"0" cellpadding=3D"0" cellspacing=3D"0" height=3D"100=
%" width=3D"100%" id=3D"backgroundTable">
					<tr>
						<td align=3D"center" valign=3D"top">
							<!-- // Begin Template Preheader \\ -->
							<table border=3D"0" cellpadding=3D"10" cellspacing=3D"0" width=3D"=
600" id=3D"templatePreheader">
								<tr>
									<td valign=3D"top" class=3D"preheaderContent">

										<!-- // Begin Module: Standard Preheader \ -->
										<table border=3D"0" cellpadding=3D"10" cellspacing=3D"0" width=3D=
"100%">
											<tr>
												<td valign=3D"top">
													<div mc:edit=3D"std_preheader_content"></div>
												</td>
												<!-- *|IFNOT:ARCHIVE_PAGE|* -->
												<td valign=3D"top" width=3D"190">
													<div mc:edit=3D"std_preheader_links"></div>
												</td>
												<!-- *|END:IF|* -->
											</tr>
										</table>
										<!-- // End Module: Standard Preheader \ -->

									</td>
								</tr>
							</table>

						</td>
					</tr>
					<tr>
						<td align=3D"center" valign=3D"top">
							<!-- // Begin Template Body \\ -->
							<table border=3D"0" cellpadding=3D"0" cellspacing=3D"0" width=3D"6=
00" id=3D"templateBody">
								<tr>
									<td valign=3D"top" class=3D"bodyContent">

										<!-- // Begin Module: Standard Postcard Content \\ -->
										<table border=3D"0" cellpadding=3D"20" cellspacing=3D"0" width=3D=
"80%">
											<tr mc:repeatable>
												<td valign=3D"top">
													<div mc:edit=3D"postcard_heading00">
														<img src=3D"http://img855.imageshack.us/img855/4207/aome.jp=
g">
														<h1 class=3D"h1"><span style=3D"color: rgb(167, 43, 77)">Pr=
ostate Cancer Lunchtime Webinars</span></h1>
														<h4><i>A multidisciplinary approach to prostate cancer unde=
rstanding and management</i></h4>
													</div>
													<br>
													<div mc:edit=3D"std_content00">
														<p>Dear Test</p>

														<p>Thank you for registering your interest in the Astellas =
Oncology live webinars.</p>
														<p><strong>Your log-in details are as follows:</strong></p>=

														<p><strong>Username: foobar@test-streamingwell.com</strong>=
</p>
														<p><strong>Password: foobar</strong></p>

														<p>Please use these log-in details every time you wish to v=
isit the webinar website: http://www.astellasoncology.co.uk/users/sign_in=
</p>

														<br>
														<p><strong>The next live webinar is as follows:</strong></p=
>

														<p>Date: Tuesday 26th November 2013</p>
														<p>Time: 12.30 to 13.15</p>
														<p><strong>Title:</strong><i>Working together: organising c=
are for optimal management of prostate cancer</i></p>
														<p><strong>Speaker(s):</strong>  Dr Simon Hughes, Consultan=
t in Clinical Oncology and Ms Louisa Fleure, Advanced Prostate Cancer Spe=
cialist Nurse Guy's Hospital, London</p>

														<p><strong>Summary:</strong>Dr Simon Hughes and Ms Louisa F=
leure will provide expert first-hand insights regarding the successful ma=
nagement of patients with prostate cancer in a multidisciplinary team (MD=
T) setup.</p>

														<p><strong>Topics:</strong></p>
														<p><li>The multidisciplinary team (MDT) structure and roles=
</li></p>

														<p><li>Managing patients with differing needs in an MDT env=
ironment</li></p>

														<p><li>Newly diagnosed patients</li></p>

														<p><li>Patients with advanced disease</li></p>

														<p><li>Meeting the challenges of a =E2=80=98working=E2=80=99=
 MDT at Guy=E2=80=99s Hospital</li></p>
														<br>
														<p>We do hope that you will be able to join us and you find=
 the webinar interesting and informative.</p>

														<p>Please note, details regarding speakers, topics and timi=
ngs for the full webinar programme are available on the website.</p>


														<p>Yours sincerely,</p>

														<p>Astellas Oncology</p>

                                                        </td>
                                                    </tr>
                                                </table>
                                                <!-- // End Module: Stand=
ard Postcard Content \\ -->
                                                =

                                            </td>
                                        </tr>
                                    </table>
                                    <!-- // End Template Body \\ -->
                                </td>
                            </tr>
                        	<tr>
                            	<td align=3D"center" valign=3D"top">
                                    <!-- // Begin Template Footer \\ -->
                                	<table border=3D"0" cellpadding=3D"10" c=
ellspacing=3D"0" width=3D"600" id=3D"templateFooter">
                                    	<tr>
                                        	<td valign=3D"top" class=3D"foot=
erContent">
                                            =

                                                <!-- // Begin Module: Sta=
ndard Footer \\ -->
                                                <table border=3D"0" cellp=
adding=3D"10" cellspacing=3D"0" width=3D"100%">
                                                    <tr>
                          =

                                                        <td valign=3D"top=
" width=3D"350">
                                                            <div mc:edit=3D=
"std_footer">
																<p><em>Astellas Pharma Ltd.</em> </p>
																<p><em>2000 Hillswood Drive </em></p>
																<p><em>Chertsey</em> </p>
																<p><em>KT16 0RS </em></p>
																<p><em>United Kingdom </em></p>
																<p><em>Registered in England and Wales under Registered N=
o 00787610 </em></p>
																<br />
																=

																<em>Please do not reply to this email</em>
																<em>Date of preparation: October 2013 Job code: XTD13057U=
Kl</em>
                                                            <p><em>These =
webinars are organised and funded by Astellas Pharma Ltd.</em></p>
												=

											=


															<small>Important: The information transmitted in this mess=
age is intended only for the person or entity to which it is addressed an=
d may contain confidential and/or privileged material. Any review, retran=
smission, dissemination or other use of, or taking of any action in relia=
nce upon, this information by persons or entities other than the intended=
 recipient is prohibited. If you receive this message in error, please co=
ntact the sender and delete the material from any computer.</small>

														<br>
														<br>
														&nbsp;<a href=3D"*|UNSUB|*">unsubscribe from this list</a>&=
nbsp;

														</div>
													</td>
												</tr>
														=

														<!-- // Begin PI \\ -->
                                                                <tr>
                                                        <td colspan=3D"2"=
 valign=3D"left">
                                                            <div>
                             =

<p><img src=3D"http://warm-dawn-9465.herokuapp.com/assets/xtandi-logo-134=
.png" align=3D"right"></p>

<br>
<br>     =


<p><strong>Xtandi&trade;</span> (enzalutamide) Prescribing Information -<=
/strong> For full prescribing information please refer to the Summary of =
Product Characteristics.</p>

<p><strong>Presentation:</strong> Xtandi&trade; 40 mg soft capsules each =
containing 40 mg of enzalutamide.</p>

<p><strong>Indication:</strong> Xtandi&trade; is indicated for the treatm=
ent of adult men with metastatic castration resistant prostate cancer who=
se disease has progressed on or after docetaxel therapy</p>

<p><strong>Posology and method of administration:</strong> Adults and eld=
erly (=E2=89=A5 65 years of age): The recommended dose is 160 mg enzaluta=
mide (four 40 mg capsules) as a single oral daily dose. If a patient miss=
es taking Xtandi&trade; at the usual time, the prescribed dose should be =
taken as close as possible to the usual time.  If a patient misses a dose=
 for a whole day, treatment should be resumed the following day with the =
usual daily dose.</p>
<p>If a patient experiences a =E2=89=A5 Grade 3 toxicity or an intolerabl=
e adverse reaction, dosing should be withheld for one week or until sympt=
oms improve to =E2=89=A4 Grade 2, then resumed at the same or a reduced d=
ose (120 mg or 80 mg) if warranted.</p>

<p>Older people: No dose adjustment is necessary for older people.</p>

<p>Hepatic impairment: No dose adjustment is necessary for patients with =
mild hepatic impairment; caution is advised in patients with moderate hep=
atic impairment; Xtandi&trade; is not recommended in patients with severe=
 hepatic impairment.</p>

<p>Renal impairment: No dose adjustment is necessary for patients with mi=
ld or moderate renal impairment.  Caution is advised in patients with sev=
ere renal impairment or end stage renal disease. Paediatric population:Th=
ere is no relevant use of enzalutamide in the paediatric population.Contr=
aception in males and females: It is not known whether enzalutamide or it=
s metabolites are present in semen. A condom is required during and for 3=
 months after treatment with enzalutamide if the patient is engaged in se=
xual activity with a pregnant woman. If the patient engages in sexual int=
ercourse with a woman of childbearing potential, a condom and another for=
m of birth control must be used during and for 3 months after treatment. =
Studies in animals have shown reproductive toxicity.</p>

<p><strong>Contraindications:</strong> Hypersensitivity to the active sub=
stance or to any of the excipients.
Women who are or may become pregnant.</p>

<p><strong>Warnings and Precautions:</strong> Caution should be used in a=
dministering Xtandi&trade; to patients with a history of seizures or othe=
rpredisposing factors. In addition, the risk of seizure may be increased =
in patients receiving concomitant medicinal products that lower the seizu=
re threshold. The AFFIRM study excluded patients with recent myocardial i=
nfarction, unstable angina, heart failure, long QT, bradycardia or uncont=
rolled hypertension. This should be taken into account if Xtandi&trade; i=
s prescribed in these patients. </p>

<p>Xtandi&trade; contains sorbitol (E420). Patients with rare hereditary =
problems of fructose intolerance should not take this medicinal product.<=
/p>

<p><strong>Drug interactions:</strong> Strong inhibitors (e.g. gemfibrozi=
l) or inducers (e.g. rifampicin) of CYP2C8 are to be avoided or used with=
 caution during enzalutamide treatment. If patients must be co-administer=
ed a strong CYP2C8 inhibitor, the dose of enzalutamide should be reduced =
to 80 mg once daily CYP3A4 plays a minor role in the metabolism of enzalu=
tamide. No dose adjustment is necessary when Xtandi&trade; is co-administ=
ered with inhibitors or inducers of CYP3A4. Enzalutamide is a potent enzy=
me inducer and increases the synthesis of many enzymes and transporters; =
therefore, interaction with many common medicinal products that are subst=
rates of enzymes or transporters is expected. Enzymes that may be induced=
 include CYP3A4 in the liver and gut, CYP2C9, CYP2C19, CYP1A2 and uridine=
 5'-diphospho-glucuronosyltransferase (UGTs - glucuronide conjugating enz=
ymes). The transport protein P-gp may also be induced, and probably other=
 transporters as well, e.g. multidrug resistance-associated protein 2 (MR=
P2), breast cancer resistant protein (BCRP) and the organic anion transpo=
rting polypeptide 1B1 (OATP1B1). In vivo studies have shown that enzaluta=
mide is a strong inducer of CYP3A4 and a moderate inducer of CYP2C9 and C=
YP2C19. The full induction potential of enzalutamide may not occur until =
approximately 1 month after the start of treatment, when steady-state pla=
sma concentrations of enzalutamide are reached, although some induction e=
ffects may be apparent earlier. Patients taking medicinal products that a=
re substrates of CYP3A4, CYP2C9, CYP2C19, CYP1A2 or UGT1A1 should be eval=
uated for possible loss of pharmacological effects (or increase in effect=
s in cases where active metabolites are formed) during the first month of=
 enzalutamide treatment, and dose adjustment should be considered as appr=
opriate. If their therapeutic effect is of large importance to the patien=
t, and dose adjustments are not easily performed based on monitoring of e=
fficacy or plasma concentrations, these medicinal products are to be avoi=
ded or used with caution. In consideration of the long half-life of enzal=
utamide (5.8 days), effects on enzymes may persist for one month or longe=
r after stopping enzalutamide. A gradual dose reduction of the concomitan=
t medicinal product may be necessary when stopping enzalutamide treatment=
. In vitro data indicate that enzalutamide may be an inhibitor of the eff=
lux transporter P-gp. The effect of enzalutamide on P-gp substrates has n=
ot been evaluated in vivo; however, under conditions of clinical use, enz=
alutamide may be an inducer of P-gp via activation of the nuclear pregnan=
e receptor (PXR). Medicinal products with a narrow therapeutic range that=
 are substrates for P-gp (e.g. colchicine, dabigatran etexilate, digoxin)=
 should be used with caution when administered concomitantly with Xtandi&=
trade; and may require dose adjustment to maintain optimal plasma concent=
rations.
The safety and efficacy of concomitant use of Xtandi&trade; with cytotoxi=
c chemotherapy has not been established.</p>

<p><strong>Undesirable effects:</strong>  Very Common (=E2=89=A5 1/10): h=
eadache, hot flush; Common (=E2=89=A5 1/100 to < 1/10): neutropenia, visu=
al hallucinations, anxiety, cognitive disorders, memory impairment, hyper=
tension, dry skin, pruritus, fractures, falls; Uncommon (=E2=89=A5 1/1,00=
0 to < 1/100): leucopenia, seizure, amnesia, disturbance in attention. (I=
n the AFFIRM study, six patients (0.8%) experienced a seizure out of 800 =
patients treated with a daily dose of 160 mg enzalutamide).</p>

<p><strong>Packs and Cost:</strong> 40mg capsules x 112: =C2=A32,734.67 L=
egal Classification: POM. Marketing authorisation number: EU/1/13/846/001=
</p>

<p><strong>Date of Preparation of PI:</strong> June 2013. <strong>Job num=
ber of PI:</strong> PRE13003UK  <strong>Further information available fro=
m:</strong> Astellas Pharma Ltd, 2000 Hillswood Drive, Chertsey. KT16 0RS=
.  <strong>For Medical Information phone:</strong> 0800 783 5018 </p>

<div class=3D"adverse">
<p>Adverse events should be reported. Reporting forms and information can=
 be found at <a href=3D"www.mhra.gov.uk/yellowcard">www.mhra.gov.uk/yello=
wcard</a>. Adverse events should also be reported to Astellas Pharma Ltd.=
 Please contact 0800 783 501 </p>
</div>
<!-- // Begin PI \\ -->
                                                            </div>
                                                        </td>
                                                    </tr>
                                                </table>
                                                <!-- // End Module: Stand=
ard Footer \\ -->
                                            =

                                            </td>
                                        </tr>
                                    </table>
                                    <!-- // End Template Footer \\ -->
                                </td>
                            </tr>
                        </table>
                        <br />
                    </td>
                </tr>
            </table>
        </center>
    </body>
</html>
</body>
</html>=


----==_mimepart_5284a944a36ce_30f080434a4c633e3--

  [1m[35m (23.5ms)[0m  commit transaction
  [1m[36m (0.1ms)[0m  [1mbegin transaction[0m
  [1m[35m (0.3ms)[0m  UPDATE "users" SET "last_sign_in_at" = '2013-11-14 10:43:17.756746', "current_sign_in_at" = '2013-11-14 10:43:17.756746', "last_sign_in_ip" = '127.0.0.1', "current_sign_in_ip" = '127.0.0.1', "sign_in_count" = 1, "updated_at" = '2013-11-14 10:43:17.780244' WHERE "users"."id" = 4
  [1m[36m (49.6ms)[0m  [1mcommit transaction[0m
Redirected to http://localhost:3000/
Completed 302 Found in 2544ms (ActiveRecord: 0.0ms)


Started GET "/" for 127.0.0.1 at 2013-11-14 10:43:18 +0000
Processing by PagesController#preregistration as HTML
  [1m[35mUser Load (0.3ms)[0m  SELECT "users".* FROM "users" WHERE "users"."id" = 4 LIMIT 1
  Rendered layouts/_title.html.erb (0.1ms)
  Rendered pages/preregistration.html.erb within layouts/application (26.4ms)
  Rendered layouts/_header.html.erb (0.6ms)
  Rendered layouts/_messages.html.erb (0.2ms)
  Rendered layouts/_footer.html.erb (0.2ms)
Completed 200 OK in 94ms (Views: 93.2ms | ActiveRecord: 0.3ms)


Started DELETE "/users/sign_out" for 127.0.0.1 at 2013-11-14 10:45:05 +0000
Processing by Devise::SessionsController#destroy as HTML
  Parameters: {"authenticity_token"=>"cRwBQrxsVSYuXdCiulDDLUSe/6BXt/03Rpf42y2NnjM="}
  [1m[36mUser Load (0.2ms)[0m  [1mSELECT "users".* FROM "users" WHERE "users"."id" = 4 LIMIT 1[0m
  [1m[35m (0.1ms)[0m  begin transaction
  [1m[36m (0.0ms)[0m  [1mcommit transaction[0m
Redirected to http://localhost:3000/
Completed 302 Found in 25ms (ActiveRecord: 0.3ms)


Started GET "/" for 127.0.0.1 at 2013-11-14 10:45:05 +0000
Processing by PagesController#preregistration as HTML
  Rendered layouts/_title.html.erb (0.0ms)
  Rendered layouts/_preregistration.html.erb (2.2ms)
  Rendered pages/preregistration.html.erb within layouts/application (4.3ms)
  Rendered layouts/_header.html.erb (0.8ms)
  Rendered layouts/_messages.html.erb (0.1ms)
  Rendered layouts/_prefooter.html.erb (0.0ms)
Completed 200 OK in 55ms (Views: 55.0ms | ActiveRecord: 0.0ms)


Started GET "/users/sign_up" for 127.0.0.1 at 2013-11-14 10:45:07 +0000
Processing by Devise::RegistrationsController#new as HTML
  Rendered layouts/_title.html.erb (0.0ms)
  Rendered devise/registrations/new.html.erb within layouts/application (27.2ms)
  Rendered layouts/_header.html.erb (0.8ms)
  Rendered layouts/_messages.html.erb (0.0ms)
  Rendered layouts/_prefooter.html.erb (0.0ms)
Completed 200 OK in 44ms (Views: 43.5ms | ActiveRecord: 0.0ms)


Started POST "/users" for 127.0.0.1 at 2013-11-14 10:45:24 +0000
Processing by Devise::RegistrationsController#create as HTML
  Parameters: {"utf8"=>"âœ“", "authenticity_token"=>"ELxHyd77QcMZyrkKWOvhArvoJM7BITrI9IDQt3rDwGM=", "user"=>{"name"=>"", "email"=>"mike.richter@streamingwell.com", "company"=>"", "job"=>"", "password"=>"[FILTERED]", "password_confirmation"=>"[FILTERED]", "reminder"=>"0", "future"=>"0"}, "commit"=>"Submit"}
  [1m[35m (0.1ms)[0m  begin transaction
  [1m[36mUser Exists (0.1ms)[0m  [1mSELECT 1 AS one FROM "users" WHERE "users"."email" = 'mike.richter@streamingwell.com' LIMIT 1[0m
Binary data inserted for `string` type on column `encrypted_password`
  [1m[35mSQL (0.6ms)[0m  INSERT INTO "users" ("company", "confirmation_token", "created_at", "current_sign_in_at", "current_sign_in_ip", "email", "encrypted_password", "future", "hcp", "job", "last_sign_in_at", "last_sign_in_ip", "name", "nothcp", "remember_created_at", "reminder", "reset_password_sent_at", "reset_password_token", "sign_in_count", "updated_at") VALUES (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?)  [["company", ""], ["confirmation_token", nil], ["created_at", Thu, 14 Nov 2013 10:45:24 UTC +00:00], ["current_sign_in_at", nil], ["current_sign_in_ip", nil], ["email", "mike.richter@streamingwell.com"], ["encrypted_password", "$2a$10$fxRf5xNAozk134AV7zVBleXTvnX6apWSBuIVu8/LyYfA93Ird5yUS"], ["future", false], ["hcp", nil], ["job", ""], ["last_sign_in_at", nil], ["last_sign_in_ip", nil], ["name", ""], ["nothcp", nil], ["remember_created_at", nil], ["reminder", false], ["reset_password_sent_at", nil], ["reset_password_token", nil], ["sign_in_count", 0], ["updated_at", Thu, 14 Nov 2013 10:45:24 UTC +00:00]]
  Rendered admin_mailer/registration_notification.text.erb (0.1ms)

Sent mail to branden.mittra@streamingwell.com (112ms)
Date: Thu, 14 Nov 2013 10:45:24 +0000
From: noreply@astellasoncology.co.uk
To: branden.mittra@streamingwell.com
Message-ID: <5284a9c49046d_30f080434a4c637f@Franciss-iMac.local.mail>
Subject: New Registration
Mime-Version: 1.0
Content-Type: text/plain;
 charset=UTF-8
Content-Transfer-Encoding: 7bit

New notification alert
--------------------------

The following user just registered:

Name: 
Email: mike.richter@streamingwell.com
Place of Work: 
Job Title: 
Reminder Emails: false
Future contact: false

  Rendered user_mailer/welcome.html.erb within layouts/mail (135.4ms)
  Rendered user_mailer/welcome.text.erb (36.9ms)

Sent mail to mike.richter@streamingwell.com (1593ms)
Date: Thu, 14 Nov 2013 10:45:25 +0000
From: noreply@astellasoncology.co.uk
To: mike.richter@streamingwell.com
Message-ID: <5284a9c5575b0_30f080434a4c64189@Franciss-iMac.local.mail>
Subject: Log-in details for the Prostate Cancer Lunchtime Webinars
Mime-Version: 1.0
Content-Type: multipart/alternative;
 boundary="--==_mimepart_5284a9c52303d_30f080434a4c638a7";
 charset=UTF-8
Content-Transfer-Encoding: 7bit



----==_mimepart_5284a9c52303d_30f080434a4c638a7
Date: Thu, 14 Nov 2013 10:45:25 +0000
Mime-Version: 1.0
Content-Type: text/plain;
 charset=UTF-8
Content-Transfer-Encoding: quoted-printable
Content-ID: <5284a9c53493d_30f080434a4c63914@Franciss-iMac.local.mail>

Prostate Cancer Lunchtime Webinars =

A multidisciplinary approach to prostate cancer understanding and managem=
ent
-------------------------------------------------------------------------=
---

Dear =


Thank you for registering your interest in the Astellas Oncology live web=
inars.


Your log-in details are as follows:
Username: mike.richter@streamingwell.com
Password: richter35

Please use these log-in details every time you wish to visit the webinar =
website:
www.astellasoncology.co.uk


The next live webinar is as follows:

Date: Tuesday 26th November 2013
Time: 12.30 to 13.15
Title: Working together: organising care for optimal management of prosta=
te cancer
Speaker(s): Dr Simon Hughes, Consultant in Clinical Oncology and Louisa F=
leure, Advanced Prostate Cancer Specialist Nurse Guy's Hospital, London

Summary: Dr Simon Hughes and Ms Louisa Fleure will provide expert first-h=
and insights regarding the successful management of patients with prostat=
e cancer in a multidisciplinary team (MDT) setup.
Topics:
The multidisciplinary team (MDT) structure and roles

Managing patients with differing needs in an MDT environment

Newly diagnosed patients

Patients with advanced disease

Meeting the challenges of a =E2=80=98working=E2=80=99 MDT at Guy=E2=80=99=
s Hospital



We do hope that you will be able to join us and you find the webinar inte=
resting and informative.

Please note, details regarding speakers, topics and timings for the full =
webinar programme are available on the website.

Yours sincerely,

Astellas Oncology

Astellas Pharma Ltd. =

2000 Hillswood Drive =

Chertsey =

KT16 0RS =

United Kingdom =

Registered in England and Wales under Registered No 00787610 =


Please do not reply to this email.
Date of preparation: September 2013 	Jobcode:XTD13057UKl
These webinars are organised and funded by Astellas Pharma Ltd.

-------------------------------------------------------------------------=
---

Important: The information transmitted in this message is intended only f=
or the person or entity to which it is addressed and may contain confiden=
tial and/or privileged material. Any review, retransmission, disseminatio=
n or other use of, or taking of any action in reliance upon, this informa=
tion by persons or entities other than the intended recipient is prohibit=
ed. If you receive this message in error, please contact the sender and d=
elete the material from any computer.

													=


														&nbsp;<a href=3D"*|UNSUB|*">unsubscribe from this list</a>&=
nbsp;
														<!-- // Begin PI \\ -->
												=


Xtandi&trade; (enzalutamide) Prescribing Information - For full prescribi=
ng information please refer to the Summary of Product Characteristics.

Presentation: Xtandi&trade; 40 mg soft capsules each containing 40 mg of =
enzalutamide.

Indication: Xtandi&trade; is indicated for the treatment of adult men wit=
h metastatic castration resistant prostate cancer whose disease has progr=
essed on or after docetaxel therapy

Posology and method of administration: Adults and elderly (=E2=89=A5 65 y=
ears of age): The recommended dose is 160 mg enzalutamide (four 40 mg cap=
sules) as a single oral daily dose. If a patient misses taking Xtandi&tra=
de; at the usual time, the prescribed dose should be taken as close as po=
ssible to the usual time.  If a patient misses a dose for a whole day, tr=
eatment should be resumed the following day with the usual daily dose.
If a patient experiences a =E2=89=A5 Grade 3 toxicity or an intolerable a=
dverse reaction, dosing should be withheld for one week or until symptoms=
 improve to =E2=89=A4 Grade 2, then resumed at the same or a reduced dose=
 (120 mg or 80 mg) if warranted.

Older people: No dose adjustment is necessary for older people.

Hepatic impairment: No dose adjustment is necessary for patients with mil=
d hepatic impairment; caution is advised in patients with moderate hepati=
c impairment; Xtandi&trade; is not recommended in patients with severe he=
patic impairment.

Renal impairment: No dose adjustment is necessary for patients with mild =
or moderate renal impairment.  Caution is advised in patients with severe=
 renal impairment or end stage renal disease. Paediatric population:There=
 is no relevant use of enzalutamide in the paediatric population.Contrace=
ption in males and females: It is not known whether enzalutamide or its m=
etabolites are present in semen. A condom is required during and for 3 mo=
nths after treatment with enzalutamide if the patient is engaged in sexua=
l activity with a pregnant woman. If the patient engages in sexual interc=
ourse with a woman of childbearing potential, a condom and another form o=
f birth control must be used during and for 3 months after treatment. Stu=
dies in animals have shown reproductive toxicity.

Contraindications: Hypersensitivity to the active substance or to any of =
the excipients.
	Women who are or may become pregnant.

	Warnings and Precautions: Caution should be used in administering Xtandi=
&trade; to patients with a history of seizures or otherpredisposing facto=
rs. In addition, the risk of seizure may be increased in patients receivi=
ng concomitant medicinal products that lower the seizure threshold. The A=
FFIRM study excluded patients with recent myocardial infarction, unstable=
 angina, heart failure, long QT, bradycardia or uncontrolled hypertension=
. This should be taken into account if Xtandi&trade; is prescribed in the=
se patients. =


	Xtandi&trade; contains sorbitol (E420). Patients with rare hereditary pr=
oblems of fructose intolerance should not take this medicinal product.

	Drug interactions: Strong inhibitors (e.g. gemfibrozil) or inducers (e.g=
. rifampicin) of CYP2C8 are to be avoided or used with caution during enz=
alutamide treatment. If patients must be co-administered a strong CYP2C8 =
inhibitor, the dose of enzalutamide should be reduced to 80 mg once daily=
 CYP3A4 plays a minor role in the metabolism of enzalutamide. No dose adj=
ustment is necessary when Xtandi&trade; is co-administered with inhibitor=
s or inducers of CYP3A4. Enzalutamide is a potent enzyme inducer and incr=
eases the synthesis of many enzymes and transporters; therefore, interact=
ion with many common medicinal products that are substrates of enzymes or=
 transporters is expected. Enzymes that may be induced include CYP3A4 in =
the liver and gut, CYP2C9, CYP2C19, CYP1A2 and uridine 5'-diphospho-glucu=
ronosyltransferase (UGTs - glucuronide conjugating enzymes). The transpor=
t protein P-gp may also be induced, and probably other transporters as we=
ll, e.g. multidrug resistance-associated protein 2 (MRP2), breast cancer =
resistant protein (BCRP) and the organic anion transporting polypeptide 1=
B1 (OATP1B1). In vivo studies have shown that enzalutamide is a strong in=
ducer of CYP3A4 and a moderate inducer of CYP2C9 and CYP2C19. The full in=
duction potential of enzalutamide may not occur until approximately 1 mon=
th after the start of treatment, when steady-state plasma concentrations =
of enzalutamide are reached, although some induction effects may be appar=
ent earlier. Patients taking medicinal products that are substrates of CY=
P3A4, CYP2C9, CYP2C19, CYP1A2 or UGT1A1 should be evaluated for possible =
loss of pharmacological effects (or increase in effects in cases where ac=
tive metabolites are formed) during the first month of enzalutamide treat=
ment, and dose adjustment should be considered as appropriate. If their t=
herapeutic effect is of large importance to the patient, and dose adjustm=
ents are not easily performed based on monitoring of efficacy or plasma c=
oncentrations, these medicinal products are to be avoided or used with ca=
ution. In consideration of the long half-life of enzalutamide (5.8 days),=
 effects on enzymes may persist for one month or longer after stopping en=
zalutamide. A gradual dose reduction of the concomitant medicinal product=
 may be necessary when stopping enzalutamide treatment. In vitro data ind=
icate that enzalutamide may be an inhibitor of the efflux transporter P-g=
p. The effect of enzalutamide on P-gp substrates has not been evaluated i=
n vivo; however, under conditions of clinical use, enzalutamide may be an=
 inducer of P-gp via activation of the nuclear pregnane receptor (PXR). M=
edicinal products with a narrow therapeutic range that are substrates for=
 P-gp (e.g. colchicine, dabigatran etexilate, digoxin) should be used wit=
h caution when administered concomitantly with Xtandi&trade; and may requ=
ire dose adjustment to maintain optimal plasma concentrations.
		The safety and efficacy of concomitant use of Xtandi&trade; with cytoto=
xic chemotherapy has not been established.

		Undesirable effects:  Very Common (=E2=89=A5 1/10): headache, hot flush=
; Common (=E2=89=A5 1/100 to < 1/10): neutropenia, visual hallucinations,=
 anxiety, cognitive disorders, memory impairment, hypertension, dry skin,=
 pruritus, fractures, falls; Uncommon (=E2=89=A5 1/1,000 to < 1/100): leu=
copenia, seizure, amnesia, disturbance in attention. (In the AFFIRM study=
, six patients (0.8%) experienced a seizure out of 800 patients treated w=
ith a daily dose of 160 mg enzalutamide).

		Packs and Cost: 40mg capsules x 112: =C2=A32,734.67 Legal Classificatio=
n: POM. Marketing authorisation number: EU/1/13/846/001

		Date of Preparation of PI: June 2013. Job number of PI: PRE13003UK  Fur=
ther information available from: Astellas Pharma Ltd, 2000 Hillswood Driv=
e, Chertsey. KT16 0RS.  For Medical Information phone: 0800 783 5018 =


		Adverse events should be reported. Reporting forms and information can =
be found at www.mhra.gov.uk/yellowcard. Adverse events should also be rep=
orted to Astellas Pharma Ltd. Please contact 0800 783 501 =


----==_mimepart_5284a9c52303d_30f080434a4c638a7
Date: Thu, 14 Nov 2013 10:45:25 +0000
Mime-Version: 1.0
Content-Type: text/html;
 charset=UTF-8
Content-Transfer-Encoding: quoted-printable
Content-ID: <5284a9c53ba95_30f080434a4c640b2@Franciss-iMac.local.mail>

<html>
<head>
  <title></title>
</head>
<body>
  <!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://=
www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html>
<head>
	<meta http-equiv=3D"Content-Type" content=3D"text/html; charset=3DUTF-8"=
 />

	<!-- Facebook sharing information tags -->
	<meta property=3D"og:title" content=3D"*|MC:SUBJECT|*" />

	<title>*|MC:SUBJECT|*</title>
	<style type=3D"text/css">
	/* Client-specific Styles */
	#outlook a{padding:0;} /* Force Outlook to provide a "view in browser" b=
utton. */
	body{width:100% !important;} .ReadMsgBody{width:100%;} .ExternalClass{wi=
dth:100%;} /* Force Hotmail to display emails at full width */
	body{-webkit-text-size-adjust:none;} /* Prevent Webkit platforms from ch=
anging default text sizes. */

	/* Reset Styles */
	body{margin:0; padding:0;}
	img{border:0; height:auto; line-height:100%; outline:none; text-decorati=
on:none;}
	table td{border-collapse:collapse;}
	#backgroundTable{height:100% !important; margin:0; padding:0; width:100%=
 !important;}

	/* Template Styles */

	/* /\/\/\/\/\/\/\/\/\/\ STANDARD STYLING: COMMON PAGE ELEMENTS /\/\/\/\/=
\/\/\/\/\/\ */

			/**
			* @tab Page
			* @section background color
			* @tip Set the background color for your email. You may want to choose=
 one that matches your company's branding.
			* @theme page
			*/
			body, #backgroundTable{
				/*@editable*/ background-color:#FAFAFA;

			}

			/**
			* @tab Page
			* @section email border
			* @tip Set the border for your email.
			*/
			#templateContainer{
				/*@editable*/ border: 1px solid #DDDDDD;
				background-image: url('http://streamingwell.tv/img/email-bg.jpg');
				background-repeat: no-repeat;
			}

			/**
			* @tab Page
			* @section heading 1
			* @tip Set the styling for all first-level headings in your emails. Th=
ese should be the largest of your headings.
			* @style heading 1
			*/
			h1, .h1{
				/*@editable*/ color:#939598;
				display:block;
				/*@editable*/ font-family:Arial;
				/*@editable*/ font-size:20px;
				/*@editable*/ font-weight:bold;
				/*@editable*/ line-height:100%;
				margin-top:10px;
				margin-right:0;
				margin-bottom:10px;
				margin-left:0;
				/*@editable*/ text-align:left;
			}

			/**
			* @tab Page
			* @section heading 2
			* @tip Set the styling for all second-level headings in your emails.
			* @style heading 2
			*/
			h2, .h2{
				/*@editable*/ color:#202020;
				display:block;
				/*@editable*/ font-family:Arial;
				/*@editable*/ font-size:30px;
				/*@editable*/ font-weight:bold;
				/*@editable*/ line-height:100%;
				margin-top:0;
				margin-right:0;
				margin-bottom:10px;
				margin-left:0;
				/*@editable*/ text-align:left;
			}

			/**
			* @tab Page
			* @section heading 3
			* @tip Set the styling for all third-level headings in your emails.
			* @style heading 3
			*/
			h3, .h3{
				/*@editable*/ color:#202020;
				display:block;
				/*@editable*/ font-family:Arial;
				/*@editable*/ font-size:26px;
				/*@editable*/ font-weight:bold;
				/*@editable*/ line-height:100%;
				margin-top:0;
				margin-right:0;
				margin-bottom:10px;
				margin-left:0;
				/*@editable*/ text-align:left;
			}

			/**
			* @tab Page
			* @section heading 4
			* @tip Set the styling for all fourth-level headings in your emails. T=
hese should be the smallest of your headings.
			* @style heading 4
			*/
			h4, .h4{
				/*@editable*/ color:#202020;
				display:block;
				/*@editable*/ font-family:Arial;
				/*@editable*/ font-size:11px;
				/*@editable*/ font-weight:100;
				/*@editable*/ line-height:100%;
				margin-top:0;
				margin-right:0;
				margin-bottom:10px;
				margin-left:0;
				/*@editable*/ text-align:left;
			}

			.h4 i {
				font-weight: 100;
				color: rgb(167, 43, 77);
				background: #fff;
			}



			/* /\/\/\/\/\/\/\/\/\/\ STANDARD STYLING: PREHEADER /\/\/\/\/\/\/\/\/\=
/\ */

			/**
			* @tab Header
			* @section preheader style
			* @tip Set the background color for your email's preheader area.
			* @theme page
			*/
			#templatePreheader{
				/*@editable*/ background-color:#FAFAFA;
			}

			/**
			* @tab Header
			* @section preheader text
			* @tip Set the styling for your email's preheader text. Choose a size =
and color that is easy to read.
			*/
			.preheaderContent div{
				/*@editable*/ color:#505050;
				/*@editable*/ font-family:Arial;
				/*@editable*/ font-size:10px;
				/*@editable*/ line-height:100%;
				/*@editable*/ text-align:left;
			}

			/**
			* @tab Header
			* @section preheader link
			* @tip Set the styling for your email's preheader links. Choose a colo=
r that helps them stand out from your text.
			*/
			.preheaderContent div a:link, .preheaderContent div a:visited, /* Yaho=
o! Mail Override */ .preheaderContent div a .yshortcuts /* Yahoo! Mail Ov=
erride */{
				/*@editable*/ color:#336699;
				/*@editable*/ font-weight:normal;
				/*@editable*/ text-decoration:underline;
			}



			/* /\/\/\/\/\/\/\/\/\/\ STANDARD STYLING: HEADER /\/\/\/\/\/\/\/\/\/\ =
*/

			/**
			* @tab Header
			* @section header style
			* @tip Set the background color and border for your email's header are=
a.
			* @theme header
			*/
			#templateHeader{
				/*@editable*/ background-color:#FFFFFF;
				/*@editable*/ border-bottom:0;
			}

			/**
			* @tab Header
			* @section header text
			* @tip Set the styling for your email's header text. Choose a size and=
 color that is easy to read.
			*/
			.headerContent{
				/*@editable*/ color:#202020;
				/*@editable*/ font-family:Arial;
				/*@editable*/ font-size:34px;
				/*@editable*/ font-weight:bold;
				/*@editable*/ line-height:100%;
				/*@editable*/ padding:0;
				/*@editable*/ text-align:center;
				/*@editable*/ vertical-align:middle;
			}

			/**
			* @tab Header
			* @section header link
			* @tip Set the styling for your email's header links. Choose a color t=
hat helps them stand out from your text.
			*/
			.headerContent a:link, .headerContent a:visited, /* Yahoo! Mail Overri=
de */ .headerContent a .yshortcuts /* Yahoo! Mail Override */{
				/*@editable*/ color:#336699;
				/*@editable*/ font-weight:normal;
				/*@editable*/ text-decoration:underline;
			}

			#headerImage{
				height:auto;
				max-width:600px;
			}

			/* /\/\/\/\/\/\/\/\/\/\ STANDARD STYLING: MAIN BODY /\/\/\/\/\/\/\/\/\=
/\ */

			/**
			* @tab Body
			* @section body style
			* @tip Set the background color for your email's body area.
			*/
			#templateContainer, .bodyContent{
				/*@editable*/ background-color:#FFFFFF;
				background-image: url('http://streamingwell.tv/img/email-bg.jpg');
				background-repeat: no-repeat;
			}

			/**
			* @tab Body
			* @section body text
			* @tip Set the styling for your email's main content text. Choose a si=
ze and color that is easy to read.
			* @theme main
			*/
			.bodyContent div{
				/*@editable*/ color:#505050;
				/*@editable*/ font-family:Arial;
				/*@editable*/ font-size:14px;
				/*@editable*/ line-height:150%;
				/*@editable*/ text-align:left;
			}

			/**
			* @tab Body
			* @section body link
			* @tip Set the styling for your email's main content links. Choose a c=
olor that helps them stand out from your text.
			*/
			.bodyContent div a:link, .bodyContent div a:visited, /* Yahoo! Mail Ov=
erride */ .bodyContent div a .yshortcuts /* Yahoo! Mail Override */{
				/*@editable*/ color:#336699;
				/*@editable*/ font-weight:normal;
				/*@editable*/ text-decoration:underline;
			}

			.bodyContent img{
				display:inline;
				height:auto;
			}

			/* /\/\/\/\/\/\/\/\/\/\ STANDARD STYLING: FOOTER /\/\/\/\/\/\/\/\/\/\ =
*/

			/**
			* @tab Footer
			* @section footer style
			* @tip Set the background color and top border for your email's footer=
 area.
			* @theme footer
			*/
			#templateFooter{
				/*@editable*/ background-color:#FFFFFF;
				/*@editable*/ border-top:0;
			}

			/**
			* @tab Footer
			* @section footer text
			* @tip Set the styling for your email's footer text. Choose a size and=
 color that is easy to read.
			* @theme footer
			*/
			.footerContent div{
				/*@editable*/ color:#707070;
				/*@editable*/ font-family:Arial;
				/*@editable*/ font-size:12px;
				/*@editable*/ line-height:125%;
				/*@editable*/ text-align:left;
			}

			/**
			* @tab Footer
			* @section footer link
			* @tip Set the styling for your email's footer links. Choose a color t=
hat helps them stand out from your text.
			*/
			.footerContent div a:link, .footerContent div a:visited, /* Yahoo! Mai=
l Override */ .footerContent div a .yshortcuts /* Yahoo! Mail Override */=
{
				/*@editable*/ color:#336699;
				/*@editable*/ font-weight:normal;
				/*@editable*/ text-decoration:underline;
			}

			.footerContent img{
				display:inline;
			}

			/**
			* @tab Footer
			* @section social bar style
			* @tip Set the background color and border for your email's footer soc=
ial bar.
			* @theme footer
			*/
			#social{
				/*@editable*/ background-color:#FAFAFA;
				/*@editable*/ border:0;
			}

			/**
			* @tab Footer
			* @section social bar style
			* @tip Set the background color and border for your email's footer soc=
ial bar.
			*/
			#social div{
				/*@editable*/ text-align:center;
			}

			/**
			* @tab Footer
			* @section utility bar style
			* @tip Set the background color and border for your email's footer uti=
lity bar.
			* @theme footer
			*/
			#utility{
				/*@editable*/ background-color:#FFFFFF;
				/*@editable*/ border:0;
			}

			/**
			* @tab Footer
			* @section utility bar style
			* @tip Set the background color and border for your email's footer uti=
lity bar.
			*/
			#utility div{
				/*@editable*/ text-align:center;
			}

			#monkeyRewards img{
				max-width:190px;
			}
			</style>
		</head>
    <body leftmargin=3D"0" marginwidth=3D"0" topmargin=3D"0" marginheight=
=3D"0" offset=3D"0" background-image=3D"http://streamingwell.tv/img/email=
-bg.jpg" background-repeat: "no repeat">
			<center>
				<table border=3D"0" cellpadding=3D"0" cellspacing=3D"0" height=3D"100=
%" width=3D"100%" id=3D"backgroundTable">
					<tr>
						<td align=3D"center" valign=3D"top">
							<!-- // Begin Template Preheader \\ -->
							<table border=3D"0" cellpadding=3D"10" cellspacing=3D"0" width=3D"=
600" id=3D"templatePreheader">
								<tr>
									<td valign=3D"top" class=3D"preheaderContent">

										<!-- // Begin Module: Standard Preheader \ -->
										<table border=3D"0" cellpadding=3D"10" cellspacing=3D"0" width=3D=
"100%">
											<tr>
												<td valign=3D"top">
													<div mc:edit=3D"std_preheader_content"></div>
												</td>
												<!-- *|IFNOT:ARCHIVE_PAGE|* -->
												<td valign=3D"top" width=3D"190">
													<div mc:edit=3D"std_preheader_links"></div>
												</td>
												<!-- *|END:IF|* -->
											</tr>
										</table>
										<!-- // End Module: Standard Preheader \ -->

									</td>
								</tr>
							</table>

						</td>
					</tr>
					<tr>
						<td align=3D"center" valign=3D"top">
							<!-- // Begin Template Body \\ -->
							<table border=3D"0" cellpadding=3D"0" cellspacing=3D"0" width=3D"6=
00" id=3D"templateBody">
								<tr>
									<td valign=3D"top" class=3D"bodyContent">

										<!-- // Begin Module: Standard Postcard Content \\ -->
										<table border=3D"0" cellpadding=3D"20" cellspacing=3D"0" width=3D=
"80%">
											<tr mc:repeatable>
												<td valign=3D"top">
													<div mc:edit=3D"postcard_heading00">
														<img src=3D"http://img855.imageshack.us/img855/4207/aome.jp=
g">
														<h1 class=3D"h1"><span style=3D"color: rgb(167, 43, 77)">Pr=
ostate Cancer Lunchtime Webinars</span></h1>
														<h4><i>A multidisciplinary approach to prostate cancer unde=
rstanding and management</i></h4>
													</div>
													<br>
													<div mc:edit=3D"std_content00">
														<p>Dear </p>

														<p>Thank you for registering your interest in the Astellas =
Oncology live webinars.</p>
														<p><strong>Your log-in details are as follows:</strong></p>=

														<p><strong>Username: mike.richter@streamingwell.com</strong=
></p>
														<p><strong>Password: richter35</strong></p>

														<p>Please use these log-in details every time you wish to v=
isit the webinar website: http://www.astellasoncology.co.uk/users/sign_in=
</p>

														<br>
														<p><strong>The next live webinar is as follows:</strong></p=
>

														<p>Date: Tuesday 26th November 2013</p>
														<p>Time: 12.30 to 13.15</p>
														<p><strong>Title:</strong><i>Working together: organising c=
are for optimal management of prostate cancer</i></p>
														<p><strong>Speaker(s):</strong>  Dr Simon Hughes, Consultan=
t in Clinical Oncology and Ms Louisa Fleure, Advanced Prostate Cancer Spe=
cialist Nurse Guy's Hospital, London</p>

														<p><strong>Summary:</strong>Dr Simon Hughes and Ms Louisa F=
leure will provide expert first-hand insights regarding the successful ma=
nagement of patients with prostate cancer in a multidisciplinary team (MD=
T) setup.</p>

														<p><strong>Topics:</strong></p>
														<p><li>The multidisciplinary team (MDT) structure and roles=
</li></p>

														<p><li>Managing patients with differing needs in an MDT env=
ironment</li></p>

														<p><li>Newly diagnosed patients</li></p>

														<p><li>Patients with advanced disease</li></p>

														<p><li>Meeting the challenges of a =E2=80=98working=E2=80=99=
 MDT at Guy=E2=80=99s Hospital</li></p>
														<br>
														<p>We do hope that you will be able to join us and you find=
 the webinar interesting and informative.</p>

														<p>Please note, details regarding speakers, topics and timi=
ngs for the full webinar programme are available on the website.</p>


														<p>Yours sincerely,</p>

														<p>Astellas Oncology</p>

                                                        </td>
                                                    </tr>
                                                </table>
                                                <!-- // End Module: Stand=
ard Postcard Content \\ -->
                                                =

                                            </td>
                                        </tr>
                                    </table>
                                    <!-- // End Template Body \\ -->
                                </td>
                            </tr>
                        	<tr>
                            	<td align=3D"center" valign=3D"top">
                                    <!-- // Begin Template Footer \\ -->
                                	<table border=3D"0" cellpadding=3D"10" c=
ellspacing=3D"0" width=3D"600" id=3D"templateFooter">
                                    	<tr>
                                        	<td valign=3D"top" class=3D"foot=
erContent">
                                            =

                                                <!-- // Begin Module: Sta=
ndard Footer \\ -->
                                                <table border=3D"0" cellp=
adding=3D"10" cellspacing=3D"0" width=3D"100%">
                                                    <tr>
                          =

                                                        <td valign=3D"top=
" width=3D"350">
                                                            <div mc:edit=3D=
"std_footer">
																<p><em>Astellas Pharma Ltd.</em> </p>
																<p><em>2000 Hillswood Drive </em></p>
																<p><em>Chertsey</em> </p>
																<p><em>KT16 0RS </em></p>
																<p><em>United Kingdom </em></p>
																<p><em>Registered in England and Wales under Registered N=
o 00787610 </em></p>
																<br />
																=

																<em>Please do not reply to this email</em>
																<em>Date of preparation: October 2013 Job code: XTD13057U=
Kl</em>
                                                            <p><em>These =
webinars are organised and funded by Astellas Pharma Ltd.</em></p>
												=

											=


															<small>Important: The information transmitted in this mess=
age is intended only for the person or entity to which it is addressed an=
d may contain confidential and/or privileged material. Any review, retran=
smission, dissemination or other use of, or taking of any action in relia=
nce upon, this information by persons or entities other than the intended=
 recipient is prohibited. If you receive this message in error, please co=
ntact the sender and delete the material from any computer.</small>

														<br>
														<br>
														&nbsp;<a href=3D"*|UNSUB|*">unsubscribe from this list</a>&=
nbsp;

														</div>
													</td>
												</tr>
														=

														<!-- // Begin PI \\ -->
                                                                <tr>
                                                        <td colspan=3D"2"=
 valign=3D"left">
                                                            <div>
                             =

<p><img src=3D"http://warm-dawn-9465.herokuapp.com/assets/xtandi-logo-134=
.png" align=3D"right"></p>

<br>
<br>     =


<p><strong>Xtandi&trade;</span> (enzalutamide) Prescribing Information -<=
/strong> For full prescribing information please refer to the Summary of =
Product Characteristics.</p>

<p><strong>Presentation:</strong> Xtandi&trade; 40 mg soft capsules each =
containing 40 mg of enzalutamide.</p>

<p><strong>Indication:</strong> Xtandi&trade; is indicated for the treatm=
ent of adult men with metastatic castration resistant prostate cancer who=
se disease has progressed on or after docetaxel therapy</p>

<p><strong>Posology and method of administration:</strong> Adults and eld=
erly (=E2=89=A5 65 years of age): The recommended dose is 160 mg enzaluta=
mide (four 40 mg capsules) as a single oral daily dose. If a patient miss=
es taking Xtandi&trade; at the usual time, the prescribed dose should be =
taken as close as possible to the usual time.  If a patient misses a dose=
 for a whole day, treatment should be resumed the following day with the =
usual daily dose.</p>
<p>If a patient experiences a =E2=89=A5 Grade 3 toxicity or an intolerabl=
e adverse reaction, dosing should be withheld for one week or until sympt=
oms improve to =E2=89=A4 Grade 2, then resumed at the same or a reduced d=
ose (120 mg or 80 mg) if warranted.</p>

<p>Older people: No dose adjustment is necessary for older people.</p>

<p>Hepatic impairment: No dose adjustment is necessary for patients with =
mild hepatic impairment; caution is advised in patients with moderate hep=
atic impairment; Xtandi&trade; is not recommended in patients with severe=
 hepatic impairment.</p>

<p>Renal impairment: No dose adjustment is necessary for patients with mi=
ld or moderate renal impairment.  Caution is advised in patients with sev=
ere renal impairment or end stage renal disease. Paediatric population:Th=
ere is no relevant use of enzalutamide in the paediatric population.Contr=
aception in males and females: It is not known whether enzalutamide or it=
s metabolites are present in semen. A condom is required during and for 3=
 months after treatment with enzalutamide if the patient is engaged in se=
xual activity with a pregnant woman. If the patient engages in sexual int=
ercourse with a woman of childbearing potential, a condom and another for=
m of birth control must be used during and for 3 months after treatment. =
Studies in animals have shown reproductive toxicity.</p>

<p><strong>Contraindications:</strong> Hypersensitivity to the active sub=
stance or to any of the excipients.
Women who are or may become pregnant.</p>

<p><strong>Warnings and Precautions:</strong> Caution should be used in a=
dministering Xtandi&trade; to patients with a history of seizures or othe=
rpredisposing factors. In addition, the risk of seizure may be increased =
in patients receiving concomitant medicinal products that lower the seizu=
re threshold. The AFFIRM study excluded patients with recent myocardial i=
nfarction, unstable angina, heart failure, long QT, bradycardia or uncont=
rolled hypertension. This should be taken into account if Xtandi&trade; i=
s prescribed in these patients. </p>

<p>Xtandi&trade; contains sorbitol (E420). Patients with rare hereditary =
problems of fructose intolerance should not take this medicinal product.<=
/p>

<p><strong>Drug interactions:</strong> Strong inhibitors (e.g. gemfibrozi=
l) or inducers (e.g. rifampicin) of CYP2C8 are to be avoided or used with=
 caution during enzalutamide treatment. If patients must be co-administer=
ed a strong CYP2C8 inhibitor, the dose of enzalutamide should be reduced =
to 80 mg once daily CYP3A4 plays a minor role in the metabolism of enzalu=
tamide. No dose adjustment is necessary when Xtandi&trade; is co-administ=
ered with inhibitors or inducers of CYP3A4. Enzalutamide is a potent enzy=
me inducer and increases the synthesis of many enzymes and transporters; =
therefore, interaction with many common medicinal products that are subst=
rates of enzymes or transporters is expected. Enzymes that may be induced=
 include CYP3A4 in the liver and gut, CYP2C9, CYP2C19, CYP1A2 and uridine=
 5'-diphospho-glucuronosyltransferase (UGTs - glucuronide conjugating enz=
ymes). The transport protein P-gp may also be induced, and probably other=
 transporters as well, e.g. multidrug resistance-associated protein 2 (MR=
P2), breast cancer resistant protein (BCRP) and the organic anion transpo=
rting polypeptide 1B1 (OATP1B1). In vivo studies have shown that enzaluta=
mide is a strong inducer of CYP3A4 and a moderate inducer of CYP2C9 and C=
YP2C19. The full induction potential of enzalutamide may not occur until =
approximately 1 month after the start of treatment, when steady-state pla=
sma concentrations of enzalutamide are reached, although some induction e=
ffects may be apparent earlier. Patients taking medicinal products that a=
re substrates of CYP3A4, CYP2C9, CYP2C19, CYP1A2 or UGT1A1 should be eval=
uated for possible loss of pharmacological effects (or increase in effect=
s in cases where active metabolites are formed) during the first month of=
 enzalutamide treatment, and dose adjustment should be considered as appr=
opriate. If their therapeutic effect is of large importance to the patien=
t, and dose adjustments are not easily performed based on monitoring of e=
fficacy or plasma concentrations, these medicinal products are to be avoi=
ded or used with caution. In consideration of the long half-life of enzal=
utamide (5.8 days), effects on enzymes may persist for one month or longe=
r after stopping enzalutamide. A gradual dose reduction of the concomitan=
t medicinal product may be necessary when stopping enzalutamide treatment=
. In vitro data indicate that enzalutamide may be an inhibitor of the eff=
lux transporter P-gp. The effect of enzalutamide on P-gp substrates has n=
ot been evaluated in vivo; however, under conditions of clinical use, enz=
alutamide may be an inducer of P-gp via activation of the nuclear pregnan=
e receptor (PXR). Medicinal products with a narrow therapeutic range that=
 are substrates for P-gp (e.g. colchicine, dabigatran etexilate, digoxin)=
 should be used with caution when administered concomitantly with Xtandi&=
trade; and may require dose adjustment to maintain optimal plasma concent=
rations.
The safety and efficacy of concomitant use of Xtandi&trade; with cytotoxi=
c chemotherapy has not been established.</p>

<p><strong>Undesirable effects:</strong>  Very Common (=E2=89=A5 1/10): h=
eadache, hot flush; Common (=E2=89=A5 1/100 to < 1/10): neutropenia, visu=
al hallucinations, anxiety, cognitive disorders, memory impairment, hyper=
tension, dry skin, pruritus, fractures, falls; Uncommon (=E2=89=A5 1/1,00=
0 to < 1/100): leucopenia, seizure, amnesia, disturbance in attention. (I=
n the AFFIRM study, six patients (0.8%) experienced a seizure out of 800 =
patients treated with a daily dose of 160 mg enzalutamide).</p>

<p><strong>Packs and Cost:</strong> 40mg capsules x 112: =C2=A32,734.67 L=
egal Classification: POM. Marketing authorisation number: EU/1/13/846/001=
</p>

<p><strong>Date of Preparation of PI:</strong> June 2013. <strong>Job num=
ber of PI:</strong> PRE13003UK  <strong>Further information available fro=
m:</strong> Astellas Pharma Ltd, 2000 Hillswood Drive, Chertsey. KT16 0RS=
.  <strong>For Medical Information phone:</strong> 0800 783 5018 </p>

<div class=3D"adverse">
<p>Adverse events should be reported. Reporting forms and information can=
 be found at <a href=3D"www.mhra.gov.uk/yellowcard">www.mhra.gov.uk/yello=
wcard</a>. Adverse events should also be reported to Astellas Pharma Ltd.=
 Please contact 0800 783 501 </p>
</div>
<!-- // Begin PI \\ -->
                                                            </div>
                                                        </td>
                                                    </tr>
                                                </table>
                                                <!-- // End Module: Stand=
ard Footer \\ -->
                                            =

                                            </td>
                                        </tr>
                                    </table>
                                    <!-- // End Template Footer \\ -->
                                </td>
                            </tr>
                        </table>
                        <br />
                    </td>
                </tr>
            </table>
        </center>
    </body>
</html>
</body>
</html>=


----==_mimepart_5284a9c52303d_30f080434a4c638a7--

  [1m[36m (323.1ms)[0m  [1mcommit transaction[0m
  [1m[35m (0.1ms)[0m  begin transaction
  [1m[36m (0.4ms)[0m  [1mUPDATE "users" SET "last_sign_in_at" = '2013-11-14 10:45:27.101413', "current_sign_in_at" = '2013-11-14 10:45:27.101413', "last_sign_in_ip" = '127.0.0.1', "current_sign_in_ip" = '127.0.0.1', "sign_in_count" = 1, "updated_at" = '2013-11-14 10:45:27.103580' WHERE "users"."id" = 5[0m
  [1m[35m (36.1ms)[0m  commit transaction
Redirected to http://localhost:3000/
Completed 302 Found in 2761ms (ActiveRecord: 0.0ms)


Started GET "/" for 127.0.0.1 at 2013-11-14 10:45:27 +0000
Processing by PagesController#preregistration as HTML
  [1m[36mUser Load (0.3ms)[0m  [1mSELECT "users".* FROM "users" WHERE "users"."id" = 5 LIMIT 1[0m
  Rendered layouts/_title.html.erb (0.1ms)
  Rendered pages/preregistration.html.erb within layouts/application (5.7ms)
  Rendered layouts/_header.html.erb (0.7ms)
  Rendered layouts/_messages.html.erb (0.1ms)
  Rendered layouts/_footer.html.erb (0.1ms)
Completed 200 OK in 99ms (Views: 98.4ms | ActiveRecord: 0.3ms)
